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Abstract 
Selective oxyfunctionalization of hydrocarbons is a major challenge in industrial organic 
synthesis. The biocatalytic activation of alkanes under mild reaction conditions, using 
molecular oxygen as benign oxidant, has emerged as an interesting alternative synthesis route. 
In this regard, cytochrome P450 monooxygenases represent a promising class of catalysts for 
the selective hydroxylation of non-activated carbon atoms. Successful development of 
biocatalysts that meet the process requirements can be achieved by combination of enzyme 
engineering, as well as reaction and process engineering. 
A novel process concept was developed based on the multi-enzymatic double oxidation of 
alkanes to alkanones in a one-pot synthesis, employing a cell free as well as a whole cell 
catalytic system that were benchmarked against each other. The enzymatic component of the 
catalytic cascade are a P450 BM3 monooxygenase and (S)- or (R)-selective alcohol 
dehydrogenases (RE-ADH and Lb-ADH). As model compounds n-heptane and cyclooctane 
were employed. Additionally, for n-heptane as substrate, a strategy for chiral resolution of (S)- 
or (R)-heptanols was developed. Initially, by means of protein engineering the monooxygenase 
variant P450 BM3 CM1NADH was generated, showing a high coupling efficiency for NADH as 
cofactor (44%) and a high turnover frequency with the substrate n-heptane (600 min-1).  
The initial step of the biocatalytic oxidation cascade consists in the hydroxylation of the alkyl 
chain, catalyzed by a P450 BM3 monooxygenase under consumption of NAD(P)H to produce 
(R/S)-heptanols or cyclooctanol. In the second oxidation step and depending on the selectivity 
of the employed ADH, the oxidation of (S)- or (R)-heptanol or complete oxidation of 
cyclooctanol to the corresponding ketones is achieved. In addition, the ADH-catalyzed 
sequential oxidation allows the direct regeneration of the cofactor. As further extension, the 
complete oxidation of n-heptane employing both ADHs in a three enzyme system was 
achieved, allowing a shift of the reaction equilibrium completely to the ketone products. 
Whole cells catalysis with the engineered P450 BM3 monooxygenases in the described multi-
enzymatic oxidation process yielded up to 4-fold higher product concentrations compared to 
the in vitro system. For the conversion of n-heptane, employing a biphasic reaction system, a 
total product concentration of 5.7 mM (656 mg L-1) was obtained. The conversion of 
cyclooctane yielded 94% of cyclooctanone with a concentration of 5.2 mM (652 mg L-1). The 
concept of the double oxidation cascade with P450 BM3 monooxygenases and ADHs was 
successfully proven and enables further extension to other catalysts and substrates. The 
enzymatic components can be employed in a modular manner, allowing the synthesis of 
enantiomerically enriched alcohols or ketones, which represent important building blocks in 
the manufacturing of pharmaceuticals, agrochemicals, food additives and synthetic polymers. 
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1 Introduction 
1.1 Oxyfunctionalization of hydrocarbons: Current challenges 
Petrochemical feedstocks are currently used as main raw materials for the production of bulk 
and fine chemicals. A selective oxyfunctionalization of hydrocarbons remains one of the most 
challenging tasks in chemistry, especially with regard to simple alkanes, arenes and benzylic 
positions[1] (Figure 1-1), mainly due to a low reactivity of the C-H bonds[2] and the poor 
chemo- and stereoselectivity of most chemocatalysts[3]. 
 
 
 
The non-activated C-H bond is thermodynamically very strong (~400 kJ mol-1) and is usually 
classified as kinetically inert at room temperature and towards mild oxidizing reagents.[2] In 
fact, alkanes can readily react with oxygen in air, but only at elevated temperatures (deep 
oxidation or burning), to produce the thermodynamically stable products water and carbon 
dioxide.[2] Alkanes such as methane and ethane, main components of natural gas, are used for 
example mainly as fuel for combustion in industry and private households.[4] However, the 
combustion of alkanes from valuable petrochemical sources is not interesting from a synthetic 
point of view.[2] 
Traditional synthetic routes for functionalization of hydrocarbons involve the use of harsh 
reaction conditions with temperatures above 100 °C and/or strong oxidizing agents or acids. 
The autooxidation of alkanes can be promoted by application of elevated temperatures and a 
chain initiator resulting in the formation of free radicals in a chain process. Transition metal 
ions can serve as catalyst for this autooxidation process.[2] A great number of oxidation 
reactions are also carried out using stoichiometric amounts of inorganic oxidation agents, 
mainly dissolved salts of redox-active metals such as permanganate, manganese dioxide, and 
Figure 1-1: Some examples of representative hydrocarbons: alkanes, arenes, benzylic compounds. 
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chromium(VI) reagents, or other oxidizing agents like periodate, halides, peroxides or ozone.[5] 
A main problem of these processes is the low selectivity due to the high exothermic nature of 
the reaction, resulting in multiple byproducts.   
The aerobic oxidation of C-H bonds represents a “dream reaction”, since molecular oxygen is a 
highly abundant, non-toxic and clean oxidant.[1] Nevertheless, the activation of the dioxygen 
represents a further hurdle, since O2 in the ground or triplet state (two unpaired electrons with 
parallel spin) is rather unreactive.[6] To circumvent the spin restriction the triplet state has to 
change (spin inversion), a kinetically impeded reaction, leading to the formation of more 
reactive oxygen species (e. g. hydroxyl radicals, peroxides).[7] To facilitate the activation of 
oxygen and the C-H bond, transition metal complexes, containing copper, iron or manganese 
can be used. The Wacker oxidation[8] catalyzed by PdCl2 represents one of the most efficient 
chemical methods for oxyfunctionalization of olefins and enables the synthesis of aldehydes 
and ketones[9]. 
Recent developments in the aerobic oxidation of alkanes using organometallic complexes in 
homogeneous or heterogeneous catalyzed oxidations have been reported. For heterogeneous 
catalyzed alkane functionalization transition metals such as Mn, Co or Pd are introduced within 
a defined framework consisting of crystalline nanoporous aluminophosphates (AlPOs)[10], 
microporous zeolites[11] or nanoporous carbon materials[12]. This type of catalyst resembles a 
metal substituted molecular sieve. 
In the field of homogeneous catalysis, research has focused mainly on the use of hydrogen 
peroxide as oxidizing agent. When oxygen is used as oxidant, activation is achieved by mean 
of an artificial reducing agent or an active metal complex with a porphyrin ligand.[1] A well-
known example of such a biomimetic metal-complex for the oxidation of alkanes to ketones is 
the ‘Gif System’, which consists of an iron catalyst, metallic zinc as reductant and acetic acid 
(or other acids) as proton source.[13] This system displays however an undesired oxidation 
selectivity for branched alkanes (order secondary > tertiary > primary) and no selectivity for 
oxidation of arenes and olefins. Other biomimetic approaches using metallo-porphyrins with 
diverse ligands are inspired by the reaction mechanisms of cytochrome P450 monooxygenases 
and of the methane monooxygenase[14]. Satisfactory results have been achieved using MnIII-
porphyrin,[15] FeII-porphyrin[16] or Ru-porphyrin[17] complexes in the presence of ascorbic acid, 
hydrogen sulfide or acetaldehyde. In most of the cases, a compromise between selectivity and 
catalytic activity takes place. Simultaneous regio- and chemoselectivity are often not meet by 
these catalysts.[4] The most striking advances in the field of selective oxidation with molecular 
INTRODUCTION 
 
 
3 
 
oxygen are summarized in a comprehensive way in the recent reviews by Roduner et al.[1] and 
Bordeaux et al.[4] 
Nonetheless, the stoichiometric need of prohibitive transition metal reagents[18], or large 
quantities of organic solvents and acids, and the laborious separation and recycling steps for 
products, solvents and catalysts renders most of the currently used chemical synthesis routes 
unfavorable in regard to environmental impact and sustainability.[5a] Despite of great advances 
in the development of novel processes for the organic synthesis, there is still the necessity to 
find more environmental friendly and sustainable solutions, especially in the field of selective 
oxidations. Environmental acceptable processes and products should fulfill certain guidelines 
that are defined as principles of ‘Green Chemistry’.[19] Some of these principles are: efficient 
use of preferably renewable raw materials, atom efficiency, prevention of waste, less 
hazardous/ toxic chemical, and higher energy efficiency among others.[5a] Therefore, the 
application of biocatalysis in the organic synthesis offers promising alternatives to meet the 
goals of ‘Green Chemistry’. 
1.2 Biocatalysis in industrial synthesis 
Biocatalysis can be defined as the application of enzymes and microbes in the synthetic 
chemistry, usually employing catalysts from natural sources for new purposes.[20] In industrial 
biocatalysis, isolated enzymes or whole cells are used for the desired biotransformation of a 
target compounds to a value-added product. The portfolio of industrially relevant products that 
can be synthesized by biocatalytic routes covers active pharmaceuticals, food ingredients, 
intermediates for agrochemicals and pharmaceuticals, as well as bulk chemicals.[21] 
The origin of biocatalysis goes back to the ancient cultures of Mesopotamia, China and Japan 
where it was applied for the manufacture of foods and beverages. One of the first studies on the 
biocatalytic action of enzymes was developed in France by Payen and Persoz (1833), who 
described the isolation of diastase, a mixture of amylases from the active extract of germinating 
barley for the hydrolytic conversion of starch to dextrin and sugars.[22] It was first in 1835 
when the Swedish chemist Berzelius designated such a process as a catalytic reaction. Between 
1835 and 1897, further investigation by the German scientists Schwann, who discovered 
Pepsin, Kühne who proposed the term ‘enzyme’ and the Buchner brothers, who demonstrated 
that alcoholic fermentation did not require whole cells but only the cell-free extract of yeast, 
contributed to the further development of biocatalysis as an independent research field. The 
first company to commercialize standardized enzyme preparations for industrial production, 
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namely isolated rennet for cheese making, was founded in 1874 by the Danish chemist 
Christian Hansen.[23]  
One substantial breakthrough to achieve a more widespread application of enzymes in 
industrial processes came along with the development of immobilization techniques to 
overcome stability and recyclability issues. Major processes that uses immobilized enzymes in 
a product scale of more than 10,000 tons per year are the production of high fructose corn 
syrup with a glucose isomerase, the acrylamide production catalyzed by the nitrile hydratase 
and the synthesis of 6-aminopenicillanic acid as building block for semisynthetic penicillin and 
cephalosporin antibiotics employing a penicillin amidase.[23b] 
The next crucial breakthrough in biocatalysis was achieved by introduction of DNA 
technologies for engineering of enzymes from 1970 upwards. Amylases, glucose isomerases, 
subtisilin (in washing powders) and penicillin amidases are used currently as recombinant 
enzymes in some of the most important industrial processes.[24] Further development of protein 
engineering techniques has enabled the synthesis of non-natural intermediates, mainly for the 
pharmaceutical and the fine chemical industry. Nowadays, optimization of process stability and 
development of novel activities towards non-natural substrates are some of the main 
challenges, which are tackled by enzyme engineering approaches in the search for new or 
alternative synthetic processes.[20] 
In the last decades, the use of biocatalysis in industrial manufacturing process has settled down 
as a key technology next to more traditional organic synthesis routes. Up to 2006 Straathof 
estimated that more than 150 biotransformation processes had started on an industrial scale, 
most of them involving hydrolases or redox biocatalysts.[25] Judging from the number of 
established processes, biocatalysis is applied at the moment mainly in the production of fine 
chemical that are employed in the development of pharmaceuticals.[26] 
In the last years growing interest also in the application of biocatalytic processes for production 
of bulk chemicals has emerged, not only within the academic but also the industrial research 
areas. In part, this turn is a result of a more widespread awareness of the environmental impact 
that current production processes have in our society. It is now accepted that more 
environmental friendly and sustainable technologies are required in the chemical industry.[5a] 
Some of the striking advantages of enzymes over organo or metallo-catalysts used in chemical 
synthesis are their remarkably high chemo-, regio- and stereoselectivity and the capability of 
accepting a varied range of substrates, consisting of simple or complex structures. Enzymatic 
reactions are performed in regard to temperature and pressure usually under mild reaction 
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conditions. Toxic reagents or higher amount of solvents are in general not required.[27] These 
are intrinsic characteristics of enzymes due to their incidence in natural environments, where 
they carry out very specific tasks in a complex regulated and fine-tuned network of metabolic 
pathways. Another relevant aspect is the fact that biomass can be produced in a much simpler 
and cost-effective way in larger amounts and short periods of time. As the biocatalysts 
themselves are biodegradable, the environmental impact can be reduced.[27] 
 Stereo-chemical synthesis of alcohols 1.2.1
Most of the produced optically active chemicals, such as amines, alcohols and carboxylic acids 
are used in the pharmaceutical, agrochemical and food industry. In the pharmaceutical and 
agrochemical industries an estimated share of 15% of the market accounts for chiral 
intermediates, which are used as chemical building blocks, auxiliaries or advanced 
intermediates.[28] In this regard, the synthesis of optically pure compounds is partly imposed by 
the strict regulations of the US Food and Drug Administration (FDA) and the European 
Committee for Proprietary Medicinal Products for registration of new active compounds.[28-29] 
The production of chiral compounds can be classified in three different groups that comprise 
the classical methods, such as chemical racemic resolution or chromatographic separation, the 
asymmetric (chemical) resolution and the biotechnological (biocatalytic) processes.[30] As an 
example, the synthesis of chiral alcohols starting from prochiral ketones and olefins is often 
achieved by asymmetric reduction using either chiral boron reagents[31] and chiral phosphorous 
ligands[32] or by enzymatic ketone reduction[33]. 
Biotechnological processes offer in most cases an economical attractive[33] and 
environmentally preferable access to optically active compounds.[24, 34] Therefore, the number 
of industrial processes employing biocatalytic methods has increased significantly in the last 
years.[35] 
Biocatalytic processes which involve the generation of chiral centers during the catalyzed 
reaction employ mainly kinetic resolution and asymmetric synthesis.[26]  Hydrolases, especially 
lipases, are the most commonly employed enzymes in industrial processes, catalyzing the 
hydrolytic cleavage of carbon-oxygen single bonds to produce acids and alcohols. Upon 
addition of an acyl donor, kinetic resolution of the produced racemix mixture is achieved, as 
shown in Figure 1-2.[24, 27] Lyases are another enzyme class which is usually employed for the 
synthesis of chiral alcohols. They catalyze the formation of C-C bonds, enabling upon addition 
of ketones or aldehydes as substrate the production of the corresponding alcohols.[36] 
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Oxidoreductases catalyze redox reactions (electron transfer from or to substrates) and are 
usually cofactor-dependent. Among the class of oxidoreductases the alcohol dehydrogenases 
(ADHs) play up to date the most relevant role in an industrial scale. The oxidation of chiral 
secondary alcohols with an enantioselective ADH enables the accumulation of one enantiomer 
through kinetic resolution, but a maximal yield of 50% is achieved when the starting material 
is a racemate (Figure 1-3 A).[27] 
 
 
 
Stereoselective asymmetric reduction of prochiral ketones using oxidoreductases is often the 
prefered route to chiral alcohols over kinetic resolution, since higher product yields can be 
achieved (theoretically up to 100%; Figure 1-3 B).[33] 
An interesting approach to circumvent the limiting yield of 50% in kinetic resolutions is the 
ADH-catalyzed deracemization of alcohols. Using two ADHs with complementary 
stereoselectivity and differing cofactor dependency the stereoinversion of one enantiomer is 
carried out, facilitating the enrichment of the desired enantiomer (Figure 1-4).[37] 
 
Figure 1-2: Kinetic resolution of primary alcohols by means of a lipase from Pseudomonas sp. The reaction 
is carried out in an organic solvent (e. g. benzene or CHCl3) using an acyl donor such as vinyl acetate or acetic 
anhydride. Redrawn from Faber.[27] 
Figure 1-3: Alcohol dehydrogenase-catalyzed synthesis of chiral alcohols: Kinetic resolution (A) and 
asymmetric reduction of prochiral ketones (B). Modified from Faber.[27] 
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Using this multi-enzymatic cascade reaction the entire potential of redox-catalysis can be 
utilized to achieve higher atom efficiencies.[38] 
Monooxygenases comprise a further group of oxidoreductases that are able to produce chiral 
alcohols, in this case by selective oxidation of a non-activated C-H bond. This synthetic 
approach is still not widely applied, with only a few applications in industrial processes, mostly 
based on the modification of a complex and large framework such as steroids (e.g. 
11-deoxycortisol, progesterone) for pharmaceutical applications.[27, 39] A further example is the 
production of  the cholesterol-lowering drug pravastatin by hydroxylation of compactin with 
whole cells of Streptomyces sp. containing CYP105A3.[40] In recent years much attention has 
been attracted to the advantageous use of cheaper substrates (e.g. alkanes) and the broad scope 
of available monooxygenase-catalyzed reaction for stereo-chemical hydroxylation reaction.[41] 
The direct biocatalytical activation of alkanes is an interesting and more cost-effective 
alternative to the use of prochiral ketons in stereo-chemical synthesis, making the enzymatic 
oxyfunctionalization a key factor for the future applications of oxygenases.[42] A more detailed 
introduction to this type of monooxygenase-catalyzed stereoselective enzymatic oxidation 
reactions can be found in chapter 1.3. 
 Production of ketones 1.2.2
Ketones are important building blocks in the chemical industry. Cycloalkanones are used in 
large scale industrial manufacturing of synthetic polymers like polyamides.[43] The Bashkirov 
oxidation[44] represents one traditional chemical synthesis route for the production of 
cycloalkanols employing molecular oxygen as oxidizing agent in presence of boric acid. 
Cycloalkanones are obtained by a further catalyzed dehydration reaction of the alcohols.[45] In 
this multi-step process stoichiometric amounts of boric acid are required, as well as multiple 
catalysts and only low conversions with modest selectivities are achieved.[43] Therefore, 
alternative synthesis routes to cycloalkanones using biocatalysis with a lower environmental 
impact and higher productivities are desirable. 
Figure 1-4: Deracemization of alcohols using enantio-complementary ADHs in a bi-enzymatic one-pot 
redox reaction. Redrawn from Hollmann et al.[38] 
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Aliphatic ketones and aldehydes are usually used industrially for the production of flavors and 
fragrances.[46] The generation of flavors by means of microbial biotransformation processes has 
one of the longest traditions, being employed in the preparation of food and beverages such as 
cheese, bread, wine and beer for many centuries. Accordingly, the biotechnological production 
of flavors is a well-established procedure in the chemical industry. Some fungal species can 
produce methylketones in aerobic fermentation processes under growth limiting conditions as a 
result of an overflow metabolism in the ß-oxidation of fatty acids.[46] 2-Heptanone and 
2-nonanone are for instance important for the characteristic taste of Roquefort cheese. The 
production of C5 to C9 methylketones by transformation of the corresponding C6 to C10 fatty 
acids using Penicillium roquefortii spores in solid-state fermentation of buckwheat seeds has 
been reported. This process can yield up to 75 g L-1 of 2-heptanone and 60 g L-1 
2-nonanone.[47] 
 Biocatalytic functionalization of alkanes 1.2.3
Enzyme-catalyzed oxidation of non-activated alkanes is in general achieved with higher 
selectivities than with chemocatalysts.[38] Several enzymes that catalyze alkane oxygenation 
reactions occur naturally. The main classes are oxygenases and peroxidases.[39] Peroxidases 
catalyze mainly oxygen transfer reactions, such as olefin epoxidations and sulfoxidations. 
Recently, the peroxygenase from Agrocybe aegerita was reported as first peroxidase to 
hydroxylate aliphatic chains (from propane to hexadecane) using H2O2 as oxidizing agent.[48] A 
few oxidases and dehydrogenases are also capable of catalyzing hydroxylations. One example 
is the nicotinate dehydrogenase from Bacillus niacini, which uses water as oxygen donor.[49] 
Oxygenases comprise a more diverse catalytic family due to their intrinsic physiological role in 
detoxification, synthesis of secondary metabolites or hydrocarbon degradation.[39] Some of the 
most relevant classes of oxygenases that catalyze the oxidation of alkanes are shown in Table 
1-1. Despite of differences in the catalytic mechanism all the depicted natural alkane 
oxygenases can be classified as transition-metal organocatalysts, using strictly iron or copper 
as metal. They share common features such as the availability to hydroxylate alkanes as a 
result of natural evolution, the use of molecular oxygen from air as sole oxidizing agent and the 
use of reduced nicotinamide dinucleotides (NAD(P)H) as electron suppliers. 
Nevertheless, industrial applications of oxygenases are often hindered, mainly due to their low 
reaction rates, stabilities and cofactor-dependency.[41a] 
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Enzyme class Source Features Substrate range Ref 
Soluble methane 
monooxygenase  
Methanotrophic 
bacteria 
Dinuclear iron; soluble 
reductase 
C1-C8 (halogenated)-
alkanes, alkenes, 
cycloalkanes 
[51] 
Particulate methane 
monooxygenase 
Methanotrophic 
bacteria 
Mononuclear or dinuclear 
copper; membrane bound 
hydroxylase 
C1-C5 (halogenated)-
alkanes, alkenes [51] 
AlkB-related alkane 
hydroxylases 
Acinetobacter, 
Alcanivorax, 
Pseudomonas, etc. 
Dinuclear iron rubredoxin; 
Membrane hydroxylase 
C5-C16 alkanes, fatty 
acids, alkylbenzenes, 
cycloalkanes, etc. 
[52] 
Eukaryotic P450  
(CYP52, class II) 
Candida maltosa, 
Candida tropicalis, 
Yarrowia lipolytica 
Microsomal oxygenase; 
P450 heme reductase 
C10-C16 alkanes, fatty 
acids [53] 
Bacterial P450 oxygenase 
system (CYP153, class I) 
Acinetobacter, 
Alcanivorax, 
Rhodococcus, etc. 
P450 oxygenases; heme 
ferredoxin + ferredoxin 
reductase, FAD 
C5-C10 alkanes, 
(cyclo)-alkanes, 
alkylbenzenes, etc. 
[54] 
Dioxygenase Acinetobacter sp. Homodimer; copper C10-C30 alkanes [55] 
 
A further constraint for an in vitro application of most of the oxygenases in Table 1-1 is the 
multicomponent and membrane associated character. The difficult recombinant expression and 
preparation of multicomponent, membrane-bound enzymes remains so far a limiting factor. A 
possible solution to overcome most of these challenges is their use as whole cell catalytic 
systems for synthetic applications.[41b] Very promising is also the investigation of the recently 
discovered CYP153 family, whose members despite of the multicomponent character are 
soluble bacterial P450s.[56] 
Besides of the natural occurring alkane hydroxylating oxygenases described above, other 
cytochrome P450 enzymes have been engineered by means of protein evolution to accept 
alkanes as substrate. Most of the evolution studies have been performed with cytochrome P450 
BM3 from Bacillus megaterium (B. megaterium; CYP102A1) and P450cam from 
Pseudomonas putida (CYP101). P450 BM3 is a soluble and self-sufficient medium- to long-
chain fatty acid hydroxylase[57] that has been evolved by different research groups towards a 
broad scope of substrates (reviewed by Whitehouse et al.[58]) and especially by the research 
group of Arnold to a highly active alkane monooxygenase[59]. As P450 BM3 is the scope of 
this thesis a more detailed introduction to this enzyme class is found in chapter 1.3.1. P450cam 
is a further soluble but multicomponent bacterial monooxygenase from Pseudomonas 
putida,[60] which have been evolved successfully towards the hydroxylation of ethane[61] 
instead of its natural substrate camphor. Bell et al. achieved this substrate shift through 
progressive adaption and shrinking of the substrate pocket by replacement of some of the 
original amino acids with more hydrophobic and larger residues.[61] The biocatalytic 
Table 1-1: Enzyme classes involved in the oxidation of alkanes. Adapted from van Beilen and Funhoff.[50] 
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oxyfunctionalization of alkanes, combined with the possibility to tailor biocatalysts by protein 
evolution, offers a wide applicability of oxygenases for alternative processes in the oxidative 
chemistry. 
 Cofactor regeneration 1.2.4
The activity of oxidoreductases is dependent on the use of cofactors. Most oxygenases require 
the rather expensive nicotinamide cofactors NADH or NADPH as electron suppliers. An 
application of stoichiometric amounts of such cofactors for synthetic processes is economically 
not feasible. Therefore, an in situ regeneration of the oxidized and reduced nicotinamide 
cofactors is indispensable for a successful synthetic application.  
To overcome the so called “cofactor challenge” in cell-free biocatalysis two basic strategies 
have been investigated: the use of enzymatic regeneration systems[62] and regeneration by 
chemical, electrochemical or photochemical setups[63]. The enzymatic regeneration strategy is 
currently the most efficient approach and commonly employed in industry and academia. It can 
be classified in two different types, substrate-coupled and enzyme-coupled regeneration[62], 
depending on the reaction concept that is employed as shown in Figure 1-5. 
 
 
 
In the substrate-coupled system the same enzyme catalyzes the main reaction as well as the 
cofactor regenerating reaction. This approach is mainly applied with alcohol dehydrogenases, 
where a cheap alcohol is employed as sacrificial substrate for cofactor regeneration. 
Nevertheless, in this approach the selection of a suitable auxiliary substrate is restricted to the 
specificity of the biocatalyst.[64] Isopropanol, commonly applied as cosubstrate in the 
production of (R)-alcohols from prochiral ketones, is oxidized to acetone with alcohol 
dehydrogenases like those from Lactobacillus kefir and Lactobacillus brevis.[62] 
Figure 1-5: Different strategies for the regeneration of nicotinamide cofactors. A) The substrate-coupled 
system employs only one enzyme for the reduction of the substrate (main reaction) and for cofactor 
regeneration. B) In the enzyme-coupled approach the regeneration reaction is catalyzed by a second enzyme. 
Adapted from Weckbecker et al.[62] 
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In the enzyme-coupled strategy two enzymes and two substrates are required. The cofactor 
regeneration is carried out by the second enzyme independently from the main reaction. This 
system has a wide applicability not only for alcohol dehydrogenases as main catalyst, but also 
for other enzyme classes, since the selection of a regenerating enzyme and a cosubstrate is 
more flexible. Formate dehydrogenase (FDH) is often applied as regenerating enzyme in view 
of several advantages over other enzymes.[65] FDH catalyzes the oxidation of formate, a cheap 
cosubstrate, to carbon dioxide. Formate and CO2 are almost innocuous to almost all enzymes. 
Since this oxidation is irreversible the reaction equilibrium can be shifted to the product site. A 
disadvantage is its low specific activity (4-6 U mg-1) compared to other dehydrogenases like 
alcohol or glucose dehydrogenase.[62] 
Glucose dehydrogenase (GDH) is also applied in lab- and industrial-scale for the enzyme-
coupled regeneration of both types of reduced cofactors, NAD+ and NADP+, through oxidation 
of β-D-glucose to D-glucono-1,5-lactone, which hydrolyzes spontaneously to gluconic acid. 
The hydrolysis rate depends on the employed pH in a buffered reaction. A GDH can be 
produced in recombinant form, is commercially available, highly active and stable. The GDH 
from B. megaterium can achieve a specific activity of up to 550 U mg-1 and glucose conversion 
rates in the range of 10-100 mM h-1 have been determined.[62, 66] General disadvantages in the 
use of isolated enzymes for cofactor regeneration are the higher cost in the preparation 
(isolation and purification), as well as the limited stabilities of the catalysts. 
In whole cell catalysis with metabolic active cells (growing or resting cells), the regeneration 
of cofactors is achieved intrinsically in the cell by the cells metabolism (catabolic activity) 
using a carbon and energy source such as glucose. The glucose metabolism in Escherichia coli 
(E. coli) resting cells was simulated by Blank et al. to estimate the NADH regeneration 
capacity. The net NADH formation was calculated using an optimal glucose uptake rate of 
2.4 mmol gCDW-1 h-1 and taking into account the energy required (ATP) for cell maintenance. A 
maximal yield of 10.3 mol NADH per mole glucose was calculated, which results in a NADH 
formation rate of 22 mmol gCDW-1 h-1.[67] For redox biocatalysis, assuming a stoichiometric 
relation between product formation and cofactor consumption, this regeneration rate 
corresponds to a catalytic activity of 367 U gCDW-1.[68]  
Another strategy for cofactor regeneration in the host cell is the heterologous expression of a 
regenerating enzyme (e.g. GDH, FHD or ADH), similar to the described cell-free enzyme-
coupled regeneration system using a sacrificial cosubstrate. In this way a metabolism-
independent catalyst is generated. The external addition of cofactor is in most cases not 
necessary, since the intracellular cofactor pool is sufficient for the regeneration to proceed.[69] 
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Traditionally, whole cells of Saccharomyces cerevisiae (S. cerevisiae) have been used for 
cofactor regeneration in industrial processes using the cellular metabolism, mainly for the 
reduction of ketones.[70] Other organisms have also been implemented successfully, for 
example the resting cells of Lactobacillus kefir containing an alcohol dehydrogenase for the 
stereoselective reduction of 2,5-hexanedione to (2R,5R)-hexanediol.[71] 
Different recombinant whole cell catalytic systems have been designed, so-called designer 
bugs expressing the main catalytic enzyme and an auxiliary enzyme for cofactor 
regeneration.[69, 72] This system has also been applied for multi-step reactions.[73] 
 In vitro and whole cell catalysis 1.2.5
Biocatalytic processes can be performed using either isolated enzymes for in vitro 
biotransformation processes or whole cells containing a naturally compartmentalized form of 
the catalytic active enzyme. A further classification of these two basic formulations is 
dependent on the preparation of the biocatalyst as described below. 
Isolated enzymes can be used as crude cell lysate or in a purified form. Purification of the 
catalysts is more expensive but can contribute to avoid side reactions and contaminations with 
other cell compounds.[74] The low stability of most isolated enzymes is a challenging task, 
tackled in industrial processes mainly through immobilization techniques and nowadays also 
through protein engineering. Up to date, the majority of published papers on enzymatic 
biocatalysis report the use of isolated enzymes.[74] In contrast, the majority of industrial 
biotechnological processes for synthetic applications in a large scale make use of whole 
cells.[25] This demonstrates that within the academic research field a well-defined system, such 
as the isolated enzyme itself, is essential for a thorough investigation and characterization of 
the biocatalytic process, but in industrial manufacturing processes the whole cell as biocatalytic 
entity seem to meet the process requirements in a more economical fashion. 
Whole cells can be used as living, metabolically active organisms or as inactive (dead) cells. In 
either case the cell provides a natural and therefore stabilizing environment for the catalytic 
enzyme.[75] Metabolic active cells are needed in fermentative processes, in biotransformations 
with growing or resting cells that require cofactor regeneration, mainly for oxidoreductase-
catalyzed reactions, and in biotransformations that are directly linked to the central carbon 
metabolism.[76] For application of whole cells several parameters, besides of the main 
enzymatic activity, affect the performance of biotransformations. The most important 
parameters are mass transfer (of substrates, products, and oxygen), protein synthesis, cellular 
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metabolism, compartmentalization, cell growth and cell inactivation. Therefore, in whole cell 
catalysis the cell and not the enzyme is defined as the catalytic unit.[76] 
An economical advantage of biocatalysis over chemical catalysis is the simpler production of 
the highly regio- and enantioselective biocatalyst through fermentation. High-cell density 
fermentations yielding more than 100 gCDW L-1 have been reported for various 
microorganisms.[77] 
One striking drawback in whole cell processes is the possible contamination with byproducts 
as a result of other metabolic activities of the cell. In some cases, lower optical purities are 
yielded as a result of overlapping substrate specificities from native enzymes with a differing 
selectivity.[64] Nowadays, the development of ‘designer cells’ for overexpression of the desired 
enzyme or coexpression of multiple enzymes is achieved using genetic engineering 
techniques.[62] The possibility to avoid competing activities of other undesired enzymes can be 
achieved by gene knockout or disruption of  entire metabolic pathways in the host organism.[78] 
The recent developments in metabolic engineering offer the possibility of optimizing the 
metabolic flux, for example in regard to availability of reducing equivalents, and detecting 
possible limiting factors.[23b, 67] 
The limiting mass transfer in whole cells is another parameter that attracts much attention. The 
cell membrane can affect transfer of substrates and products, which on their part have a strong 
influence on the membrane integrity and fluidity. In the application of metabolically active 
cells target substrates or products are often toxic to the cell.[75] In the case of organic solvents 
like short-chain aliphatic alkanes, that are small hydrophobic molecules, accumulation in the 
cytoplasmic membrane can occur. The loss of membrane integrity is considered to be a 
principal cause of toxicity in whole cell processes.[79] Hence, the final disintegration of the 
membrane will result in the loss of proteins and cofactors. The partition of substrates and 
products between a membrane and an aqueous medium (Pm/aq) correlates to the partitioning 
coefficient of the same in an octanol-water mixture (logPo/w). As a rule of thumb, high cell 
toxicity is ascribed to compounds with a logPo/w value between 1 and 4 (e.g. phenol, 1-octanol 
or chloroform).[79b, 80] With a logPo/w below 1 a compound is too hydrophobic to be able to 
enter the cell membrane. Above a logPo/w of 4 the solubility of the compound is too low to be 
available in the aqueous phase.[79b] However, the toxic effect depends strongly on the 
organism. The mass transfer coefficient of these compounds will depend not only on properties 
like size and hydrophobicity, but also on the availability of uptake or excretion mechanism in 
the cell.[76] On the one hand the availability of substrates has to be assured to achieve sufficient 
reaction rates; on the other hand the long term stability of the cell is vital for the process 
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performance, for example in processes using catabolic cofactor regeneration. A technical 
solution to this dilemma is the use of organic/aqueous two-liquid phase system[81] as shown in 
Figure 1-6. 
 
 
 
The application of a two-liquid phase system can optimize the availability of low-water soluble 
compounds (hydrophobic substrates) because it serves as substrate and product sink.[81] 
Accumulation of products in the organic phase, so-called in situ product removal, enables the 
presence of only low concentrations of toxic compounds in the aqueous phase, protecting so 
the biocatalysts (whole cell or isolated enzyme).[82] The selection of a suitable organic solvent 
as liquid phase has to take into account several parameters such as solvent capacity, toxicity, 
biocompatibility, flammability and availability.[81] Solvents that have a logPo/w value higher 
than 4 are water-immiscible and will probably not disturb the water shell around the 
biocatalyst.[80] However, the biocompatibility of the solvent has to be evaluated for each case 
empirically. Some of the compounds that have been utilized as organic phase are: short- to 
medium-chain alkanes (i.e. n-heptane, n-octane, decane, dodecane)[83], MTBE[84] or bis-(2-
ethylhexyl)-phthalate[85]. It has been observed that whole cells are less sensitive to inactivation 
at the liquid-liquid interface than isolated enzymes.[76] The in situ product removal also 
supports a direct down-stream processing of products.[81] Under appropriate circumstances the 
substrate could also serve as bulk organic phase. This was demonstrated by Julsing et al. for 
the ω-oxyfunctionalization of fatty acids methyl esters.[86] 
Under some circumstances the low substrate uptake can still limit the reaction rates. To 
circumvent this problem permeabilization of the cell membrane has been applied successfully. 
Freeze-thawing, sonication and application of detergents and solvent represent some of the 
methods for permeabilization of cells.[87] The engineering of the host cell, for example by 
deletion of lipopolysaccharides or lipoproteins in the outer cell membrane to facilitate substrate 
uptake has been described.[88] In a similar way, the incorporation of an outer membrane protein 
for the passive transport of substrates, for example the AlkL membrane protein of 
Figure 1-6: Organic/aqueous two-liquid phase system in biocatalysis. Partitioning of the substrate and the 
biotransformation product takes place between organic and aqueous phase. Thereby, the organic phase serves as 
substrate source and product sink, reducing inhibitory or toxic effects. Adapted from Heipieper et al.[79b] 
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Pseudomonas sp. which facilitates alkane uptake has been reported. This strategy was 
demonstrated for the hydroxylation of (S)-limonene to (S)-perillyl alcohol.[89] 
Both isolated enzymes and whole cells can be immobilized in or on a carrier material to afford 
an easier recovery/re-use of the catalyst and higher process stabilities. The immobilization of 
whole cells involved in oxygen-dependent redox biocatalysis is however not recommended, 
since slow oxygen diffusion will rather limit the reaction rates.[25] Depending on the targeted 
biotransformation reaction the application of the most suitable process strategy has to be 
studied in detail. 
 Multi-enzymatic cascades 1.2.6
One surpassing advantage of enzymes as natural components of living cells is their 
compatibility with each other under similar operational conditions. This property makes the use 
of multi-enzymatic cascade processes feasible, by coupling two or more biocatalytic reactions 
in a single flask (one-pot) as shown in Figure 1-7 A.[27, 90] Such a process resembles the mode 
of action of cell metabolic pathways. 
 
 
 
Growing interest has focused in the investigation of biocatalytic processes, which involve 
multi-enzymatic, chemo-enzymatic and enzyme-initiated cascades, and the application of 
either isolated enzymes or whole cell catalysts. The main benefits of a multi-enzymatic system 
are the reduction or omission of time-consuming isolation and purification steps, as well as the 
Figure 1-7: Multi-enzymatic cascade reactions. (A) Representation of a biocatalytic one-pot (multi-step) 
cascade reaction comprising 3 steps. Redrawn from Wohlgemuth.[91] (B) Classification of enzymatic cascades 
according to process design: 1) linear cascade, 2) orthogonal cascade, 3) parallel cascade, 4) cyclic cascade. 
Redrawn from Ricca et al.[90] 
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possibility to shift the reaction equilibrium to the target product by selection of a suitable 
reaction sequence.[91] This also means that the amount of waste can be minimized due to the 
lower requirement of solvents and working volume as well as the higher volumetric and space-
time yield that can be achieved.[92] Bottlenecks such as low compatibility of the enzymatic 
components or the reaction conditions can be circumvented by immobilization strategies, 
reactor design or directed protein evolution.[92] Since combination of enzymes and metal 
catalysts is feasible, several possibilities for the design of new synthetic approaches are 
available (e.g. in the application of dynamic kinetic resolution).[93] 
Multi-enzymatic processes are usually classified based on the type of intermediate that is 
formed.[90] The term “domino reaction” is employed when an unstable intermediate is 
generated and a spontaneous reaction leads to the stable product. “Tandem reactions” are those 
processes consisting of multiple biotransformation steps with concomitant formation of stable 
intermediates and products. A further classification of biocatalytic cascades into 4 main groups 
is based on the process design (Figure 1-7 B)[90]: In linear cascades (1) a single substrate is 
converted to a single product after formation of the reactions intermediate. In orthogonal 
cascades (2) the main catalytic reaction is coupled to a second auxiliary reaction, either for 
regeneration of cofactors/cosubstrates or elimination of byproducts. Similar to the orthogonal 
approach, the parallel cascade (3) couples two main reactions for production of two products 
via an auxiliary reaction, which in turn involves the regeneration of cofactors or cosubtrates. 
The cyclic cascade (4) enables the accumulation of one target compound from a mixture of 
substrates (e.g. racemic mixtures) after iterative (cyclic) transformation of the unwanted 
substrate into an intermediate and subsequent transformation of the intermediate back to the 
starting racemic material. Depending on the process demands combination of different types of 
cascades is possible. Orthogonal cascades are classically used in processes that involve 
regeneration of cofactors as described in chapter 1.2.4, for example in the application of 
oxidoreductases. 
Recently, several artificial multi-enzyme cascades have been developed for the production of 
optically active alcohols, amines and amino acids. Dehydrogenases and transaminases have 
been widely used for this purpose. An overview of this type of cascade reactions for synthesis 
of optically enriched compounds is given in Table 1-2. 
One novel approach represent the deracemization and stereo-inversion of secondary alcohols 
using an ADH-catalyzed tandem reaction[37, 94] as shown in Table 1-2, entry 1 (see also chapter 
1.2.1, Figure 1-4). Another novel strategy is the biocatalytic amination of primary alcohols by 
means of two sequential, coupled reaction steps.[95] The first step comprises the ADH-
INTRODUCTION 
 
 
17 
 
catalyzed oxidation of the primary alcohol leading to production of the aldehyde, which is 
aminated in the second step by means of a ω-transaminase. The amide donor L-Alanine is 
regenerated from pyruvate by an L-alanine dehydrogenase, which in turn regenerates the 
nicotinamide cofactor NADH for the first reaction step. The described approach represents 
therefore a so called redox self-sufficient biocatalysis network (Table 1-2, entry 7). To broaden 
the concept, the authors developed a double amination tandem process for production of 1,ω-
diols, involving in total four sequential reactions and two cofactor regeneration reactions. 
 
Entry Substrate Product Type of reaction Enzymes[a] Ref 
Optically active alcohols 
1 Racemic 
sec-alcohols 
Pure 
stereoisomers 
of sec-alcohols 
Deracemization via 
stereoinversion 
Two ADHs with opposite 
enantioselectivity (Prelog, anti-
Prelog) and opposite cofactor 
specificity; two independent CRS 
[94]
 
2 Cholic acid 12-Ketourso-
deoxycholic 
acid 
Sequential oxidation and 
reduction 
(stereoinversion) 
Three hydroxysteroid 
dehydrogenases (7α-HSDH, 7β-
HSDH with opposite cofactor 
specificity; 12α-HSDH); two 
independent CRS 
[96]
 
3 Racemic 
alcohols, 
sulfides 
Alcohols, 
sulfoxides 
Concurrent kinetic 
resolution of alcohols 
and asymmetric 
synthesis of sulfoxides 
ADH, Baeyer-Villiger 
monooxygenase (BVMO) [97]
 
Amino acids 
4 α-Hydroxy 
acids 
L-Amino acids Asymmetric synthesis by 
coupled oxidation and 
reductive amination 
(redox-neutral)* 
ADH and amino acid 
dehydrogenase (AADH); same 
cofactor specificity 
[98]
 
5 Racemic 
α-amino 
acids 
L-Amino acids Deracemization by 
coupled oxidation and 
asymmetric reductive 
amination 
D-Amino acid oxidase (D-AAO), 
leucine dehydrogenase (LeuDH); 
FDH (for cofactor regeneration); 
catalase (for degradation of H2O2) 
[99]
 
Amines 
6 Ketones α-Chiral 
primary amine 
Asymmetric synthesis, 
removal of by-product 
pyruvate 
ω-Transaminase (TA), lactate 
dehydrogenase (LDH), GDH (for 
cofactor regeneration) 
[100]
 
7 Primary 
alcohols 
Primary 
amines 
Amination of primary 
alcohols (coupled 
oxidation and amination) 
ADH, ω-TA, L-Alanine 
dehydrogenase (for recycling of 
alanine and cofactor) 
[95]
 
[a]
 CRS: Cofactor regeneration system 
* Redox-neutral cascades are those that do not require external oxidation or reduction equivalents. 
Table 1-2: Examples of multi-enzyme cascade reactions for the production of optically enriched 
compounds. 
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Another major focus of investigation has been the synthesis of complex molecules from 
simpler and cheap substrates as starting material using carbon-carbon bond forming enzymes 
like aldolases and nitrile hydratases.[90] Besides, the synthesis of complex glycoconjugates is 
also achieved by multi-enzyme cascades by combination of pathway or pathway-unrelated 
enzymes.[101] 
Apart from the utilization of multi-enzymatic cascades in cell free systems, their application in 
whole cell approaches is very promising. Metabolic engineering[102] can be employed for 
optimization of such in vivo catalysts. For utilization of a native production host the pathway 
flux can be enhanced by over-expression of rate-limiting metabolic genes using promoter 
engineering[103], or by disruption of competing genes/pathways[78]. An alternative is the 
engineering of heterologous expression hosts like E. coli or S. cerevisiae, which are most likely 
the best characterized production platforms so far. In this way, a new metabolic (artificial) 
route can be introduced in whole cells for synthesis of the target compound.[104] To identify 
competing pathways or rate-limiting steps metabolic modeling or random approaches can be 
applied.[104] 
1.3 Cytochrome P450 monooxygenases 
Oxidoreductases are one class of enzymes characterized by the catalytic availability to transfer 
electrons to the substrate, so called redox reactions.[105] The oxidoreductases are divided into 
four main groups: oxygenases, peroxidases, oxidases and dehydrogenases. Oxygenases have a 
ubiquitous occurrence in all classes of living organisms, from eukaryotic to prokaryotic 
cells.[67] They are capable of introducing oxygen into chemically inert C-H bonds.[106] The 
catalytic mechanism of the different oxygenases is very diverse, some employ copper or iron as 
catalytic metal, others are for instance flavin-dependent. Oxygenases are further divided into 
monooxygenases and dioxygenases, catalyzing the specific oxyfunctionalization of carbon 
atoms by insertion of 1 or 2 oxygen atoms respectively.[106] With exception of peroxidases and 
some dioxygenases, the oxidoreductase activity is dependent on redox cofactors, typically the 
nicotinamide cofactors NAD(P)H and NAD(P)+ that act as electron donors or acceptors.[67] 
Cytochrome P450 monooxygenases are one class of heme-containing oxygenases, capable of 
oxidizing non-activated C-H bonds.[107] The name cytochrome P450 is originated from its 
properties as a hemoprotein and its characteristic spectrum with an absorption maximum at 
450 nm upon reduction and binding of carbon monoxide (CO).[108] The general P450-catalyzed 
reaction is shown in Equation 1[107]: 
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RH + O2 + NAD(P)H + H+  →  ROH + H2O + NAD(P)+ 
 
The heme is a prosthetic group of the type protoporphyrin IX that contains an iron nucleus, 
which is directly responsible for the activation of O2. One atom of molecular dioxygen is often 
incorporated stereo- and regioselectively into the substrate, while the second atom is reduced to 
water.[109] Aliphatic and aromatic hydroxylations are commonly catalyzed, but also other 
reactions such as epoxidations, dehydrogenations, deamination, dealkylation, as well as 
carbon-carbon bond formation or cleavage were reported.[110] P450 monooxygenases are 
involved in diverse physiological reactions that are coupled to anabolic or catabolic pathways. 
They are responsible for hormone synthesis, drug metabolism and xenobiotic detoxification in 
mammalian and insect cells, as well as for herbicide resistance in plant cells.[107] Microbial 
P450s are usually related to metabolic and synthetic pathways, for example for the synthesis of 
antibiotics or the degradation of hydrocarbons.[58] 
Cytochrome P450s use external electron donors for the activation of oxygen and a respective 
electron-supporting system, mostly from the microsomal or mitochondrial/bacterial type. 
P450s can be further classified based on the type of electron transport system used. Up to now 
10 different classes of electron transport systems have been described, being the most 
frequently encountered the class I (bacterial and mitochondrial P450s) and the class II 
(bacterial and microsomal P450s).[111] Class I P450 systems consist of three components, a 
FAD-containing reductase, a ferredoxin and the hemoprotein (P450). In bacterial P450s all 
three components are soluble, whereas in mitochondrial P450s the hemoprotein and the 
reductase are bound to the inner mitochondrial membrane, while the ferredoxin is present as a 
soluble protein in the mitochondrial matrix. Class II P450 systems are composed of two 
components, the cytochrome P450 and a microsomal NADPH-reductase that contains FAD 
and FMN. In the microsomal type the two components are membrane-associated. The Class 
VIII comprises self-sufficient P450s (e.g. P450 BM3 from Bacillus megaterium) that share the 
same components of Class II (reductase and P450 hemoprotein), fused as a single peptide and 
in soluble form. In microsomal and in self-sufficient cytochrome P540s the electron transfer 
takes place from NAD(P)H to the heme iron via the electron transfer partners.[107, 111] 
The catalytic cycle of P450 monooxygenases have been studied extensively[109, 112] and an 
actual representation is shown in Figure 1-8. The porphyrin is embedded in the protein core, 
through coordination of the ferric iron atom by the thiolate ligand from cystein, the four 
equatorial nitrogen ligands and a water ligand in the axial position, proximal to the thiolate 
(six-coordinated).[113] 
Equation 1 
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In the substrate free form the iron atom FeIII retains in the low-spin state (I). Upon binding of a 
viable substrate the axial water ligand is displayed, causing a shift in the ferric spin state from 
low-spin to high-spin (II).The redox potential of the heme changes, facilitating the transfer of 
one electron supplied by NAD(P)H from the redox partner to the heme, with concomitant 
reduction of FeIII to FeII (III). Dioxygen can bind now leading to formation of the oxy-complex 
(IV), whereupon a second electron is shuttled to the heme, generating the ferric peroxy 
complex (V). 
 
 
 
Protonation of the terminal oxygen atom leads to formation of the hydroperoxy compound (VI, 
Compound 0). This adduct is protonated a second time triggering the hydrolytic cleavage of the 
O-O bond and the release of water under generation of the Compound I (VII), which is 
considered as the active oxygen species responsible for the oxygenation of the substrate. 
Compound I is two oxidation states above the resting ferric state.[109] In hydroxylation 
reactions the substrate is oxygenated via a radical rebound mechanism (VIII), where the 
hydrogen from the substrate is first abstracted (•R; VIII) by compound I. The generated radical 
Figure 1-8: The catalytic cycle of P450 Monooxygenases. Since NAD(P)H consumption is not fully coupled 
to the product formation, possible uncoupling pathways are also depicted (dashed line). Modified from 
Whitehouse et al.[58] 
Superoxide 
 Uncoupling 
Peroxide 
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combines with oxygen to form the oxygenated product. The product is then released from the 
active site allowing the ferric atom to return to the fifth-ligand coordinated resting state (IX).[58] 
Most monooxygenases display a certain degree of uncoupling between the consumption of 
NAD(P)H as cofactor and the product formation. This means, the consumption of cofactor is 
not stoichiometric in relation to the product formation. For the natural enzyme´s substrate the 
coupling efficiency is higher, as in the case of P450cam and camphor.[114] Thus, three different 
uncoupling reactions can possibly take place at different stages during the catalytic cycle. A 
hindered binding of dioxygen (IV) can result in the loss of superoxide, probably due to a too 
slow electron transfer (superoxide uncoupling). If the substrate is loosely bound, water release 
could be inhibited and protonation of the wrong oxygen atom in the hydroperoxy compound 
(VI) would lead instead to the release of hydrogen peroxide (peroxide uncoupling). Finally, if 
the positioning of the substrate is not convenient for the abstraction of hydrogen to take place 
(VII), the reactive oxygen atom (compound I) will be reduced to water (oxidase 
uncoupling).[58, 109, 112a] 
Some examples of industrially employed monooxygenase-catalyzed biotransformations are 
given in Table 1-3. The production of dicarboxylic acids by Candida tropicalis is one of the 
most representative industrial processes catalyzed by a cytochrome P450 enzyme, where a 
combination of protein and process engineering was applied to generate a tailor-made 
biocatalyst. This process allows a significantly higher product concentration (>100 g L-1) and 
productivity (1.9 g L-1 h-1).[41b] 
 
Reaction Catalyst Product titer Company/ Ref 
11-Deoxycortisol  
→ Hydrocortisone 
P450lun 
(Curvulara lunata) 
n.a Pfizer Inc./ Bayer Schering 
Pharma AG [115] 
Amorpha-4,11-dien  
→ Artemisinic acid 
CYP71AV1 
(Saccharomyces cerevisiae) 
0.12 g L-1 Amyris Biotechnologies 
Inc. [116] 
Compactin  
→ Pravastin 
CYP105A3 
(Streptomyces sp. Y-110) 
1.0 g L-1 Sankyo Comp./ Bristol 
Myers Squibb Comp. [40] 
n-Tridecane 
→ α,ω-Tridecanedioic acid 
CYP52A1 
(Candida tropicalis) 
166 g L-1 Cognis Inc. [117] 
 Cytochrome P450 BM3 from Bacillus megaterium 1.3.1
Cytochrome P450 BM3 (CYP102A1) was isolated as third P450 from Bacillus megaterium by 
Fulco et al.[118] in the 1980s. The enzyme was expressed as recombinant protein in E. coli[57] 
and sequenced[119] some years after identification. P450 BM3 is particularly interesting for in 
Table 1-3: Industrial biotransformations with cytochrome P450 enzymes. Adapted from Julsing et al.[41b] 
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vitro applications and synthetic processes since it is a soluble and redox self-sufficient 
monooxygenase with the FAD-FMN-reductase and hemoprotein domain on one polypeptide 
chain.[57] A representation of this natural P450-reductase fusion system is shown in Figure 1-9. 
Characterization of the enzyme revealed a molecular weight of 119 kDa, consisting of the 
55 kDa heme-domain and the 65 kDa reductase-domain. The reductase consists of two 
prosthetic flavin groups, FAD and FMN, each of them present in an equimolar ratio.[57] The 
natural fusion system offers several advantages over multi-component systems, such as higher 
expression levels and easier isolation. Besides, trough close proximity of the hemoprotein and 
the reductase partners the electron transfer is very fast, making of P450 BM3 the 
monooxygenase with the highest reported activities so far.[58] The electrons are shuttled within 
one reductase monomer (FAD to FMN) and from the FMN domain of one monomer to the 
heme-domain of the second monomer. Hence, the catalytically functional and predominant 
form is a dimer. Dimerization is most likely dependent on the protein concentration.[120] 
 
 
 
The physiological role of P450 BM3 is still not fully clear. For many years it was assumed that 
straight-chain saturated fatty acids (e.g. lauric acid) were the natural substrate of the enzyme. 
However, these straight-chain fatty acids do not induce the enzymes expression in 
B. megaterium[122] and their oxidation is not fully coupled to the product formation.[58] Some 
studies give evidence on the utilization of branched-chain fatty acids as natural substrates[123], 
since they are major components of membrane lipids in bacteria such as B. megaterium.[124] 
The hydroxylation of linear and branched medium- to long-chain fatty acids (C12-C20) takes 
place in subterminal positions, at the ω-1, ω-2 and ω-3 carbon atoms, with high turnover 
frequencies (up to 3500 min-1) and coupling efficiencies between 88 and 98%.[118a, 118b, 123, 125] 
Several crystal structures of the P450 BM3 heme-domain in the substrate-free and various 
Figure 1-9: Schematic representation of catalytically active cytochrome P450 BM3 dimer. The cytochrome 
P450 from Bacillus megaterium is a soluble and self-sufficient monooxygenase, containing the FAD-reductase 
and the hemoprotein domain on one polypeptide chain. Adapted from Bernhardt[107] and Girvan et al.[121] 
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substrate-bound forms (mainly fatty acids as substrate) have been resolved.[126] Alignment of 
the two forms demonstrated that significant conformational changes in the hemoprotein take 
place upon substrate binding. Re-orientation of side-chains from some residues in the active 
site makes the substrate pocket narrower. These changes reduce the accessibility of solvent 
molecules (e.g. water) to the active site and alter the ligation of the heme iron. The sixth 
coordination of the iron to the axial water ligand is lost allowing the binding of molecular 
oxygen.[126c] The crystal structure of the heme domain revealed a long and mainly hydrophobic 
substrate access channel, containing at the entrance the amino acid residues R47 and Y51, 
which are regarded as gate keeper residues, restricting the entrance of substrates to the active 
site.[127] These two residues regulate the binding of fatty acid substrates, mainly by interaction 
with the carboxyl group of the substrate with R47, and also the accession of water and 
cosolvents such as DMSO.[128] Another key residue in P450 BM3 is F87, which is positioned 
close to the heme iron. In the substrate free structure, F87 is oriented perpendicular to the iron 
center, but rotates almost 90° to reach close proximity to the iron when the substrate is bound. 
The displacement of F87 is probably responsible for the loss of the water-iron interaction.[126c] 
The crystal structures of the FMN-domain and very recently of the FAD-domain were 
resolved.[126a, 129] However, the complete structure of P450 BM3 as fusion of reductase- and 
hemoprotein-domain is not yet available. 
 Evolution of cytochrome P450 BM3 1.3.2
The sole identification and isolation of a specific enzyme as biocatalyst for its implementation 
in a certain synthetic process is not always sufficient. Very often the process requirements are 
not directly met by the wild type (WT) enzyme.[130] In this respect, some intrinsic limitations of 
cytochrome P450 monooxygenases are the rather low stabilities and reaction rates, the 
cofactor-dependency, and in most cases the lacking specificity for an industrial relevant 
product.[131] The development of a tailor-made biocatalyst for industrial applications is 
nowadays feasible using molecular biology methods combined with a medium or high 
throughput screening system. In this way, the protein function is manipulated at the amino acid 
sequence level. Several properties of biocatalysts can be improved using protein evolution 
techniques and a screening (selection) system. Cytochrome P450 BM3 has been engineered 
extensively to broaden the substrate spectra, to enhance reaction activities and rates, to increase 
thermal or process stability, and to accept alternative electron transfer systems.[58, 132] For this 
purpose random mutagenesis, as well as focused mutagenesis which comprises rational and 
semi-rational protein design have been applied effectively.[132a] 
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The rational design of proteins is based on a detailed bioinformatic analysis (in silico). 
Therefore, the DNA or amino acid sequence, the protein structure as well as information on 
structure-function relationships are required. In some cases the amino acid sequence and a 
good homology model are sufficient for preliminary studies. Using in silico analysis the 
identification of specific amino acid positions for focused mutagenesis is possible. Whole 
plasmid amplification with mutagenic primers, for example by Site-Directed Mutagenesis 
(SDM), is the most commonly applied method to introduce site specific mutations of the 
selected amino acid residues. The main advantage of the rational protein engineering is the 
generation of rather small libraries, thereby reducing the screening effort. In addition, it allows 
the rational analysis of the structure-function relationship for a mutated residue. In a similar 
manner, the semi-rational protein design allows randomization of a selected residue to all 20 
possible canonical amino also known as Site-Saturation Mutagenesis (SSM). In this way, the 
best amino acid exchange at the selected position can be detected.[133] To limit the size of a 
library degenerated oligonucleotide primers are commonly employed. NNK-degenerated 
primers code for a total of 32 codons, covering all 20 amino acids exchanges. NDT-
oligonucleotide primers, which code for 12 distinctive amino acids, can also be used for a 
further reduction of the library size.[134] To investigate the synergistic effect of neighbored 
amino acid positions simultaneous saturation can be performed (up to 5 target amino acids), 
using more recently developed methods such as CASTing[135], TrimerDimer[136] or 
OmniChange[137]. 
In contrast to rational design the concept of directed evolution of biocatalysts does not require 
information on structure and function of the protein. Substitutions of single amino acids are 
generated randomly by introducing mutations in a target DNA sequence. The main 
requirements for successful protein evolution are the functional expression of the protein in a 
microbial host and the availability of a high-throughput screening system to sample the 
targeted property.[138] Mutagenesis and screening can thereby be repeated in iterative 
cycles.[132a] The direct evolution strategy is illustrated in Figure 1-10. 
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A direct evolution experiment comprises three steps[132a]: 1) generation of genetic diversity by 
introduction of random mutations, 2) identification of improved variants by means of a reliable 
screening system and 3) isolation of the improved variant followed by iterative cycles of 
diversity generation and screening. The accumulation of beneficial mutations can lead to 
significant improvement of a desired property and also to identification of essential amino acid 
positions in the protein structure, which are referred to as ‘hot spot’ residues. These residues 
can be further randomized by SSM to find the best amino acid exchange for a specific 
residue.[133] Directed evolution also contributes largely to understand structure-function 
relationship of enzymes that cannot be explained by rational approaches.[139] The generation of 
diversity is most commonly achieved by mutagenesis methods such as error-prone polymerase 
chain reaction (epPCR).[140] In an ideal case the introduction of mutations occurs with an even 
frequency, equal distribution and unbiased introduction of mutations throughout the entire gene 
sequence.[139, 141] The commonly employed epPCR method is robust and easy to handle but has 
the disadvantage of a biased mutational spectrum, displaying a higher frequency of transitions, 
a lack of consecutive mutations, and high dependency on the degeneracy of the genetic 
code.[139, 142] In average, an exchange of only 6 amino acids out of 20 will occur.[143] To 
circumvent this limitation the development of alternative methods for diversity generation is 
ongoing. One example is the Sequence Saturation Mutagenesis method (SeSaM) for 
randomization of a gene of interest at virtually every amino acid position, independently of the 
polymerase bias.[141-142] 
Figure 1-10: Scheme of a directed evolution experiment. Three steps are usually employed during the 
evolution of a biocatalyst: 1) Generation of diversity, 2) Screening, 3) Iterative cycles of evolution. Taken from 
Tee and Schwaneberg.[132a] 
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Most products that are attractive for an industrial application of P450 monooxygenases are not 
natural substrates of the enzyme. Therefore, great effort has been applied in enzyme 
engineering to achieve broader substrate spectra. P450 BM3 variants showing hydroxylation 
activities towards non-natural substrates as diverse as pharmaceuticals and complex 
biomolecules, precursors for flavors, fragrances and pheromones, aliphatic hydrocarbons, and 
aromatic substrates have been evolved in the last two decades.[58]  
 
Variant Mutagenesis 
method 
Preferred 
substrate 
TTN[a] Features Ref 
139-3 Random/ 
Recombination 
n-heptane 2100 Enlarged hydrophobic pocket, better alkane binding 
(improved exclusion of substrate from solvent); 
broadened substrate scope (e.g. terpenes), changed 
in regioselectivity. 
[144]
 
35E11 DNA-
shuffling/ 
SSM/ 
Recombination 
n-hexane 6350 Restriction and compartmentalization of the active 
site cavity (better positioning of the alkane chain); 
reduced stability due to accumulation of mutations. 
[145]
 
19A12 SDM/ 
Random 
propane 10550 Changed conformation of helixes (shorter distance 
between helix F and helix B'), significant gain in 
catalytic activity towards short-chain alkanes (i.e. 
propane). 
[146]
 
P450PMO 
R2 
SSM/ 
SDM/ 
Recombination 
propane 45800 Further restriction of the substrate channel, 
exchange to polar residues in the substrate channel; 
highest activity on alkanes reported so far. 
[146]
 
[a]
 TTN: Total Turnover Number (µmolTotal product µmolP450-1).  
 
In particular, P450 BM3 mutants with a changed substrate specificity and selectivity for 
medium- and short-chain alkanes were successfully engineered.[59] Some of the engineered 
P450 BM3 monooxygenase variants and the corresponding substrate preferences are displayed 
in Table 1-4. The P450 BM3 wild type (WT) enzyme hydroxylates C6-C10 alkanes with low 
activities, but does not convert short-chain alkanes (<C6).[59] In contrast, the engineered variant 
19A12 prefers short chain alkanes (C3-C7) as substrates. This variant hydroxylates propane 
with a NADPH-oxidation rate of 420 min-1 and a total turnover number (TTN) of 10550. 
Employing n-heptane as substrate a TTN of 5360 ± 1020 was reached.[146] The representation 
of the heme-domain structure of P450 BM3 in Figure 1-11 highlights a total of 18 amino acid 
residues in the P450 BM3 WT structure that were exchanged in the heme domain of the 19A12 
variant. The substitutions in P450 BM3 variant 19A12 are: R47C, L52I, V78F, A82S, K94I, 
P142S, T175I, A184V, L188P, F205C, S226R, H236Q, E252G, R255S, A290V, A328F, 
L353V, I366V.[146] 
 
Table 1-4: Evolved P450 BM3 variants towards medium- and short-chain alkanes 
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Only two of the mutated amino acid residues, A82S and A328F are directly positioned in the 
active site cavity. The remaining residues are pointing towards the substrate channel (R47, 
V78, L188, A184) or are buried within the protein structure. The mutations along the substrate 
channel and the active site, especially A328F, allow the compartmentalization of the enzymes 
access channel into an inner heme pocket and a more solvent accessible substrate channel.[59] 
The inner heme pocket has thereby a reduced cavity volume.[59] Furthermore, Fasan et al. 
proposed that the substitution L188P represents the so called ‘turning point’ in the substrate 
specificity along the P450 BM3 ‘evolutionary lineage’ towards a higher catalytic activity with 
short-chain alkanes. The variant 19A12 displays only poor activities with long-chain alkanes 
and fatty acids.[59, 146] 
Engineering of P450 BM3 monooxygenases has also focused on the search for alternative 
electron transfer systems and alteration of the cofactor specificity, since the use of the wild 
type enzyme is preferentially towards the NADPH cofactor.[147] Maurer et al. and Neeli et al. 
Figure 1-11: Structure of the substrate-bound heme-domain of cytochrome P450 BM3 (PDB code 
1JPZ)[126c]. Eighteen amino acid residues that were mutated in the P450 BM3 variant 19A12[146] are displayed 
together with the heme in stick representation. The co-crystalized substrate N-palmitoyl glycine (NPG) is shown 
in pink. 
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identified that mutagenesis of W1046 in the reductase domain of P450 BM3 results in a switch 
of cofactor specificity from NADPH to NADH.[147-148] Introducing a second mutation R966D 
into the variant W1046S showed a more than 100-fold increased kcat value compared to the 
separately introduced mutations into the WT enzyme.[149] Figure 1-12 shows the interaction of 
the two key positions W1046 and R966 with the phosphorylated form of the nicotinamide 
cofactor NADP+. 
 
 
 
The conserved aromatic residue W1046 acts as a hydrophobic ‘lid’ over the FAD in the 
reductase domain. Upon binding of NADPH the electron transfer will only occur when the side 
chain of tryptophan moves away.[129] This ‘gate keeper’ residue is therefore important for 
discrimination between the phosphorylated and non-phosphorylated cofactors NADPH and 
NADH.[147, 150] If W1046 is substituted to alanine, histidine or serine, the aromatic interaction 
is reduced together with the specificity for NADPH.[147] 
Figure 1-12: Representation of FAD binding to the ligand NADP+ in the P450 BM3 FAD/NADPH-binding 
domain. Some of the amino acid residues that interact with FAD are shown (W854, R966, W1046). The 
aromatic side chain of W1046 faces the isoalloxazine ring of FAD and acts as a hydrophobic ‘lid’ controlling 
the electron transfer.[129] The crystal structure of FAD/NADP+-binding domain of P450 BM3 (PDB code 
4DQL)[129] was used for visualization. 
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2 Aim of the Thesis 
Selective oxyfunctionalization of alkanes remains a major challenge in the field of organic 
chemistry. In this regard, the implementation of biocatalytical processes under mild reaction 
conditions allows efficient and environmentally sustainable solutions in the oxidative 
chemistry. 
The main goal of this study is the development and the validation of a double oxidation 
cascade making use of monooxygenases for oxyfunctionalization of alkanes in cell free and 
whole cell biotransformation processes according to the reaction Scheme 1. 
 
 
 
The proposed double oxidation concept (Scheme 1) represents a novel synthesis route to obtain 
alkanones and/or chiral alcohols directly from non-activated alkanes in a regio and stereo 
selective manner. In contrast to most chemical oxyfunctionalization reaction, the use of 
biocatalysts allows introducing the desired selectivity in the catalytic process. A 
comprehensive validation of this synthesis concept will contribute to the development of an 
emerging technology platform, based on the application of multi-enzymatic redox processes.   
A P450 monooxygenase from Bacillus megaterium (P450 BM3), catalyzing the initial 
hydroxylation of the alkyl chain, and an alcohol dehydrogenase from Rhodococcus 
erythropolis (RE-ADH) for a subsequent oxidation of the in situ produced alcohol were 
selected to perform the catalytic reaction. n-Heptane was selected as model compound for the 
preliminary evaluation of the described double oxidation concept.  
P450 BM3 monooxygenase has an intrinsically lower activity than most alcohol 
dehydrogenases. Therefore, the P450-catalyzed hydroxylation of the alkane could be the rate 
limiting step in the coupled oxidation reaction. The dependency of monooxygenase-catalyzed 
Scheme 1: Biocatalytic direct oxidation of alkanes to alkanones. 
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reactions on the regeneration of the nicotinamide cofactor is a further constraint for a 
biocatalytic application. In the described concept, the use of an alcohol dehydrogenase for the 
second oxidation step can afford simultaneously an enzyme coupled regeneration of the 
cofactor NAD(P)H. By means of protein engineering, fine tuning of the monooxygenase to 
achieve improved catalytic activity at a low mutational load was intended. The regio- and 
enantioselectivity as well as the cofactor compatibility of the P450 BM3 enzyme should be 
engineered to meet the requirements of the multi-enzymatic cascade process. In this way, a 
suitable cofactor regeneration strategy will be developed. A detailed characterization of the 
engineered monooxygenases as well as a thorough evaluation of the coupled oxidation reaction 
in terms of product formation and yields will give better insight into the process performance 
and the potential for optimization of the oxidation cascade. 
Essential parameters that affect the catalytic performance and the product yields such as 
catalyst or substrate concentration and cofactor regeneration capacity should be investigated 
and optimized. By comparing the performance of in vitro and in vivo biotransformations, the 
catalytic efficiency of the system can be evaluated and further optimized for key parameters 
such as product yields and turnover numbers. Furthermore, a proof of the broad applicability of 
the synthesis concept should be pursuit by expanding the system to other enzymatic 
components (e.g. other alcohol dehydrogenases) and other substrate types. 
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3 Experimental 
3.1 Chemicals, reagents and kits 
All chemicals used were of analytical grade or higher and were purchased, if not stated 
otherwise from Sigma Aldrich (Steinheim, Germany), AppliChem (Darmstadt, Germany), TCI 
Europe (Eschborn, Germany), Merck (Darmstadt, Germany) and Carl Roth (Karlsruhe, 
Germany). Enzymes and dNTPs were purchased from Fermentas (St. Leon-Rot, Germany), 
New England Biolabs (Frankfurt, Germany) and Sigma Aldrich (Steinheim, Germany). All 
employed HPLC-purified oligonucleotides were purchased from Eurofins MWG Operon 
(Ebersberg, Germany). The kits “NucleoSpin Plasmid kit” and “NucleoSpin Gel and PCR 
Clean-up” for purification of plasmid DNA and amplified DNA were purchased from 
Macherey Nagel (Düren, Germany). 
3.2 Devices 
5 L-Bioreactor Biostat MD   Sartorius, Göttingen, Germany 
Äktaprime plus/ UV detector   GE Healthcare, München, Germany 
Bench top shaker Certomat    Sartorius, Göttingen, Germany 
BioPhotometer Plus    Eppendorf, Hamburg, Germany 
Centrifuge 5424    Eppendorf, Hamburg, Germany 
Centrifuge 5810 R    Eppendorf, Hamburg, Germany 
Centrifuge rotors A-4-81, A-4-62-MTP Eppendorf, Hamburg, Germany 
Centrifuge Sorvall RC-6    Thermo Fischer Scientific, Wilmington, USA 
CO-lecture bottle station   Sigma Aldrich, Steinheim, Germany 
Drying cabinet FP 53    Binder GmbH, Tuttlingen, Germany 
DNA electrophoresis chamber  Bio-Rad, München, Germany 
Evaporator IKA RV 10 basic    IKA-Werke, Staufen, Germany 
GC-FID 2010 and 2010-Plus   Shimadzu GmbH, Duisburg, Germany 
GC-MS QP2010    Shimadzu GmbH, Duisburg, Germany 
Gel documentation U:Genius   Syngene, Cambridge, UK 
Glass column TAC15/125PE5-AB-2  YMC Europe GmbH, Dinslaken, Germany  
High Pressure Homogenizer   Avestin, Ottawa ON, Canada 
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Lyophilizer Alpha 1-2 LD plus  Christ, Osterode am Harz, Germany 
Microtiter plate reader Tecan Sunrise Tecan Group AG, Männendorf, Switzerland 
Microtiter plate shaker Microtron  INFORS, Heinsbach, Germany 
Mini-Protean Tetra Cell system  Bio-Rad, München, Germany 
Multipoint magnet stirrer Variomag 15 Thermo Fischer Scientific, Wilmington, USA 
NanoDrop Spectrophotometer 1000  Thermo Fischer Scientific, Wilmington, USA 
PCR thermocycler Mastercycler pro S Eppendorf, Hamburg, Germany 
Polarimeter 241 MC     Perkin Elmer, Waltham, USA 
Power supply Consort EV265  Consort bvba, Turnhout, Belgium 
Sonicator Vibra-Cell VCX130  Sonics & Materials, Newton, USA 
Spectrophotometer Varian Cary 50 UV Agilent Technologies, Darmstadt, Germany 
Thermomixer Comfort   Eppendorf, Hamburg, Germany 
Vortex Genie 2    Scientific Industries Inc., New York, USA 
3.3 Culture media, additives and buffers 
All media were sterilized by autoclaving at 120 °C for 20 min and were stored at room 
temperature until further use. The media additives and the antibiotics were sterilized by 
filtration through a 0.2 µm sterile polyvinylidene difluoride (PVDF) filter (Carl Roth, 
Karlsruhe, Germany) and stored at -20 °C if not stated otherwise.  
LB medium (Lysogeny Broth) contained 10 g L-1 peptone, 5 g L-1 yeast extract, 10 g L-1 NaCl; 
pH 7.5 adjusted with 1 M HCl or NaOH. For the preparation of agar plates the medium 
contained additionally 20 g L-1 agar-agar. The medium was supplemented with the appropriate 
antibiotic depending on the employed E. coli strain (refer to Table 3-2 for plasmids and 
antibiotic resistance). 
SOC medium (Super Optimal broth with Catabolite repression) contained 20 g L-1 tryptone, 
2 g L-1 NaCl, 5 g L-1 yeast extract and 2.5 g L-1 KCl. 10 mM MgCl2, 10 mM MgSO4 and 
20 mM glucose were added as a sterile solution after autoclaving. 
TB medium (Terrific Broth) contained 12 g L-1 peptone, 24 g L-1 yeast extract, 4 g L-1 glycerol 
(solution A; 800 mL), 2.31 g L-1 KH2PO4 and 12.54 g L-1 K2HPO4 (solution B; 200 mL). The 
solutions A and B were prepared separately and mixed together after autoclaving. The 
following medium additives were used for expression of P450 BM3 monooxygenases: Trace 
Elements Solution (0.64 µM CuSO4, 0.69 µM ZnSO4, 0.72 µM MnSO4, 0.76 µM CoCl2, 59.43 
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µM Na2-EDTA, 61.79 µM FeCl3; stored at 4 °C after autoclaving and sterile filtration), 
5-Aminolevulinic acid hydrochloride (ALA; 0.5 mM), Isopropyl-β-D-thiogalactopyranoside 
(IPTG; 0.1 mM), Thiamine hydrochloride (0.1 g L-1) and the respective antibiotic (see Table 
3-2). The additives were added to the TB medium from a 1000x concentrated stock solution. 
E. coli Minimal Medium (EMM) contained 7 g L-1 K2HPO4, 3 g L-1 KH2PO4, 0.57 g L-1 
sodium citrate dihydrate, 0.205 g L-1 MgSO4 heptahydrate, 1 g L-1 (NH4)2SO4, 50 mM Tris 
(pH 7.4). 
Potassium phosphate buffer (KPi-buffer) was prepared in a concentration of 0.1 M and 
varying pH-values (7.0, 7.5 and 8.0) using stock solutions of 1 M K2HPO4 and 1 M KH2PO4. 
The stock solutions were stored at 4 °C until further use. 
Tris/HCl buffer for purification of P450 BM3 monooxygenase contained 0.1 M Tris/HCl, 
pH 7.8 (12.11 g L-1 Tris, pH adjusted by titration with 37% (v/v) HCl). Tris/HCl elution 
buffer contained additionally 1 M NaCl. The buffers were freshly prepared and filtered using a 
glass filter. 
3.4 Strains, vectors and preparation of chemically competent cells  
The strains used in this work (Table 3-1) are E. coli DH5α for sub-cloning and storage, and 
E. coli BL21 Gold (DE3) and E. coli BL21 Gold (DE3) lacIQ1 for recombinant gene 
expression. The vectors used in this work are listed in Table 3-2. 
 
Strain Genotype Origin/ Ref 
E. coli DH5α F- φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ- 
[151]
 
E. coli BL21Gold (DE3) F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI lacUV5-T7 
gene 1 ind1 sam7 nin5])  
Novagen [152] 
E. coli BL21Gold (DE3) 
lacIQ1 
Same as E. coli BL21Gold (DE3); additionally pGRG36-lacIQ 
was employed for site-specific integration of lacI into the 
chromosome 
[153]
 
 
Chemically competent E. coli cells for plasmid transformation were prepared based on a 
standard protocol[154] with some modifications. In the first washing step cells were resuspended 
in TFB-solution 1 (30 mM potassium acetate, 50 mM MnCl2, 100 mM RbCl2, 10 mM CaCl2, 
15% (w/v) glycerol; pH 6.8), in the second washing step cells were resuspended in TFB-
Table 3-1: Strains and their genotype 
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solution 2 (10 mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 15% (w/v) glycerol; pH 6.8). With 
this method a transformation efficiency of 5 x 106 - 1 x 107 cfu µg-1 pUC19 was yielded.  
 
 
3.5 Molecular biology methods 
 Cloning 3.5.1
Two different cloning techniques were used for construction of the protein expression vectors 
for the single expression and the coexpression of the enzymes used in this study (P450 BM3 
monooxygenases and RE-ADH). 
For restriction cloning endonucleases from Fermentas (St. Leon-Rot Germany) or New 
England Biolabs (Frankfurt, Germany) were used according to manufacturer instructions. 
Insert and vector DNA (1-2 µg) were cut for 1 h with 1 U of the corresponding restriction 
endonuclease. The linearized DNA fragments were purified either directly with a DNA clean 
up kit or if necessary by gel extraction and subsequent clean up (NucleoSpin® Gel and PCR 
Clean-up, Macherey-Nagel, Düren, Germany). In case of the pACYCDuet-1 vector additional 
incubation of 60 min at 37 °C with 0.5 U of alkaline phosphatase (Calf Intestinal Phosphatase, 
New England Biolabs, Frankfurt, Germany) per µg vector DNA was performed to reduce 
background by removal of the 5´phosphate groups. The ligation of insert and vector DNA in a 
molar ratio 1:10 was performed using T4 DNA Ligase (Fermentas, St. Leon-Rot Germany) 
following the suppliers recommendations (incubation of 1 h at RT or overnight at 16 °C). The 
ligation reaction (4 µL) was subsequently transformed into chemically competent E. coli cells 
(chapter 3.5.2).  
Table 3-2: Vectors for recombinant protein expression 
Vector Promoter Antibiotic resistance/ 
Concentration 
Replicon Origin/ Ref 
pET28a(+) T7 Kanamycin (Kan)/ 50 µg mL-1 ColE1 
(pBR322) 
Novagen (Merck) [154] 
pALXtreme-1a T7 Kanamycin (Kan)/ 50 µg mL-1 ColE1 
(pBR322) 
Derived from 
pET28a(+), ∆lacIQ [153] 
pACYCDuet-1 T7 Chloramphenicol (Cm)/ 34 µg mL-1 P15A 
(pACYC184) 
Novagen (Merck) 
pKA1 T7 Chloramphenicol (Cm)/ 34 µg mL-1 P15A 
(pACYC184) 
Derived from 
pACYC18 [155] 
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As alternative to restriction cloning the ligase-independent cloning method PLICing 
(Phosphorothioate-based ligase-independent gene cloning) was used.[153] In the first step the 
vector backbone and the target gene were amplified in a polymerase chain reaction (PCR), 
using oligonucleotide primers containing twelve complementary phosphorothioated 
nucleotides and a high-fidelity DNA polymerase. A standard PCR contained the template DNA 
(10-30 ng), 1 U Phusion DNA polymerase, 0.2 mM dNTPs, 1 x Phusion high fidelity buffer 
and 0.2 µM of each primer in 50 µL of final volume. Following temperature program was used 
for amplification in a PCR cycler Mastercycler pro S (Eppendorf, Hamburg, Germany): initial 
denaturation at 98 °C for 2 min, 25 cycles of denaturation at 98 °C for 30 s, annealing at 50-
60 °C for 1 min and elongation at 72 °C for 1 min kb-1. A final elongation step at 72 °C for 
5 min was performed. The annealing temperature was chosen according to the employed 
primers as listed in Table 6-1. Subsequently, the PCR products were analyzed by agarose gel 
electrophoresis and purified using a PCR cleanup kit. Agarose gel electrophoresis was 
performed as described by Sambrook and Russell[156] using a 0.8% (w/v) agarose gel and Roti-
Safe GelStain from Carl Roth (Karlsruhe, Germany) for visualization of DNA. For 
identification of DNA size the GeneRuler 1 kb DNA Ladder from Fermentas (St. Leon-Rot, 
Germany) was used. The template DNA was digested by incubation at 37 °C for 16 h using 
20 U of DpnI endonuclease. 
In the second step chemical cleavage of the introduced phosphorothioated nucleotides was 
achieved by incubation of the amplified DNA with an iodine/ethanol solution. The cleavage 
reaction contained 0.12 pmol vector DNA or 0.2 pmol insert DNA, 6 mM iodine, 6% (v/v) 
ethanol, 50 mM Tris-HCl buffer (pH 9.0) in a final volume of 5 µL. The reaction mix was 
incubated for 5 min at 70 °C. In the last step, the hybridization of the linearized vector and 
insert DNA is performed by mixing equal volumes of the cleavage reactions (typically 5 µL of 
vector and 5 µL of insert) prior to incubation at RT (25 °C) for 5 min. The hybridization 
reaction (commonly 4 µL) was subsequently transformed into chemically competent E. coli 
cells (chapter 3.5.2). 
 Transformation of DNA into chemically competent E. coli cells 3.5.2
For transformation of DNA into chemically competent E. coli cells, 4 µL of the ligation or 
hybridization reaction or 30 to 50 ng of plasmid DNA were employed. The DNA was added to 
100 µL frozen competent E. coli cells followed by incubation for 20 min on ice. DNA uptake 
was achieved by heat-shock at 42 °C for 45 s, followed by incubation for 2 min on ice. For 
regeneration 0.9 mL SOC medium were added to the cells followed by incubation at 37 °C for 
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45 min and 250 rpm. The cells were spread on LB agar plates containing appropriate 
antibiotics. The plates were incubated at 37 °C overnight. 
 Verification of clones 3.5.3
The obtained clones after transformation were verified by colony PCR or by linearization of 
the isolated plasmid DNA using appropriate restriction endonucleases (following the supplier 
instructions) and subsequent visualization by agarose gel electrophoresis as described in 
chapter 3.5.1. For colony PCR a single colony was picked from the agar plate, resuspended in 
15 µL ddH2O and incubated at 98 °C for 15 min to achieve cell lysis and solubilization of 
plasmid DNA. The PCR mixture contained 5 µL of colony DNA, 5 U of Taq DNA 
polymerase, 0.2 mM dNTPs, 1x Taq buffer and 0.4 µM each forward and reverse primer in 
15 µL. Following temperature program was used: initial denaturation at 98 °C for 2 min, 
followed by 25 cycles of denaturation at 98 °C for 30 s, annealing at 58 °C for 30 s and 
elongation at 72 °C for 1 min kb-1. After cyclic amplification a final elongation at 72 °C for 
10 min was performed. 
 Construction of heterologous protein expression strains 3.5.4
 Expression of P450 BM3 monooxygenases and alcohol dehydrogenases 3.5.4.1
Recombinant gene expression of the employed P450 BM3 monooxygenase variants was 
performed using the pET28a(+)-derived pALXtreme-1a vector[153], which is a smaller version 
of the pET vector lacking the lacI gene (appendix, Figure 6-1). To reconstitute regulation of 
the lac-operon the E. coli strain BL21 Gold (DE3) lacIQ1 was used. An overview of the 
generated strains is shown in the appendix section (Error! Reference source not found.). 
The cytochrome P450 BM3 wild type (WT) gene from B. megaterium (CYP102A1) was 
cloned into pALXtreme-1a by PLICing (see chapter 3.5.1). Phosphorothioated oligonucleotide 
primers were used for this purpose (see Table 6-1, Nr. 1-4). For construction of the P450 BM3 
19A12 expression vector the heme-domain of the P450 BM3 19A12 variant[146] was purchased 
as synthetic DNA (Life Technologies, Darmstadt, Germany) and subcloned by  restriction 
cloning (chapter 3.5.1) using endonucleases NcoI and MssI (PmeI) into the pALXtreme-1a 
vector harboring the P450 BM3 WT gene, replacing the wild type heme domain by the 
synthetic 19A12 heme domain. The P450 BM3 variant CM1 was generated by SSM and 
screening (chapter 3.5.7 and 3.9) using oligonucleotide primers for position R255 (Nr. 13, 
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Table 6-4). The P450 BM3 mutants containing the single mutations R255P and P329H were 
constructed using SDM and the corresponding primers (Nr. 1-4, Table 6-3).  
The expression vector pKA1, harboring the (S)-alcohol dehydrogenase from Rhodococcus 
erythropolis (R. erythropolis, RE-ADH)[157], and the (R)-alcohol dehydrogenase gene from 
Lactobacillus brevis (L. brevis, Lb-ADH)[158] were kindly provided by Prof. Dr. W. Hummel 
(Institute of Molecular Enzyme Technology, H.-H.-University, Research Centre Jülich, 
Germany). The Lb-ADH gene was cloned into the expression vector pKA1 by restriction 
cloning (chapter 3.5.1) using the restriction sites NdeI and BamHI. The expression vectors 
were transformed into chemically competent E. coli BL21 Gold (DE3) cells (vector map in 
appendix, Figure 6-2). 
 Construction of NADH-dependent P450 BM3 mutants 3.5.4.2
To switch cofactor specificity of P450 BM3 variants the mutations T1046S and R966D were 
introduced in the P450 BM3 genes WT, 19A12 and CM1 by SDM (chapter 3.5.6) using the 
corresponding forward and reverse primers (Nr. 5-8, Table 6-3). 
 Coexpression strategies for P450 BM3 and ADHs 3.5.4.3
Three different coexpression strategies for the heterologous expression of P450 BM3, RE-
ADH and Lb-ADH in the same E. coli host were tested. An overview of the generated 
coexpression strains is given in the appendix section (Table 6-8). The first strategy consisted of 
transformation of two plasmids in one E. coli strain. For expression of two proteins, the 
plasmids pALXtreme-1a, harboring the corresponding P450 BM3 gene and pKA1, harboring 
the RE-ADH or the Lb-ADH gene were chosen. For expression of three proteins, the 
pALXtreme-1a plasmid containing the operon-fusion P450 BM3-RE-ADH (see below) and the 
pKA1 plasmid containing the Lb-ADH were used (see vector maps, appendix Figure 6-1 and 
Figure 6-2). Chemically competent E. coli BL21(DE3) Gold lacIQ1 cells were transformed with 
50 ng of each plasmid simultaneously and were spread on agar plates containing both 
antibiotics (Chloramphenicol, Kanamycin) for selection. 
The second strategy is based on the coexpression using the commercial vector pACYCDuet-1 
from Merck (Darmstadt, Germany), which contains two multiple cloning sites (MCS; vector 
map, appendix Figure 6-3).[159] Cloning of both target genes was performed by restriction 
cloning (chapter 3.5.1). First, the RE-ADH gene was cloned in the multiple cloning site MCS2 
using the restriction sites NdeI and EcoRV. The restriction site EcoRV was introduced at the 
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end of the RE-ADH gene-sequence by PCR using oligonucleotide primers containing the 
corresponding mutation (Nr. 1-2, Table 6-2). The PCR contained 40 ng pKA1 RE-ADH as 
template, 1 U of Phusion DNA polymerase, 0.2 mM dNTPs, 1x Phusion buffer and 0.4 µM 
each forward and reverse primer in a final volume of 50 µL. Following temperature program 
was used: initial denaturation at 98 °C for 2 min, followed by 25 cycles of denaturation at 
98 °C for 30 s, annealing at 57 °C for 30 s and elongation at 68 °C for 30 s, as well as a final 
elongation at 72 °C for 10 min. The resulting pACYCDuet-1 plasmid containing the RE-ADH 
was used for cloning of the P450 BM3 monooxygenase variants into the multiple cloning site 
MCS1 using restriction sites EcoRI and NcoI, followed by transformation into E. coli BL21 
(DE3) Gold cells. 
The third coexpression strategy is based on the generation of a synthetic operon-fusion for 
simultaneous expression of both proteins from a single T7 promoter in the pALXtreme-1a 
vector. Construction of the synthetic operon-fusion was performed using the PLICing 
methodology. Hence, four phosphorothioated oligonucleotide primers (No. 5-8, Table 6-1) 
were design for amplification of the RE-ADH gene (smaller fragment; insert DNA), and the 
P450 BM3 monooxygenase gene together with the pALXtreme-1a vector backbone (larger 
fragment; vector DNA). A schematic representation of the generated operon-fusion containing 
plasmid is shown in Figure 3-1. 
By means of the forward primer for the RE-ADH gene (RE-ADH Fwd_Op_PTO) a second 
ribosome binding site containing the Shine-Dalgarno sequence (SD: UAAGGAGGU)[160] and 
an optimal sequence spacing[161] between SD and translational initiation (ATG) of 5 
nucleotides was introduced. PLICing was performed as described in chapter 3.5.1 with some 
modifications. 
The vector pALXtreme-1a P450 BM3 was used as template DNA for amplification of the 
vector backbone. Prior to amplification the plasmid was linearized by digestion using the 
EcoRI restriction site. RE-ADH was amplified directly from the circular pKA1 plasmid. A 
two-step PCR was used as described in chapter 3.5.6. In the first step, 5 cycles of linear 
amplification with one single primer were carried out with an elongation time of 9 min for 
P450 BM3 and of 2 min for RE-ADH). For the second exponential amplification step with 
both primers 25 cycles and an elongation time of 6 min for P450 BM3 and 1 min for RE-ADH 
were used. The resulting amplified products for PLICing are shown in the appendix section 
(Figure 6-7). 
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PlICing, transformation in chemically competent E. coli BL21(DE3) Gold lacIQ1 cells and 
verification of the generated coexpression clones was performed as previously described in 
chapter 3.5.2. 
 
 
 
 
 
 
 DNA sequencing 3.5.5
The generated plasmids for single expression and coexpression of recombinant proteins used in 
this work were verified by sequencing of the target genes. Isolation and purification of plasmid 
DNA was performed using the NucleoSpin Plasmid kit from Macherey Nagel (Düren, 
Germany) following the supplier instructions. Concentration of DNA was determined with the 
NanoDrop spectrophotometer 1000 (Thermo Scientific, Wilmington, USA). Plasmid DNA 
pALXtreme-1a BM3-RE-ADH
6129 bps
1000
2000
3000
4000
5000
6000
RE-ADH Fwd_Op_PTO 3166
BM3 Rev_Op_PTO 3177C
BM3 Fwd_Op_PTO 4241
RE-ADH Rev_Op_PTO 4252C
P450 BM3
RBS2
RE-ADH
T7 terminator
KanR
T7 promotor
RBS1
Figure 3-1: Plasmid map of the expression vector operon-fusion pALXtreme-1a P450 BM3-RE-ADH. 
Nucleotide sequences containing the PTO-primer annealing sites for PLICing (Phosphorothioate-based ligase-
independent gene cloning) are indicated below (red). Generation of an operon-fusion between P450 BM3 and RE-
ADH is achieved by introducing a second ribosome binding site between both gene, consisting of the Shine-
Dalgarno (SD) sequence and a spacing of 5 nucleotides between SD and translation initiation codon (ATG). 
RE-ADH Rev_Op_PTO 
BM3 Fwd_Op_PTO 
BM3 Rev_Op_PTO 
RE-ADH Fwd_Op_PTO 
SD     spacer 
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containing P450 BM3 was sent for sequencing at Eurofins MWG Operon (Ebersberg, 
Germany) using appropriate oligonucleotide primers (sequencing primers Nr. 1 to 4, appendix 
Table 6-6). Sequencing of SSM clones of P450 BM3 was done partially covering gene 
fragments containing the targeted codon. In this case sequencing was performed in 96-well 
MTPs at GATC Biotech AG (Konstanz, Germany) using primers Nr. 1 or 2 (appendix Table 
6-6). 
 Site-Directed Mutagenesis 3.5.6
The introduction of point mutations in the target genes was achieved using a modified two-
stage[162] Site-Directed Mutagenesis (SDM) protocol based on the QuikChange SDM System 
developed by Stratagene (La Jolla, CA). 
In the first PCR-step linear amplification of the target DNA with a single oligonucleotide 
primer is performed (forward or reverse), avoiding in this way primer dimerization. In the 
second PCR-step equal parts of amplified products from the first step are mixed together 
followed by exponential DNA amplification. Both forward and reverse oligonucleotide primers 
containing the desired mutation were designed based on the recommendations of the 
QuikChange Site-Directed Mutagenesis manual. The employed oligonucleotide primers are 
listed in the appendix section, Table 6-3. 
The PCR mixture for SDM contained template DNA (10-20 ng), 1 U Phusion DNA 
polymerase, 0.2 mM dNTPs, 1x Phusion buffer and 0.2 µM forward or reverse primer in 50 µL 
final volume. Following temperature program was used for the first amplification step: initial 
denaturation at 98 °C for 2 min, followed by 3 cycles of denaturation at 98 °C for 30 s, 
annealing at 55 °C for 1 min and elongation at 72 °C for 1 min kb-1. Subsequently, 25 µL of 
forward and 25 µL of reverse reaction were mixed together and 0.5 U of Phusion DNA 
polymerase was added. The second amplification step was analogous to the first one, using 15 
amplification cycles instead of 3 and followed by a final elongation step at 72 °C for 5 min. 
The PCR products were analyzed by agarose gel electrophoresis and purified using a PCR 
cleanup kit. Template DNA was digested by addition of 20 U of DpnI endonuclease followed 
by incubation at 37 °C for 16 h. The mutated plasmid (30 to 50 ng) was transformed into 
chemically competent cells (chapter 3.5.2). 
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 Site-Saturation Mutagenesis 3.5.7
Site-saturation Mutagenesis (SSM) is used to introduce a randomize codon at a specific amino 
acid position in the gene of interest. The employed procedure is analogue to SDM except for 
the use of so called wobble primers, which contain instead of a single point mutation a 
randomized (wobble) codon. Degenerated NNK-oligonucleotides were used, where N codes 
for G, A, T and C, and K codes for G and T, enabling the introduction of all 32 base triplets 
into a gene sequence. The targeted codon is therefore randomized to all 20 canonical amino 
acids. The design of oligonucleotide primers and the mutagenic procedure were performed as 
described for the SDM protocol (chapter 3.5.6). 
The oligonucleotide primers used for generation of randomized mutant libraries of P450 BM3 
wild type (WT) as starting template are listed in Table 6-4. Employing P450 BM3 variant 
19A12 as template the primers in Table 6-5 were used for SSM. In both cases the smaller 
vector pALXtreme-1a was used, allowing for a higher transformation efficiency and higher 
number of obtainable colonies for generation of the mutant library. The mutated plasmid (30 to 
40 ng) was transformed into competent E. coli BL21 (DE3) Gold lacIQ1 cells, following 
cultivation on agar plates containing kanamycin. 
 Error-prone PCR using P450 BM3 variant 19A12 as template 3.5.8
Error-prone PCR (epPCR) is a modified version of the standard PCR procedure to increase the 
natural error rate of the employed DNA polymerase, typically a Taq DNA polymerase. One 
possible way to enhance the error rate is to supplement the PCR with altered concentrations of 
MnCl2, modified dNTPs ratios or the use a highly error-prone polymerase.[163] 
In this study varying concentrations of MnCl2 (0, 10, 20, 40 and 60 nM) were tested, along 
with the use of an optimized error-prone-Taq DNA polymerase, to achieve an inactivation ratio 
of 50%. The mutation frequency in an epPCR library can be estimated on the basis of the 
inactivation ratio (fraction of inactive clones) by sampling a small number of clones, 
commonly 90 clones in a MTP. In previous experiments an inactivation ratio of 50% showed 
to be beneficial when screening for enhanced activity of P450 BM3 monooxygenases.[164] 
Therefore, an inactivation ratio of 50% was pursuit to identify clones with improved catalytic 
performance. 
Phosphorothioated oligonucleotide primers 1 and 2 (appendix Table 6-1) were used for 
amplification of the target gene DNA (P450 BM3 19A12) and primers 3 and 4 (appendix Table 
6-1) for vector DNA (pALXtreme-1a). The epPCR mixture (50 µL) for amplification of the 
EXPERIMENTAL 
 
 
42 
 
P450 BM3 gene contained 30 ng of template DNA, 5 U epTaq DNA polymerase, 0.2 mM 
dNTPs, 1x epTaq buffer, 0-60 nM MnCl2 and 0.4 µM each forward and reverse primer. 
Following temperature program was used: initial denaturation at 94 °C for 2 min, followed by 
25 cycles of denaturation at 94 °C for 30 s, annealing at 58 °C for 30 s and elongation at 68 °C 
for 1.5 min. After exponential amplification, a final elongation at 68 °C for 10 min was 
performed. The vector DNA was amplified under the same conditions, in the absence of MnCl2 
and using the high fidelity Phusion DNA polymerase (1 U) instead of the epTaq DNA 
polymerase. Cloning and transformation of the randomly mutated gene for generation of a 
mutant library was carried out using PLICing as described in chapter 3.5.1 and 3.5.2. 
3.6 Cultivation of E. coli for heterologous protein expression in 
shake flasks 
 Expression of recombinant P450 BM3 monooxygenases 3.6.1
The cultivation of recombinant E. coli strains for heterologous expression of the different P450 
BM3 monooxygenase variants took place in a volume of 50 to 400 mL, using 0.25 to 
2 L Erlenmeyer flasks. A preculture of 4 mL LB medium, supplemented with the respective 
antibiotic (Table 3-2), was prepared by inoculation from a 25% (v/v) glycerol stock of the 
corresponding strain and subsequent incubation at 37 °C and 250 rpm for 16 h overnight. The 
main culture in TB medium (see chapter 3.3), supplemented with the respective antibiotic and 
trace elements was inoculation with 1% (v/v) preculture and was incubated at 37 °C and 250 
rpm until an OD600 of 0.8 to 1 was reached (typically after 2.5 h). Protein expression was 
induced by addition of 0.1 mM IPTG, 0.5 mM ALA and 0.1 g L-1 thiamine and the flask was 
further incubated at 30 °C and 250 rpm for 20 h. 
In the course of this study optimization of the expression temperature was conducted and a 
temperature of 25 °C was selected for enhanced expression of P450 BM3 monooxygenase 
variants. E. coli cells were harvested by centrifugation (10 min, 4500 g at 4 °C) and the cells 
pellets were washed in 0.1 M KPi buffer (pH 8.0) if not stated otherwise. The cell pellets were 
stored at -20 °C until further use. 
 Expression of recombinant RE-ADH 3.6.2
The RE-ADH was expressed and partially purified according to a published protocol[155] with 
minor modifications. An E. coli BL21 Gold (DE3) pKA1 RE-ADH preculture was prepared in 
LB medium containing chloramphenicol (Cm; 34 µg mL-1; 37 °C, 250 rpm, 16 h overnight). 
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The main culture (50 mL LB medium/Cm) was inoculated with 1% (v/v) of the preculture and 
was cultivated at 37 °C and 250 rpm. After reaching an OD600 of 0.5 the expression was 
induced by addition of 25 µM IPTG and 1 mM ZnCl2 followed by cultivation for 20 h at 30 °C 
and 150 rpm. Cells were harvested by centrifugation (10 min, 4500 g at 4 °C) and the cell 
pellet was frozen until further use.  
 Coexpression of P450 BM3 monooxygenase and alcohol dehydrogenase 3.6.3
For coexpression of two proteins, a P450 BM3 monooxygenase and an alcohol dehydrogenase 
(RE-ADH or Lb-ADH), or coexpression of three proteins, the P450 BM3 and two ADHs in 
one strain (RE-ADH and Lb-ADH), the established protocol for expression of P450 BM3 was 
used (chapter 3.6.1), taking into account the addition of the corresponding antibiotics. The 
coexpression strains used in this study, together with the corresponding antibiotic resistance are 
summarized in the appendix section (Table 6-8). In addition, if the RE-ADH gene was present 
in the employed genetic construct, the main culture in TB-medium was supplemented with 1 
mM ZnCl2 directly after induction of the expression with IPTG.  
3.7 Cultivation of E. coli for heterologous expression in Microtiter 
Plates 
 Expression of a P450 BM3 monooxygenase mutant library  3.7.1
Generation of mutant libraries for activity screening was carried out by cultivation of a single 
clone in each well of a flat bottom 96-well microtiter plate (MTP) (Greiner bio-one, 
Frickenhausen, Germany) after the mutagenic procedure (SSM or epPCR). 
First a master plate was generated, which serves for long term storage and for inoculation of 
expression cultures. In each well of the MTP 150 µL LB medium, supplemented with 
kanamycin (50 µg mL-1) were pipetted. Single colonies were picked from a transformation agar 
plate using sterile toothpicks and were transferred to the corresponding well for inoculation. 
The MTP was cultivated for 16 h in a MTP-shaker (Microtone INFORS, Heinsbach, Germany) 
at 37 °C, 900 rpm and 70% air humidity. After cultivation 100 µL of 50% (v/v) glycerol were 
added to each well for storage of the plate at -80 °C. As reference samples the E. coli strains 
containing the template plasmid pALXtreme-1a P450 BM3 WT or P450 BM3 19A12 (starting 
activity control) and the empty vector (no activity control) were cultivated in triplicate in the 
same MTP. When the WT enzyme was used as starting material for mutagenesis the variant 
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19A12 served as positive control. A schematic representation of the layout of a master plate is 
shown in Figure 3-2. 
In total 2 plates with 174 clones each per saturated amino acid position were generated. The 
randomized library statistics were calculated using the web-interface GLUE-IT 
(http://guinevere.otago.ac.nz/cgi-bin/aef/glue-IT.pl).[165] Using a library size of 174 clones  and 
NNK-degenerated primers a completeness of 99.76% and a probability of 95.3% for all amino 
acids to be present in the library is achieved. 
 
 
 
Protein expression of the mutant library took place in 96-well 2 mL-deepwell microtiter plates 
(Eppendorf, Hamburg, Germany). After thawing the master plate was first replicated in a new 
flat bottom MTP containing LB medium (50 µg mL-1 kanamycin) using a 96-pin replicator. 
This preculture plate was incubated as described above and was further used for inoculation 
(1% v/v) of 600 µL TB medium, supplemented with trace elements (1x), kanamycin 
(50 µg mL-1), ALA (0.5 mM), IPTG (0.1 mM) and thiamine hydrochloride (0.1 g L-1), per well 
of the deep well MTP (chapter 3.3). The plate was covered with a sterile lid and sealed with 
parafilm for incubation at 30 °C, 900 rpm and 70% air humidity for 20 h in the MTP-shaker. 
The cells were harvest by centrifugation at 3480 g and 4 °C. The supernatant was discarded 
and the plate containing the cell pellets was stored at -20 °C overnight or until further use for 
screening. 
 Preparation of P450 BM3 crude cell lysates in MTP format 3.7.2
Cell pellets from the expression in MTP (chapter 3.7.1) were thawed for 20 min prior to 
resuspension in 0.1 M KPi buffer (pH 8.0), using a volume of 350 µL in the case of P450 BM3 
WT or 150 µL for P450 BM3 19A12. Thereafter, 250 µL freshly prepared lysozyme solution 
(5 g L-1, 0.1 M KPi buffer pH 8.0) was added to each well and the plate was incubated at 37 °C 
Figure 3-2: Layout of a master plate for cultivation and long term storage of a P450 BM3 mutant library. 
The reference samples P450 BM3 WT (red), P450 BM3 19A12 (blue) and the empty vector strain (gray) are 
cultivated in triplicate and all other wells contain one single mutagenesis clone. 
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for 1 h in the MTP-shaker (900 rpm, 70% humidity). The crude cell lysate was gained by 
centrifugation for 10 min (3480 g, 4 °C). 
3.8 Fermentation of E. coli for heterologous protein expression 
The fermentation of E. coli strains for heterologous expression of the different P450 BM3 
monooxygenase variants and production of higher amounts of cell mass was carried out in a 
5 L-bioreactor Biostat MD from Sartorius (Göttingen, Germany). The cultivation in the 
fermentor was analogue to the cultivation in shaking flask using a working volume of 5 L TB 
medium supplemented with kanamycin (50 µg mL-1) and trace elements (chapter 3.3). 
A constant aeration rate of 0.5 vvm (2.5 L min-1) and stirrer speed of 400 rpm were used. The 
initial pH of 7.1 was maintained throughout the fermentation using 15% (v/v) ammonia and 
30% (v/v) phosphoric acid solutions. To regulate foam formation (if necessary) polyethylene 
glycol was used. The cultivation was started by inoculation with an overnight culture of the 
respective E. coli strain in 100 mL LB medium (50 µg mL-1 kanamycin; 37 °C for 16 h, 
250 rpm). The temperature was controlled at 37 °C until an OD600 of 1 was achieved. At this 
point the protein expression was induced by addition of IPTG (0.1 mM), as well as ALA 
(0.5 mM) and thiamine hydrochloride (0.1 g L-1) as additives, and the temperature was 
decreased to 25 °C and was kept constant for the next 24 to 26 h until the cell harvest. 
In the course of the fermentation the dissolved oxygen content (pO2), the temperature, the pH 
and the stirrer speed, as well as the pumping volumes of acid, base and antifoam were 
measured online. For monitoring cell growth by measurement of OD600 and protein expression, 
samples of culture broth were taken regularly over the first 8 h and at the end of the 
fermentation. The protein expression was evaluated by SDS-PAGE and the P450 BM3 
concentration determined by CO-difference spectroscopy (chapter 3.10.1). For cell harvest the 
cells were separated from the culture broth by centrifugation (15 min, 4500 g at 4 °C). Cell 
pellets were washed in 0.1 M KPi buffer (pH 8.0) and stored at -20 °C until further use. 
3.9 Screening of mutant libraries with the NADPH depletion assay 
Screening for activity towards n-heptane was achieved following a published procedure.[132b] 
The reaction mixture for measuring NADPH-depletion[166] in flat bottom MTPs contained if 
not stated otherwise n-heptane (1 mM), DMSO as cosolvent (4% v/v), crude cell lysate (50 µL; 
chapter 3.7.2) and NADPH (0.2 mM) in a final volume of 250 µL KPi buffer (0.1 M; pH 8.0). 
Before addition of NADPH the mixture containing cell lysate and substrate was incubated for 
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5 min at RT. In the meantime, the blank value of the entire plate (for each well) was recorded. 
The reaction was started by addition of the NADPH and immediately thereafter absorption at 
340 nm over 10 min in 9 s intervals (60 cycles) was measured using a MTP reader Tecan 
Sunrise (Tecan Group AG, Männedorf, Switzerland). A plate without addition of substrate but 
with DMSO (cosolvent) as control reaction was prepared and measured in an analogous 
manner. 
The activity of each P450 BM3 clone towards hydroxylation of n-heptane was correlated to the 
depletion of the NADPH cofactor during the reaction. NADPH-depletion values were 
calculated as slope of the absorption decrease during the first 60 s (linear range). For each well 
the corresponding blank value was subtracted from the absolute absorption value to correct for 
the background signal. The relative activity of each clone was defined as ratio between the 
NADPH-depletion values of the respective clone and the average value of the starting activity 
control (P450 BM3 WT or P450 BM3 19A12). A plate containing in 93 wells the parent strain, 
and in the 3 remaining wells the empty vector strain as a negative control, was screened in an 
analogous way to determine the standard deviation of the assay. Clones displaying an enhanced 
activity in comparison to the parent template were selected for a rescreening using the above 
mentioned procedure. Based on the relative activity and the sequencing results (MWG Eurofins 
DNA, Ebersberg, Germany) detection of improved P450 BM3 variants was performed. 
3.10 Protein preparation and analytics 
 Evaluation of protein expression by SDS-PAGE 3.10.1
Protein expression was evaluated using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) as described by Sambrook and Russell.[156] 10% SDS-PAGE gels 
were used for electrophoresis for 75 min at 30 mA in a Mini-Protean Tetra Cell system from 
Bio-Rad (München, Germany). As a marker 4 µL of Page Ruler Prestained Protein Ladder 
from Fermentas (St. Leon-Rot, Germany) were used. For protein visualization gels were 
stained in a Coomassie Brilliant Blue solution (0.25% v/v coomasie, 45.5% v/v methanol, 
9.2% v/v acetic acid) for 20 min, followed by destaining in 10% (v/v) acetic acid solution 
overnight. 
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 Quantification of P450 concentration by CO-difference spectroscopy  3.10.2
The concentration of active P450 BM3 monooxygenase in purified samples or lyophilized 
crude cell lysates was determined from the CO-difference spectra of the reduced heme-iron 
(absorption maximum at 450 nm) using a standard procedure by Omura and Sato[108]. 
Lyophilized enzyme samples from purified protein or cell lysate were resuspended in 0.1 M 
KPi buffer (pH 8.0). The CO-difference spectra was recorded with a Varian Cary 50 
spectrophotometer (Agilent Technologies, Darmstadt, Germany) after reducing the sample by 
addition of sodium dithionite and gassing with carbon monoxide for 1 min using a lecture 
bottle station (Sigma Aldrich, Steinheim, Germany). The solely reduced sample served as 
reference to subtract the baseline signal. 
 
 
 
Figure 3-3 shows the typical CO-difference spectrum of a P450 BM3 monooxygenase. For 
calculation of the P450 BM3 concentration the Lambert-Beer law equation and an extinction 
coefficient of 91 mM-1 cm-1 were used. 
 Preparation of crude cell lysates 3.10.3
For preparation of P450 BM3 crude cell lysates frozen cell pellets were resuspended in 0.1 mM 
KPi buffer (pH 8.0) to obtain a cell-suspension of 20-25% (w/v). In case of the RE-ADH the 
frozen cell pellet was resuspended in 0.1 M KPi buffer (pH 6.0) to obtain a cell-suspension of 
1.3 g wet cells per 20 mL. Cell disruption was achieved using either 3 cycles of sonication with 
a Vibra-Cell VCX130 (Sonics & Materials, Newton, USA; 40% amplitude, 30 s/cycle, 30 s 
pause between cycles) for volumes up to 5 mL or an Avestin EmulsiFlex-C3 high pressure 
homogenizer (Ottawa, ON, Canada) for larger volumes by application of three cycles of 
1500 bar. 
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
400 450 500
A
b
so
rp
ti
o
n
  
[-
] 
Wavelenght  [nm]
Figure 3-3: Typical CO-difference spectrum of P450 BM3 WT for quantification of P450 monooxygenase 
concentrations. 
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The lysates were centrifuged (30 min, 24500 g at 4 °C) in a Sorvall RC-6 Plus centrifuge 
(Thermo Scientific, Rockford, IL, USA) and further clarified by filtration trough a 0.45 µm 
filter (Roth, Karlsruhe, Germany). For preparation of a non-purified and lyophilized enzyme 
sample, the crude cell lysate was shock-frozen in liquid nitrogen, lyophilized for 48 h at -54 °C 
in an Alpha 1-2 LD plus Freeze dryer (Christ, Osterode am Harz, Germany) and stored 
at -20 °C until further use. 
 Purification of P450 BM3 variants 3.10.4
Expression of the NADH-dependent monooxygenase mutants and preparation of crude cell 
lysates for further purification were performed as described above in a 400 mL-culture, except 
that cell pellets were resuspended in the purification buffer (0.1 M Tris/HCl, pH 7.8). The fresh 
cell lysates were subsequently purified by means of anion exchange chromatography using a 
Toyopearl DEAE 650S matrix (Tosoh Bioscience, Stuttgart, Germany) and an established 
protocol making use of a two-step elution with sodium chloride with small modifications.[167] 
An Äktaprime Plus system with UV-detector (GE Healthcare, München, Germany) and a 
packed glass column (TAC15/125PE5-AB-2 Kronlab, now YMC Europe GmbH, Dinslaken, 
Germany) were used for purification and collection of the eluate. The column was initially 
equilibrated with 0.1 M Tris/HCl buffer (pH 7.8), followed by loading of the cell lysate and 
binding of the protein to the matrix at a constant flow rate of 5 mL min-1. In the first washing 
step with 14% of the elution buffer (140 mM NaCl; conductivity 17 mS cm-1) weaker bounded 
proteins were eluted. In a second step using a gradient between 14 and 25% of elution buffer 
(140-250 mM NaCl; conductivity 17-22 mS cm-1) the P450 BM3 monooxygenase was eluted 
and collected in 5 mL fractions. A 10% SDS-PAGE gel was used for visualization of the purity 
of the eluted proteins. The fractions with highest purity were pooled together. The selected 
fractions were concentrated using an Amicon Ultra-4 centrifugation tube (30 kDa cut-off; 
Millipore, Schwalbach, Germany), followed by desalting and buffer exchange in KPi buffer 
(0.1 M; pH 8.0) using a PD-10 gel-filtration column (GE Healthcare, München, Germany). A 
purity of 80 to 90% was estimated after electrophoresis in a 10% SDS-PAGE[168] gel. 
The purified monooxygenase mutants were shock-frozen in liquid nitrogen, lyophilized for 48 
h at -54 °C in an Alpha 1-2 LD plus Freeze dryer (Christ, Osterode am Harz, Germany) and 
stored at -20 °C until further use. 
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 Characterization of P450 BM3 monooxygenases in cuvette 3.10.5
Spectrophotometric activity assay: To assay activity of the P450 BM3 mutants NADH or 
NADPH depletion was monitored in a cuvette at 340 nm using a Varian Cary 50 
spectrophotometer (Agilent Technologies, Darmstadt, Germany). The concentration of active, 
P450 BM3 monooxygenase (purified or as crude cell lysate) was first determined as described 
in chapter 3.10.2.  The standard reaction mixture consisted of n-heptane (10 mM), ethanol as 
cosolvent (2% v/v), and P450 BM3 (0.2 µM) in KPi buffer (950 µL, 0.1 M; pH 8.0) if not 
stated otherwise. After 5 min of pre-incubation the reaction was started by addition of NADH 
or NADPH from a stock solution (50 µL, 8 mM). When the cofactor was almost consumed the 
reaction was quenched by addition of concentrated HCl (100 µL, 37% v/v) and was directly 
extracted for quantification of products via GC (see chapter 3.13). The initial oxidation rate (in 
µmolcofactor µmolP450-1 min-1 or abbreviated min-1) of the corresponding P450 BM3 
monooxygenase was calculated for the first 20 s of the catalyzed hydroxylation reaction using 
the slope (in min-1) of the resulting regression curve. Quantification of the exact amount of 
consumed NAD(P)H (in µmol) was accomplished using the extinction coefficient εNAD(P)H of 
6.22 mM-1 cm-1 and the Lambert-Beer law equation. 
Determination of Turnover Frequency, Coupling Efficiency and Specific Activity: The maximal 
initial product formation rate or turnover frequency (TOF; in µmolproduct µmolP450-1 min-1 or 
abbreviated as min-1) of the corresponding P450 BM3 monooxygenase was also calculated for 
the first 20 s of the reaction, based on the quantified total product amount via GC and the 
coupling efficiency determined for the entire reaction. Coupling efficiencies (in %) for the 
hydroxylation of n-heptane were calculated for each monooxygenase as ratio between total 
product concentration and consumed cofactor in the course of the reaction (started by 
NAD(P)H addition until quenching). The specific activity (in U gP450-1) was calculation using 
the corresponding turnover frequency value and a molecular weight of P450 BM3 of 119 kDa 
(0.119 g µmol-1). 
 Purification of RE-ADH 3.10.6
Since the RE-ADH is highly thermo-stable (up to 65 °C) it can be partially purified using one 
step of heat treatment as described by Abokitse et al.[157] The freshly prepared crude cell lysate 
was incubation for 15 min at 65 °C. The removal of precipitated proteins was performed by 
centrifugation (30 min, 24500 g at 4 °C). The supernatant was further clarified by filtration 
trough a 0.45 µm filter (Roth, Karlsruhe, Germany) and stored at 4 °C. A purity of nearly 80% 
was estimated according to SDS-PAGE visualization.[168] 
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 RE-ADH and GDH activity determination 3.10.7
The activity of the heat-treated (S)-alcohol dehydrogenase from Rhodococcus erythropolis 
(RE-ADH) and of the commercially available glucose dehydrogenase (GDH) from 
Pseudomonas sp. (Sigma Aldrich, Steinheim, Germany) was assayed spectrometrically with a 
Varian Cary 50 (Agilent Technologies, Darmstadt, Germany) by measuring the increase in 
absorption of NADH at 340 nm. Volumetric activities (in U mL-1) were calculated using the 
Lambert-Beer law equation. 
For RE-ADH: The reaction mixture (999 µL; cuvette) contained the corresponding alcohol (1-, 
2-, 3- or 4-heptanol; 10 mM) and NAD+ (1 mM) in KPi buffer (0.1 M; pH 8.0). The reaction 
was started by addition of RE-ADH (1 µL; partially purified). One unit was defined as the 
amount of enzyme that reduces 1 µmol of NAD+ per minute. 
Total protein concentration was determined by the method of Bradford using bovine serum 
albumin as standard.[169] A control reaction with ethanol (4% v/v), which is used in the cascade 
reaction as cosolvent, was also recorded and revealed no activity of RE-ADH towards ethanol. 
The KM-value of the RE-ADH for the cofactor NAD+ using 2-heptanol as substrate was 
determined in an analog manner, varying the NAD+ concentration (1 to 4000 µM). 
For GDH: the reaction mixture contained KPi buffer (1 mL, 0.1 M; pH 8.0), D-glucose 
(10 mM) and NAD+ (1 mM). The reaction was started by addition of GDH (1µL). The KM-
value of the GDH for the cofactor NAD+ using D-glucose as substrate was determined in an 
analogous manner, varying the NAD+ concentration (3 to 2000 µM).  
For determination of KM-values the slope of each absorption curve was plotted against the 
NAD+ concentration and the resulting data was fitted using a Michaelis-Menten plot and 
Origin 8.6 software (OriginLab Corporation, Northampton, MA, USA). 
3.11 In vitro conversion of n-heptane  
 Hydroxylation of n-heptane by P450 BM3 monooxygenases 3.11.1
To determine product formation the in vitro conversion of n-heptane was monitored over the 
first 24 h (1 mL, stirred screw top vial, room temperature). A typical reaction mixture 
contained, if not stated otherwise, n-heptane (7 µL, 50 mM) and ethanol (13 µL, 1.3% v/v) as 
cosolvent for enhanced solubility of the organic substrate, P450 BM3 (0.5 µM), and catalase 
(600 U, to remove traces of hydrogen peroxide) in KPi buffer (1 mL, 0.1 M; pH 8.0). After an 
incubation period of 5 min the reaction was started by addition of NADH (2 mM). After a 
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reaction time of 10, 30, 60, 120, 240 min and 24 h, the reaction mixture (1 mL) was transferred 
to a reaction vessel containing HCl (100 µL) to stop the reaction and the aqueous phase was 
directly extracted as described in chapter 3.13.1. Quantification of the produced heptanol and 
heptanone regioisomers was carried out by GC analysis (chapter 3.13.2). The catalytic 
performance of the system was evaluated in terms of total turnover numbers (TTN). This TTN 
value refers to the P450 BM3-catalyzed hydroxylation, calculated for a 24 h reaction time as 
ratio between total product concentration (in µM) and concentration of the P450 BM3 catalyst 
(in µM). 
 One-pot double oxidation of n-heptane by P450 BM3 and RE-ADH 3.11.2
The biocatalytic double oxidation of n-heptane was evaluated using the P450 BM3 
monooxygenase variants together with the RE-ADH in a one-pot reaction. The reaction was 
carried out in an analogue manner as the sole hydroxylation reaction describe in chapter 3.11.1. 
The only modification consisted in the addition of 10 U of RE-ADH (referring to the activity 
determined with 2-heptanol) to the reaction mix. Sampling of the reaction was performed in 
parallel to the sole P450 reaction.  
For the reaction engineering experiments an incubation of 24 h and a varying concentration of 
the different reaction compounds was used. The TTN values of the double oxidation cascade 
were calculated as described in chapter 3.11.1. The yield for the enzymatic resolution of 
(R)-heptanol in the second RE-ADH-catalyzed oxidation step are calculated for each 
(R)-heptanol as product, starting from the enantiomeric mixture of (R)/(S)-2-heptanol or 
(R)/(S)-3-heptanol (and not n-heptane) as substrate. For the calculation of yields conversion of 
the non-chiral 1- and 4-heptanol was not considered. The products were quantified by chiral 
GC analysis as mentioned in chapter 3.13.4. 
 One-pot double oxidation of n-heptane with supplementation of glucose 3.11.3
dehydrogenase 
In parallel to the double oxidation reaction of n-heptane described in chapter 3.11.1, a second 
oxidation reaction containing a supporting NADH-regeneration system was performed. In this 
case glucose dehydrogenase (1 U) and D-glucose (2 mM) were added to the reaction mixture. 
The reaction samples were treated in an analogue manner as described in chapter 3.11.2 for 
quantification of products and calculation of TTNs. 
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3.12 Whole cell catalysis for double oxidation cascades 
The whole cell conversion of n-heptane and cyclooctane was carried out using E. coli strains 
expressing a single P450 BM3 monooxygenase or co-expressing the monooxygenase and an 
alcohol dehydrogenase (RE-ADH). The employed strains are specified in the appendix section 
(Error! Reference source not found. and Table 6-8). 
Selected E. coli strains were cultivated and expressed either in shaking flasks (chapter 3.5.6) or 
in a 5 L-bioreactor (chapter 3.8). After cultivation, the frozen cell pellets were thawed and used 
for the conversion reactions. P450 content and cell dry weight were determined for each batch 
of cells used in the biotransformation experiments.  
 Correlation of optical density to cell dry weight and P450 content 3.12.1
To characterize recombinant E. coli cells expressing a distinctive P450 BM3 monooxygenase 
from a single cultivation batch, the P450 content and the cell dry weight were correlated to a 
specific optical density at a wavelength of 600 nm (OD600). Cells were resuspended in 0.1 M 
KPi-buffer (pH 8.0) to obtain homogeneous mixtures with an approximated OD600 of 30, 40, 
50 and 60. For each adjusted OD600 value 1 mL of resuspended cells was used to obtain the 
crude cell lysate by sonication (see chapter 3.10.3) and to measure the P450 BM3 
concentration in the lysate by CO-difference spectroscopy (see chapter 3.10.2). 
For determination of the corresponding cell dry weight (CDW; in gCDW L-1) 1 mL of 
resuspended cells was centrifuged (21000 g, 2 min) followed by drying of the cell pellet in a 
drying cabinet FP 53 (Binder GmbH, Tuttlingen, Germany) at 95 °C for 48 h and subsequent 
weighing of the dried cell pellet. 
 Whole cell conversion of n-heptane and cyclooctane 3.12.2
The optimized reaction for conversion of n-heptane with resting cells was carried out in a two-
liquid phase system. The aqueous phase contained the corresponding E. coli cells in 1 mL 
0.1 M KPi-buffer (pH 8.0) for a final OD600 of 40, supplemented with 10 g L-1 D-glucose for 
cofactor regeneration. The organic phase consisted of 0.2 mL pure n-heptane. The aqueous 
phase was pipetted into a 5 mL-screw top vial (CS Chromatographie, Langerwehe, Germany) 
and was incubated together with 25 µL D-glucose that was added from a 400 g L-1 stock 
solution, for 5 min at RT, prior to the addition of n-heptane forming a second layer. The 
reaction mixture was stirred at 600 rpm with a stirring bar (3 mm x 10 mm, Carl Roth, 
Karlsruhe, Germany) on a multipoint magnet stirrer Variomag 15 (Thermo Fischer Scientific, 
EXPERIMENTAL 
 
 
53 
 
Wilmington, USA). For monitoring product formation over 48 h the reaction mixture (aqueous 
and organic phase) was transferred at a determined time point to a reaction vessel containing 
100 µL HCl to quench the reaction. 
The subsequent extraction procedure was performed as described in chapter 3.13.1. 
Quantification of the synthesized heptanol and heptanone regioisomers was carried out by GC 
analysis (chapter 3.13.2). The catalytic performance of the system was evaluated in terms of 
product concentration and product yield. Product yield on catalyst Yp/x is defined as ratio 
between the product concentration and the amount of catalyst as cell dry weight in the reaction 
(in mgproduct gCDW-1). To evaluate the expression level of recombinant P450 BM3 protein in the 
cells the P450 yield YP450/x was calculated based on the intracellular P450 concentration of a 
specific amount of cells (in mgP450 gCDW-1). 
The biotransformation of cyclooctane using E. coli resting cells was performed analogue to the 
procedure described above for n-heptane. Instead of a two-liquid-phase system the substrate 
cyclooctane was applied directly from a stock solution in ethanol (20 µL; 500 mM) to the 
aqueous phase containing the resuspended cells for a final concentration of 10 mM cyclooctane 
and 2 % (v/v) ethanol. Extraction and quantification of products by GC analysis was performed 
as described in chapter 3.13. 
3.13 Product analysis by Gas Chromatography 
 Extraction of products for GC analysis 3.13.1
The standard extraction procedure consisted in the addition of MTBE (2-Methoxy-2-
methylpropane) as solvent containing an internal standard (decane) that serves for correction of 
pipetting errors or evaporation of samples during the work out. In case of the in vitro 
conversion of n-heptane (chapter 3.11) 0.4 mL MTBE containing 1 mM decane (0.02% v/v) 
was used as solvent. For whole cell catalysis biotransformations containing a second organic 
phase of 0.2 mL n-heptane (chapter 3.12) the reaction products were extracted by addition of 
0.4 mL MTBE with 10 mM decane as internal standard (0.2 % v/v) and additionally 0.4 mL of 
n-heptane to achieve a final volume of 1 mL organic solvent. In this way product 
concentrations are related to the volume of the aqueous phase (cAq). The extraction of whole 
cell cyclooctane biotransformations was performed using 0.4 mL MTBE and 10 mM (0.2 % 
v/v) decane as internal standard.  
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After transferring the aqueous phase to a reaction vessel containing 0.1 mL concentrated HCl, 
the solvent was added carefully and the sample was mixed vigorously for 1 min. By 
centrifugation at 21000 g for 2 min separation of both liquid layers was achieved. The organic 
layer was transferred to a fresh reaction vessel, dried over NaSO4 by vigorous mixing, 
centrifuged again (21000 g, 2 min) and filled in a GC vial.  
 GC Quantification by means of a calibration curve 3.13.2
Quantification of the reaction products was performed using a Shimadzu GC-2010 gas 
chromatograph coupled to a flame ionization detector (FID) (Shimadzu, Japan). For 
quantification the GC was fitted with a column FS-Supreme-5ms (5% Phenylpolysilphenylen-
siloxane; 30 m x 0.25 mm x 0.25 µm film thickness; CS-Chromatographie, Germany). A 
typical column oven temperature program for separation of the heptanol regioisomers consisted 
of following steps: 40 °C for 19.5 min, 20 °C min-1 to 100 °C, 3 min at 100 °C. 
For each corresponding alcohol and ketone a 7-point calibration curve was generated using 
authentic standards and a defined amount of decane (1 mM or 10 mM) as internal standard. A 
characteristic GC-chromatogram and a calibration curve, exemplarily for 2-heptanol, are 
shown in the appendix section (Figure 6-4 and Figure 6-5). The authentic standards 1-heptanol 
and 2-heptanol (Merck, Darmstadt, Germany), 2-heptanone, 3-heptanol, and 4-heptanone 
(Sigma Aldrich, Steinheim, Germany), 3-heptanone, and 4-heptanol (TCI Europe, Eschborn, 
Germany) had all the purity >98%. Retention times for 1-, 2-, 3-, 4-heptanol, 2-, 3-, and 4-
heptanone were respectively: 13.7, 15.3, 15.9, 16.5, 17.2, 18.0, 22.7 min. 
The separation of cyclooctane conversion products with the same column FS-Supreme-5ms 
was achieved using following oven temperature program: 80 °C, 2 °C min-1 to 110 °C, 30 °C 
min-1 to 200 °C, 40 °C min-1 min to 300 °C for 1 min. For quantification of cyclooctane, 
cyclooctanol and cyclooctanone 4-point calibration curves were generated using authentic 
standards (purity >98%) and 10 mM decane as internal standard. Retention times for 
cyclooctane, cyclooctanol and cyclooctanone respectively: 3.4, 9.13, 8.2 min. 
 Determination of regio- and stereoselectivity of the P450 BM3 variants 3.13.3
The enzymatic hydroxylation of n-heptane, used in this study as model substrate, leads to 
generation of all possible regioisomers 1-, 2-, 3- and 4-heptanol. Additionally, in two of this 
regioisomers, 2- and 3-heptanol, chiral centers can be generated. The distribution of the regio- 
and stereoisomers upon conversion of n-heptane with the selected P450 BM3 monooxygenases 
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was analyzed via gas chromatography (GC). In terms of regioselectivity, the product 
distribution was normalized to 100% and was calculated based on GC quantification of each 
regioisomers as described in chapter 3.13.2.  Stereoselectivity was calculated as enantiomeric 
ratio (er; percentage of each enantiomer) or as enantiomeric excess (ee; percentage of excess of 
one enantiomer compared to the other). 
 Determination of the absolute configuration of (S)- and (R)-3-heptanol 3.13.3.1
Pure enantiomeric standards of 3-heptanol were not commercially available but racemic 
3-heptanol could be separated on a chiral GC column into both enantiomer peaks. Therefore, 
the absolute configuration of each GC peak was assigned based on polarimetry measurement 
and correlation to the optical rotation (or sign of the rotation) of each enantiomer according to 
following literature values: 4.9° for (R)-(-)-3-heptanol[170] and +5.8° for (S)-(+)-3-heptanol[171]. 
Samples of each enantiomer in excess were obtained through conversion of (rac)-3-heptanol, 
either with the (R)-specific alcohol dehydrogenase from Lactobacillus brevis (Lb-ADH)[158] or 
the (S)-specific RE-ADH[157]. The Lb-ADH reaction was performed using recombinant E. coli 
whole cells (OD600 of 22) in KPi-buffer (25 mL, 0.1 M, pH 6.0), containing acetone (2 mL, 
8% v/v), MgSO4 (4.25 mg), NADP+ (2 mM) and 3-heptanol (0.4 M), for 24 h at room 
temperature. E. coli whole cells containing the recombinant Lb-ADH were kindly provided by 
Prof. Dr. Hummel (FZ Jülich, Germany). The products were extracted twice by addition of 
chloroform (10 mL). After centrifugation (2 min at 21000 g) the organic layers were combined, 
dried over NaSO4 and concentrated to 1 mL using an evaporator IKA RV 10 basic (IKA-
Werke, Staufen, Germany). Subsequently, the extracted reaction was used for polarimetric 
measurement with a Perkin Elmer 241 MC Polarimeter (Waltham, USA) and for chiral GC 
analysis as described in chapter 3.13.4. The polarimeter was first blanked against chloroform 
and the optical rotation was determined at a wavelength of 589.3 nm and 25 °C. 
 Lipase-catalyzed resolution of (S)-2-heptanol 3.13.3.2
The 2-heptanol enantiomers could not be separated on a chiral GC column, therefore 
determination of the stereoselectivity was based on the lipase-catalyzed resolution of the 
(S)-2-heptanol enantiomer as described by Patel et al. with some modifications.[172] In this 
process the (R)-heptanol products are acetylated by Lipase, leaving the (S)-heptanol 
enantiomers unreacted. 
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The products of the sole P450 BM3-catalyzed hydroxylation of n-heptane (chapter 3.11.1) 
were extracted in 1 volume of n-heptane (1 mL) and splited in two equal volumes of 0.4 mL. 
One volume was treated with Lipase B for acylation of the (R)-2-heptanol [20 U, 4 mg of 
Lipase from Candida Antarctica/acrylic resin (Sigma Aldrich, Steinheim, Germany)] and 
succinic anhydride (0.2 mg), one volume without the addition of Lipase as reference reaction. 
Both samples were incubated in parallel at 35 °C and 600 rpm for 24 h. The samples were 
analyzed by gas chromatography as described in chapter 3.13.4 to determine the area of the 
2-heptanol peak in the acetylated sample and the reference sample. Comparison to the 
reference reaction without Lipase allows to calculate the total amount of 2-heptanol and the 
corresponding percentage of reacted (R)-heptanol and to determine the enantiomeric ratio. 
 Quantification of chiral products  3.13.4
For chiral separation and quantification of (R)- and (S)-3-Heptanol, as well as the remaining 
(S)-2-heptanol after acylation of the (R)-enantiomer, a GC-2010 Plus with a FID-detector 
(Shimadzu, Japan) was fitted with a column FS-Hydrodex β-TBDAc (heptakis-(2,3-di-O-
acetyl-6-O-t-butyldimethylsilyl)-β-cyclodextrin; 25 mx 0.25 mm; Macherey-Nagel GmbH, 
Düren, Germany). Following oven temperature program was used: 50 °C, 5 °C min-1 to 95 °C, 
9.5 min. Retention times for (R)- and (S)-3-heptanol respectively: 13.00, 13.28 min; for 
(S/R)-2-heptanol: 14.46 min. 
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4 Results and Discussion 
The results and discussion section is divided in three main chapters. In the first chapter the 
protein engineering of P450 BM3 monooxygenase by focused mutagenesis (10 positions for 
P450 BM3 19A12; 17 positions for P450 BM3 WT) and random mutagenesis (630 clones for 
P450 BM3 19A12 as parent) is described to improve the enzymes activity for the subterminal 
hydroxylation of n-heptane. Additionally, this chapter includes the switch in cofactor 
specificity from NADPH to NADH of selected P450 BM3 variants by mean of focused 
mutagenesis and the detailed characterization of the variants in terms of catalytic performance 
and selectivity. The second chapter comprises the ‘proof of concept’ for the in vitro one-pot 
double oxidation of n-heptane in a biocatalytic cascade, employing the engineered NADPH-
dependent P450 BM3 monooxygenase variants and the (S)-selective alcohol dehydrogenase 
from Rhodococcus erythropolis (RE-ADH). In the third chapter an extension of the 
aforementioned catalytic process to the application of whole cell catalysts is described. It 
includes a comparison of different strategies for coexpression of P450 BM3 variants and 
alcohol dehydrogenases (RE-ADH and ADH from Lactobacillus brevis - Lb-ADH), as well as 
an evaluation of the catalytic performance for the whole cell system employing n-heptane and 
cyclooctane as model substrates. 
4.1 Protein engineering of P450 BM3 monooxygenases 
This chapter is focused on the engineering of P450 BM3 monooxygenases to achieve highly 
active mutants for the selective oxyfunctionalization of medium-chain alkanes (C7-C8). The 
model substrate n-Heptane was selected due to the easier handling compared to shorter-chain 
alkanes which are gaseous at room temperature. As a first approach, the monooxygenase P450 
BM3 19A12[146] was selected as the starting variant for focused and random mutagenesis 
towards increased activity for the subterminal hydroxylation of n-heptane. Later on, the focus 
of engineering was shifted to the P450 BM3 wild type enzyme as starting template to engineer 
mutants with a reduced mutational load, but displaying a high activity on n-heptane and 
improved coupling efficiency. Furthermore, the change in cofactor specificity from NADPH to 
NADH of the selected P450 BM3 monooxygenase variants was investigated in order to 
achieve cofactor-compatibility with the NADH-dependent RE-ADH[157]. In addition, NADH is 
cheaper and more stable than NADPH making an application in cell free catalysis more 
suitable.[173] Finally, a detailed characterization of the engineered P450 BM3 variants in terms 
of catalytic performance, as well as regio and stereoselectivity was performed. 
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 Focused and random mutagenesis of P450 BM3 19A12 4.1.1
The monooxygenase variant P450 BM3 19A12 was generated by Fasan et al. in previous 
studies and displayed a higher catalytic performance compared to P450 BM3 WT with short 
and middle-chain alkanes, mainly from n-propane to n-heptane (TTN of 10500 and 5360 
respectively).[59, 146] P450 BM 19A12 contains in total 18 substitutions (R47C, L52I, V78F, 
A82S, K94I, P142S, T175I, A184V, L188P, F205C, S226R, H236Q, E252G, R255S, A290V, 
A328F, L353V, and I366V; see chapter 1.3.2). Recently, the substrate spectrum of the P450 
BM3 variant 19A12 has been further expanded from linear alkanes to cyclic alkanes such as 
cyclohexane, cyclooctane and cyclodecane.[174] 
The heme-domain of the P450 BM3 variant 19A12 was ordered as synthetic DNA and was 
subcloned into the expression vector pALXtreme-1a (see chapter 3.5.4.1). The expression of 
soluble protein from P450 BM3 19A12, together with the wild type (WT) and the empty vector 
control was analyzed by SDS-polyacrylamide gel electrophoresis (chapter 3.10.1) and the P450 
concentration was determined by CO-difference spectroscopy (chapter 3.10.2). The 
accumulation of 18 mutations in the P450 BM3 19A12 variant resulted in a significant 
decrease in expression, lower than the in the WT (Figure 4-1). 
The concentration of active monooxygenase in the cell extracts was 3 µM for 19A12 and 
51 µM for WT, when expressed in parallel shaking flasks under the same incubation conditions 
(30 °C at 250 rpm for 20 h after induction). Under this incubation conditions the variant 19A12 
achieved only 6% of active protein expression as compared to the WT. 
 
 
 
For directed evolution of P450 BM3 monooxygenase an appropriate high throughput screening 
assay was required. A product-based high throughput detection system for alcohols, such as 
Figure 4-1: Expression level of P450 BM3 wild type (WT) and BM3 19A12. Protein visualization of crude 
cell lysates on a 10% SDS-PAGE gel: (1) Molecular weight standard (PageRuler, Fermentas); (2) P450 BM3 
WT; (3) empty vector control; (4) P450 BM3 19A12. The molecular weight of P450 BM3 WT and variants is 
119 kDa. Taken from Müller et al.[175] 
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heptanol, is in practice difficult to realize. On the one hand, the gas chromatographic detection 
of alcohols is simple and can give both quantitative and qualitative values, however, only with 
a low to medium throughput. On the other hand, for chemical detection of alcohols the use of 
toxic heavy metals or harsh pH conditions is required.[176] Therefore, one feasible alternative to 
assay monooxygenase activity is the direct measurement of the cofactor-consumption during 
the hydroxylation reaction. The NAD(P)H-depletion assay has been used with success in the 
last decade for several protein evolution studies[144, 177]. An established protocol is also 
available.[166] The reported NADPH-depletion assay was adapted for P450 BM3 19A12 as 
starting template, using crude cell lysates after cultivation and expression in deep-well MTP 
format (chapter 3.7). The assay was optimized in regard to substrate concentration, as well as 
DMSO and cell lysate volumes. The best result was achieved with 0.2 mM n-heptane, 4% (v/v) 
DMSO and 50 µL lysate. 
A standard deviation of 21% for the optimized NADPH-depletion assay with n-heptane as 
substrate was determined after simultaneous screening 90 single P450 BM3 19A12 clones as 
shown in Figure 4-2. 
 
 
 
Initially, we pursued not only the detection of NADPH-consumption, but also the 
subsequential production of hydrogen peroxide as a measure for the uncoupling of the 
hydroxylation reaction (peroxide uncoupling)[178]. The ABTS-assay (2,2'-Azino-di-(3-ethyl-
benzthiazoline-6-sulphonic acid) was employed for this purpose.[179] 
Detection of hydrogen peroxide was performed under the reaction conditions used for the 
NADPH-consumption assay, with and without addition of E. coli crude cell lysate. Lysates 
from two different P450 BM3 variants, 19A12 and 139-3[144] were used. Variant BM3 139-3 
has a highly uncoupled electron transfer system (8% coupling efficiency for n-propane)[59] and 
Figure 4-2: Determination of the standard deviation of the NADPH-depletion assay: n-heptane 
hydroxylation by P450 BM3 19A12. The calculated standard deviation is 21%. 
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therefore a higher production of hydrogen peroxide during conversion of n-heptane is 
expected. Nevertheless, detection of hydrogen peroxide was not possible when crude cell 
lysate was present in the reaction mixture as shown in Figure 4-3. 
 
 
 
Based on this result it was assumed that the cell lysate contains native catalase 
(hydroperoxidase), which will degrade the hydrogen peroxide added to the reaction. It is well 
known that E. coli cells can produce hydroperoxidases (HPI and HPII) as adaptive response to 
oxidative stress, mainly during the stationary phase of cultivation.[180] Hence, an application of 
the ABTS assay in the expected format for a high throughput screening with cell lysates is not 
feasible. 
The screening of P450 BM3 muteins proceeded using only the NADPH-depletion assay. For 
the detection of clones with an improved activity compared to the parent template (P450 BM3 
19A12), the activity of the parent was set to 100% and the threshold was determined as 120% 
based on the standard deviation of the assay. Based on literature research[126b, 181] and on a 
prescreening of available P450 BM3 libraries 10 amino acid positions, which may influence 
substrate binding and conversion of substrates in the active site cavity of P450 BM3 were 
selected. 
The amino acid positions V26, A74, F87 and V184 were separately saturated, while residues 
R47-Y51, I236-E267 and A264-T268 were saturated simultaneously using for each pair a 
single oligonucleotide primer containing both randomized positions. The variant P450 BM3 
19A12 was used as template as described in chapter 3.5.7. For all positions, amplification of 
Figure 4-3: ABTS-assay for detection of hydrogen peroxide. A concentration of 0-1.2 mM H2O2 was used 
with and without supplementation of E. coli crude cell lysate. The reaction contained: 20 U mL-1 horse radish 
peroxidase, 2.6 mM ABTS, 40 µL cell lysate or buffer, varying concentration of H2O2 (0-1.2 mM) in KPi buffer 
(250 µL, 0.1 M, pH 8.0). 
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the template DNA with the mutagenic oligonucleotide primers yielded the correct 
amplification product. For each single position, 180 clones were screened using the established 
NADPH-depletion assay (chapter 3.9). In the case of two simultaneous saturated positions, 360 
clones were screened. The clones that showed a significantly higher activity than the parent 
P450 BM3 19A12 (>121 %) were selected for rescreening. 
From screening all constructed SSM libraries, only those at positions A74 and V184 showed an 
improved n-heptane hydroxylation activity under the screening conditions. From both libraries 
10 clones were selected and cultivated in shaking flask for rescreening with the NADPH-
consumption assay. The sequencing results revealed that the best two mutants harbored the 
substitution A74E, and V184S/P188Q, being P188Q a side amino acid substitution. The single 
amino acid substitutions V184S and P188Q were subsequently introduced into P450 BM3 
19A12 by SDM (chapter 3.5.6) to elucidate the individual effect of each mutation. 
After expression in shaking flask and determination of the P450 concentration (chapter 3.10.2) 
the activity of the mutants was determined by using equal amounts of enzyme (normalized 
P450 concentration of 20 nM) for the NADPH-depletion assay. Afterwards, the activity was 
calculated based on the slope of NADPH-depletion and in relation to the activity of the variant 
19A12 (100%) as shown in Figure 4-4. The single substitutions A74E, V184S and P188Q 
enhanced the activity of variant 19A12 in the NADPH-assay up to 43%. The absolute product 
formation in the hydroxylation of n-heptane was further evaluated for these mutants with 
normalized concentrations of P450 BM3 monooxygenase (chapter 3.10.5). 
 
 
 
None of the selected mutants A74E, V184S and P188Q showed an increased product formation 
rate compared to the parent variant 19A12 when equal amounts of P450 monooxygenase were 
employed in the reaction. The improved activities observed during NADPH-depletion 
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Figure 4-4: Relative activity of P450 BM3 19A12 mutants in the NADPH-depletion screening. The activity 
of the parent variant P450 BM3 19A12 (blue) as reference is set to 100%. 
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screening were most likely a result of increased expression levels of the mutant or higher 
uncoupling rates. The low and unstable expression level of P450 BM3 19A12 in MTP format 
was determined to be a bottleneck for further engineering of the protein. Based on the 
quantification of active P450 after the shake flask expression experiments it was observed, that 
mutation P188Q lead to a significant rise in the P450 concentration compared to the parent 
variant 19A12 (up to 2-fold; 4.5 µM vs. 2 µM). Therefore, during screening the side mutation 
P188Q led to an apparent improvement in activity caused only by an increased expression 
level. This result is not surprising since the destabilizing effect of the mutation L188P, despite 
of its significant benefit towards activity in BM3 19A12, was reported previously by Fasan et 
al.[59] The authors introduced the mutation L188P in the P450 BM3 variant 35E11 and 
observed a perturbation in the heme environment as indicated by CO-difference spectroscopy 
(appearance of a 420-nm peak accounting for 40% of the total enzymes concentration). They 
also investigated the impact of accumulated mutations in P450 BM3 variants on the enzyme´s 
thermostability. The half-denaturation temperature T50 as a benchmark of stability decreased 
gradually with a growing number of accumulated mutations. The T50 value of P450 BM3 
19A12 was estimated as 46 °C, 9 °C lower than the value of the WT (55 °C).[59]  
Random mutagenesis was used as a second strategy for evolution of P450 BM3 19A12 to 
improve n-heptane hydroxylation activity. An error-prone (ep) PCR library containing an 
inactivation ratio of 50% was generated (chapter 3.5.8). Different concentrations of MnCl2, in 
combination with an epTaq DNA polymerase were tested and for each concentration 96 clones 
were screened using the NADPH-depletion assay. The ratio of active clones, compared to the 
parent P450 BM3 19A12 as reference, and inactive clones, compared to the empty vector 
strain, were calculated (Figure 4-5). 
 
 
 
 
 
A MnCl2 concentration of 40 nM with an apparent inactivation rate of 53% was chosen for 
generation of the library. In total 630 clones were subjected to a first round of screening and 
out of this 49 were selected for rescreening in replicates (5-times). In the rescreening, none of 
Figure 4-5: Inactivation ratio in epPCR libraries of P450 BM3 19A12 in correlation to the concentration 
of MnCl2. 
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the selected clones displayed significantly increased activity compared to the parental P450 
BM3 variant 19A12 as shown in Figure 4-6. The relative activity of most clones did not exceed 
the activity of 19A12 within the standard deviation range of the assay (21%). As a result of 
both semi-rational and random mutagenesis approaches no improved variants were found 
based on the NADPH-depletion assay. 
 
       
Both the low stability of the 19A12 variant due to a high mutational load (in total 18 amino 
acid substitutions) and the low expression rate as compared to the wild type enzyme (6%), 
represent major bottlenecks for further evolution of the enzyme. Together with a high standard 
deviation of 21% in the NADPH-depletion assay, the low or unstable expression of the parental 
enzyme reduced the probability of finding optimized mutants. 
In previous studies from Arnold´s research group on directed evolution, especially of P450 
BM3 monooxygenases, the authors pointed out that most of the activating substitutions had 
also a destabilizing effect on the enzyme.[59, 182] In order to assure the evolvability of the P450 
BM3 mutant 35E11 the authors had to introduce two neutral but stabilizing substitutions (L52I 
and I366V) leading to the variant ETS8. In a subsequent round of mutagenesis the improved 
variant 19A12 was generated by introduction of the substitution L188P. However, this 
substitution had again a destabilizing effect on the enzyme. It has been reported, that during 
protein engineering most mutations are deleterious and therefore the preservation of fold and 
function of the protein decreases exponentially with a growing number of random 
mutations.[183] For achieving a further improved activity of P450 BM3 19A12 towards 
hydroxylation of n-heptane a change in the selection pressure, also in regard to an increased 
protein stability, would have been required. Therefore, a screening based on direct product 
detection combined with a selective pressure for stability would be advantageous. 
Figure 4-6: Rescreening of a P450 BM3 19A12 epPCR-library with n-heptane as substrate. In total 49 
clones were screened with the NADPH-depletion assay (average of 5 replicates each). Activity of 19A12 was set 
to 100%. 
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In summary, the P450 BM3 wild type enzyme with a significantly higher expression level 
(17-fold) and thermostability represents a more robust and promising starting point for directed 
evolution than the variant 19A12. 
 Focused mutagenesis of P450 BM3 WT 4.1.2
As described in chapter 4.1.1 the expression and stability of P450 BM3 19A12 is significantly 
low compared to the WT. By means of directed evolution and rational protein design of the 
19A12 variant it was not possible to yield a mutant with further improved activity towards 
n-heptane. Hence, new emphasis was placed on the investigation of single mutations 
responsible for the higher catalytic activity towards n-heptane, having into account the 
expression level of the protein. The expression level of the monooxygenase in the host cell is a 
significant factor for future application of the catalysts in whole cell biotransformation 
processes. Large part of the work in this chapter 4.1.2 was performed by Beneeta Akkapurathu 
within the frame of her master thesis.[184] 
To elucidate the contribution of each single amino acid substitutions, the 18 previously 
reported mutated positions in the P450 BM3 19A12 variant were saturated individually in BM3 
WT using degenerated NNK-oligonucleotides. In this way all possible amino acid substitutions 
at each position can be investigated.  For each of these ‘hot spot’ residues a SSM-library 
consisting of 180 clones was generated (chapter 3.5.7) and was screened with the NADPH-
depletion assay (in total 3460 clones; chapter 3.9). Due to an error in the synthesis of the 
oligonucleotide primers for position K94, this library was not taken into account. From each 
saturated position, the 10 best clones showing the highest relative activities were chosen for a 
rescreening in triplicate in MTP-format using the NADPH-depletion assay. For determining 
which substitutions were the most beneficial at each respective position, all rescreening clones 
were partially sequenced (covering the saturated site). Figure 4-7 displays the relative activity 
from the rescreening results for each position, taking into account the substitution found by 
sequence analysis of the corresponding clone. 
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The rescreening results in Figure 4-7 show that mainly substitutions of the amino acid residues 
R47, V78, L188 and to a lesser extent E252 and A290 had a significant effect on the activity 
towards the screened substrate. For the three positions 47, 78 and 188 out of 10 clones at least 
eight showed an improved activity of up to 318%. In these cases, more than one beneficial 
substitution was found. The three most active clones were R47W, V78G and R255P-P329H, 
all showing more than 3-fold improved activity in the assay. For the positions 226, 236, 252, 
and 290 also more than one clone with a distinctive substitution led to an enhanced activity. In 
regard to positions 184, 255, 328 and 353, only one distinctive substitution in each case 
displayed an enhanced activity. The positions 52, 82, 142, 175, and 366 did not show any 
significant improvement. In some positions also a high incidence of the wild type codon was 
found. This was the case for R255 and A328, displaying 7-times the WT codon, and for L353 
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Figure 4-7: Rescreening of 10 clones for 17 SSM libraries of P450 BM3 using n-heptane and NADPH-
depletion assay. The activity of the WT was set to 100% and the threshold value of the assay at 120% (dashed 
line). For each clone the corresponding mutation is depicted in the graph ((*): contains an additional mutation). 
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and E252 5-times. Sequence analysis revealed, for 7 clones, additional mutations at a different 
site than the saturated one, in most of the cases the mutation being located at the 
oligonucleotide primer site (appendix Table 6-9). Interestingly, two double mutants, containing 
an additional mutation, R255P-P329H and L353A-I254V, were the most active clone for each 
corresponding saturated position (Figure 4-7, blue*). Using a threshold of 150%, which 
represents a 1.5-fold increase in activity, the best clone per position was selected for further 
characterization. In addition, also the clone P142S, which was not significantly improved, was 
chosen as a control (selected clones are depicted in blue, Figure 4-7). 
To elucidate the effect of each single amino acid substitution in the significantly improved 
double mutant R255P-P329H, the wild type gene was subjected to SDM to generate the single 
mutants P450 BM3 R255P and P450 BM3 P329H. For simplification reasons in the following 
part of this work the double mutant R255P-P329H is abbreviated as CM1. The selected clones 
were expressed in shaking flask and characterized in terms of NADPH-oxidation (or initial 
oxidation rate), product formation (or turnover frequency, TOF) and coupling efficiency using 
crude cell lysates with normalized monooxygenase concentrations (see chapter 3.10.5). The 
characterization values are specified in Table 4-1. Figure 4-8 shows the improvement in 
productivity for each P450 BM3 variant compared to the WT as reference. 
The highest initial oxidation rate of 1788 min-1 was measured for the control variant P450 BM3 
19A12. However, this variant has a very low coupling efficiency for NADPH (14%), resulting 
in an inefficient utilization of the cofactor and thereby in a lower product formation. 19A12 
shows a 19-fold improved activity in contrast to the WT, which shows a low TOF of 13 min-1. 
Turnover frequencies (TOF) and coupling efficiencies are more representative values than 
NADPH-oxidation rates, because they correlate directly to the catalytic performance and the 
efficiency of cofactor uptake during the hydroxylation reaction. In this regard, the single 
mutant R255P and the double mutant CM1 achieve the highest TOF of 420 and 658 min-1 
respectively. The gain in product formation is proportional to the higher coupling efficiency in 
both variants (38% and 45% respectively). 
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P450 BM3 Initial oxidation rate [min-1][c] 
TOF 
[min-1][d] 
Coupling efficiency 
[%][e] 
Reference WT 68 13 20 
Variants P329H 23 7 32 
 
A290S 77 17 22 
 
F205P 115 28 25 
 
P142S 110 30 27 
 
L353A 157 31 20 
 
V78G 258 34 13 
 
R252D 143 43 30 
 
A184P 227 55 24 
 
L188P 281 77 27 
 
H236N 320 78 24 
 
S226W 291 85 29 
 
R47W 525 131 25 
 
R255P 1115 420 38 
 
CM1 (R255P-P329H) 1455 658 45 
Control 19A12[f] 1788 248 14 
[a] Characterization was performed with crude cell lysates; the reaction contained n-heptane (10 mM), ethanol as cosolvent 
(2% v/v), and P450 BM3 (0.25 µM) in KPi buffer (950 µL, 0.1 M; pH 8.0). The highest values are highlighted in bold; 
lower values than WT are underlined. 
[c]
 Initial oxidation rates in µmolNADPH µmolP450-1 min-1 from spectrophotometric measurements. [d]
 For turnover frequency (in molproduct molP450-1 min-1) products were quantified via GC. [e]
 Coupling efficiency (in %) as ratio between initial oxidation rate and TOF. 
[f]
 Reaction contained 0.02 µM P450. 
 
 
 
With exception of the variants V78G, L353A and 19A12, all mutants show an enhanced 
coupling efficiency for n-heptane as substrate when compared with the wild type enzyme 
(20%). The overall performance of the variant CM1 is significantly improved compared to the 
WT, showing a 49-fold higher product formation (Figure 4-8). The best single substitution 
leading to a higher hydroxylation activity is R255P. To a lesser extent mainly the substitutions 
R47W, S226W, H236N and L188P contribute individually to an optimized n-heptane 
hydroxylation with a 6 to 10-fold improved product formation. The single mutation P329H, 
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Table 4-1: Characterization of best P450 BM3 variants from SSM[a]  
Figure 4-8: Relative activity of selected P450 BM3 mutants. Initial NADPH oxidation and product formation 
are displayed as ratio to the wild type (WT) activity. Modified from Müller et al.[175] 
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which is present in the CM1 variant, shows an even lower activity than the WT, but an 
improved coupling efficiency of 32%. Furthermore, variant CM1 shows 56% higher TOF and 
18% higher coupling efficiency than the single amino acid substitutions R255P. It can be 
assumed that amino acid substitutions R255P and P329H contribute in CM1 in a synergistic 
manner, enabling a further enhanced catalytic performance. This single substitutions display 
individually a significantly higher coupling efficiency (38% for R255P and 32% for P329H) 
and together in the variant CM1 a further improvement to 45%. 
 
 
 
It is well known that there are conformational changes in specific regions of P450 BM3, 
induced after substrate binding.[58, 126c] One of these regions is the I-helix, which is located 
adjacent to the active site, above the heme. The rearrangement of the I-helix was reported to be 
essential for the displacement of the axial water molecule that ligands the heme-iron, which 
causes the shift from low-spin to high-spin in the initial part of the catalytic cycle.[126c] Residue 
R255 is located in the I-helix as shown in Figure 4-9. It can also be noticed that the residue 
proline at position 329 is located in close proximity to the substrate in the active site cavity, 
making an interaction feasible. Both residues, R255 and P329, are highly conserved in the 
CYP102A sub-family.[58] However, mainly the exchange of arginine at position 255 to proline 
results in a higher catalytic performance towards n-heptane hydroxylation. It can be therefore 
assumed, that the substitution to proline affects the conformation of the I-helix. In the wild type 
structure of P450 BM3, a salt bridge between R255 and D217 is described, which is extended 
upon substrate binding and is in part responsible for the rearrangement of the I-helix.[58] This 
Figure 4-9: Substrate-bound conformation of P450 BM3 WT highlighting residues R255 and P329. The I-
Helix and K-helix from the NPG-bound structure of P450 BM3 WT (PDB code 1JPZ)[126c] are displayed 
together with the heme and the substrate (ball & stick).  
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salt bridge cannot be formed in the SDM mutant R255P as well as in the variant CM1, since 
proline - in contrast to arginine - is uncharged. The single substitution P329H showed one the 
one hand a positive effect on the coupling efficiency, but on the other a negative effect on the 
product formation. Histidine is a more bulky residue than proline. The exchange to histidine at 
position 329 could therefore interfere with the entrance and positioning of the substrate in the 
active site cavity, leading to the observed decrease in hydroxylation activity. However, the 
combination of both mutations (R255P-P329H) in CM1 leads to a 50-fold higher catalytic 
activity (TOF of 658 min-1; Table 4-1), inferring a synergistic effect of both mutations. R255P 
can probably compensate the negative effect of P329H on substrate binding through 
rearrangement of the I-helix, enabling an even better and tighter positioning of the substrate. 
The highly active P450 BM3 CM1 mutant was chosen for evaluation of the in vitro and in vivo 
double oxidation of n-heptane, together with selected alcohol dehydrogenases in a biocatalytic 
cascade reaction. The P450 BM3 monooxygenases 19A12 and WT were also used as reference 
catalysts to compare and expand the catalytic concept. 
 Change in cofactor specificity of P450 BM3 variants 4.1.3
An efficient biocatalytic cascade reaction requires the compatibility of the used enzymatic 
components. In this study, the coupling of two enzymes - a P450 BM3 monooxygenase and an 
alcohol dehydrogenase from R. erythropolis (RE-ADH) - is intended. In this way an oxidation 
cascade can take place, with a first P450-catalyzed hydroxylation and therefore activation of an 
alkyl chain followed by a second ADH-catalyzed oxidation of the introduced hydroxyl group. 
These two catalysts have, however, different cofactor specificities. P450 BM3 has a high 
preference for NADPH over NADH, whereas RE-ADH is NADH specific.[147, 157] In previous 
reports from Maurer et al. and Neeli et al. the cofactors specificity of P450 BM3 was 
successfully exchanged by introducing mutations in the reductase domain of the enzyme (see 
chapter 1.3.2).[147-148] 
The previously reported substitutions W1046S and R966D[148], which lead to a switch in 
cofactor preference, were introduced in the P450 BM3 wild type, 19A12 and CM1 by SDM 
(chapter 3.5.6). In this way, the three NADH-dependent P450 BM3 variants WTNADH, 
19A12NADH, and CM1NADH were generated. For simplification efforts, the abbreviation “NADH” 
indicates the introduction of mutations W1046S and R966D in the corresponding enzyme. 
The generated NADH-dependent variants were characterized for both cofactors NADH and 
NADPH using purified enzymes. Anion-exchange chromatographic purification of the P450 
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BM3 variants (chapter 3.10.4) using a DEAE matrix and an elution gradient from 140 to 
250 mM sodium chloride yielded a purity of > 90 %. The purity was estimated by visualization 
in a SDS-PAGE gel as shown for 19A12NADH and CM1NADH in Figure 4-10 (appendix Figure 
6-6). 
 
 
 
For enzyme characterization, the initial oxidation rates, the turnover frequencies and the 
coupling efficiencies were determined as described in chapter 3.10.5. The TOF was determined 
by GC-quantification of all regioisomers (chapter 3.13.2) and was calculated by taking into 
account the overall amount of products (1-, 2-, 3-, and 4-heptanol). Figure 4-10 shows an 
overview of the characterization data. 
WTNADH displays a low activity towards n-heptane with both cofactors (A: 132 min-1 for 
NADH) and a moderate coupling efficiency (C: 18% for NADPH). The variants 19A12NADH 
and CM1NADH prefer NADH over NADPH in contrast to WTNADH (A and B). The oxidation 
rate of NADH with variant 19A12NADH is 9% higher than with the variant CM1NADH (A). 
Nevertheless, CM1NADH shows a 24% higher turnover frequency than 19A12NADH (B), which 
can mainly be attributed to its higher coupling efficiency (C: 44% vs. 32%). Using NADH as 
cofactor a TOF of 485 min-1 for 19A12NADH and 604 min-1 for CM1NADH was determined. The 
corresponding specific activities are 4075 U gP450-1 and 5073 U gP450-1 respectively (using a size 
of 119 kDa per active site). 
Figure 4-10: Purified monooxygenases P450 BM3 19A12NADH (1) and CM1NADH (2). Proteins were 
visualized on a 10% SDS-PAGE gel. Molecular weight of P450 BM3 is 119 kDa. An estimated purity of >90% 
was achieved; (M) Molecular weight standard (Prestained PageRuler, Fermentas).  
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The characterization results show that for all three P450 BM3 variants the cofactor preference 
was successfully switched from NADPH to NADH. In the case of variants 19A12NADH and 
CM1NADH not only the cofactor preference changed but also higher product yields were 
achieved using NADH as cofactor instead of NADPH (43% improvement for 19A12NADH and 
80% for CM1NADH). The catalytic performance of the NADPH-dependent variant BM3 CM1 
using NADPH as cofactor (chapter 4.1.2, Table 4-1; 658 min-1, 45%) and the NADH-
dependent variant CM1NADH with NADH (Figure 4-11 B, 604 min-1, 44%) is very similar, with 
values in the same range. The catalytic values of the variants 19A12 (NADPH; 248 min-1; 
14%) and 19A12NADH (NADH; 485 min-1; 32%) differ strongly. It has to be noticed, that in the 
case of the NADPH-dependent variants the characterization was performed with non-purified 
cell lysates and therefore differences in the catalytic performance can be expected. 
The catalytic characterization of BM3 CM1NADH showed also a comparably high activity with 
n-heptane (604 min-1 or 10 s-1 with NADH) as found for other engineered P450 BM3 variants 
for the oxidation of similar non-natural substrates like n-octane (variant 53-5H, TOF of 
660 min-1 using NADPH)[145]. In this regard, a fine compilation of kcat values for P450 BM3 
can be found in the review by Whitehouse et al.[58] 
 Determination of selectivities of NADH-dependent P450 BM3 variants 4.1.4
In synthetic approaches, mainly with regard to oxidations, one of the most remarkable 
advantages of enzymatic catalysts over chemical catalysts is the intrinsically high selectivity of 
enzymes.[38] This is predominantly the case for the selective biotransformation of native 
Figure 4-11: Initial oxidation rates, turnover frequencies and coupling efficiencies of WTNADH, 19A12NADH, 
and CM1NADH monooxygenases with the cofactors NADPH and NADH. All three BM3 variants contain the 
substitutions W1046S and R966D for switching the cofactor preference from NADPH to NADH. Figures A-C 
show: (A) Initial cofactor oxidation (molcofactor molP450-1 min-1) determined via cofactor consumption, (B) 
Turnover frequency (molproduct molP450-1 min-1) quantified by GC, and (C) Coupling efficiency (%) as ratio 
between product formation and cofactor oxidation. Taken from Müller et al.[175] 
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substrates. For engineered enzymes with a broadened substrate scope, as in the case of P450 
BM3 with non-natural substrates, the hydroxylation selectivities can differ significantly from 
the wild type enzyme. After catalytic characterization of the engineered NADH-dependent 
P450 BM3 variants WTNADH, 19A12NADH and CM1NADH, also the regio- and the stereo-
selectivity were determined as described in chapter 3.13.3. 
All possible regioisomers resulting from the biocatalytic conversion of n-heptane were 
analyzed in a qualitative and quantitative manner by gas chromatographic separation (chapter 
3.13.2). Separation of the regioisomers 1-, 2-, 3- and 4-heptanol was achieved using a column 
FS-Supreme-5ms as shown in Figure 4-12. 
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Figure 4-12: Identification of heptanol regioisomers by gas chromatography. Single hydroxylation of 
n-heptane catalyzed by P450 BM3 variants WTNADH (A), 19A12NADH (B) and CM1NADH (C). Separation was 
achieved using a column FS-Supreme-5ms (30 m x 0.25 mm x 0.25 µm film thickness; CS-Chromatographie, 
Germany) fitted in a Shimadzu GC-2010 gas chromatograph with a flame ionization detector (FID) (Shimadzu, 
Japan). The column oven temperature program was 40 °C for 19.5 min, 20 °C min-1 to 100 °C, 3 min. 
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Using GC quantification data the regioselectivity was calculated as shown in Figure 4-13. 
WTNADH is a subterminal hydroxylase with a similar regioselectivity (2-, 3- or 4-heptanol) to 
the hydroxylation pattern of fatty acids[58]. Following the same pattern, WTNADH produces all 3 
subterminal hydroxylated heptanol regioisomers in amounts higher than 24%. In contrast to the 
WT, P450 BM3 monooxygenases 19A12NADH and CM1NADH have a modified regiospecificity 
and a significant hydroxylation preference for two instead of three subterminal carbon atoms. 
19A12NADH hydroxylates mainly the C2-atom (64% 2-heptanol) followed by C3 (33% 3-
heptanol). CM1NADH produces preferentially 4-heptanol (48%) followed by 3-heptanol (42%) 
and 2-heptanol (9%). 
 
 
 
The stereoselectivity was determined likewise using a GC-based methodology. The pure 
enantiomeric standards of 3-heptanol were not commercially available, but racemic 3-heptanol 
could be separated on the chiral GC column FS-Hydrodex β-TBDAc (for details refer to 
chapter 3.13.4). The chromatographic separation of the possible hydroxylation and double-
oxidation products using the abovementioned chiral GC column is shown in Figure 4-14 A. 
The absolute configuration of the chiral GC peaks of 3-heptanol was assigned by measuring 
the polarimetry of each enantiomer in excess. Using the (R)-specific alcohol dehydrogenase 
from Lactobacillus brevis (Lb-ADH)[158] and the (S)-specific ADH from Rhodococcus 
erythropolis (RE-ADH)[157] for resolution of 3-heptanol, it was possible to obtain an excess of 
the (S)- and (R)-enantiomer respectively, as shown in Figure 4-14 B. 
For both conversions the enantiomeric excess (ee) was calculated and the absolute 
configuration was confirmed by polarimetry measurements. In the Lb-ADH-catalyzed 
Figure 4-13: Regioselectivity of the n-heptane hydroxylation by P450 BM3 monooxygenase WTNADH, 
19A12NADH and CM1NADH. The product distribution was calculated for each variant based on GC-quantification 
of the regioisomers (1-, 2-, 3- and 4-heptanol) and was normalized to 100%. Taken from Müller et al.[175] 
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resolution of 3-heptanol a high enantiomeric excess of 90.3% was obtained and a rotatory 
power value of +0.96 was determined (chloroform as solvent, 589.3 nm; 25 °C). 
 
 
 
 
Through the RE-ADH-catalyzed resolution, an enantiomeric excess of only 19.8% was 
achieved, corresponding to a rotatory power of -0.01 (chloroform; 589.3 nm; 25 °C). 
Correlation to the sign of the optical rotation data from literature (-4.9° for (R)-(-)-3-
heptanol[170] and +5.8° for (S)-(+)-3-heptanol[171]) revealed, that the first peak (retention time of 
9.88 min corresponds to (R)-3-heptanol and the second peak (10.01 min) to (S)-3-heptanol. The 
lower optical rotatory values compared to those from literature can be attributed to the lower 
concentrations obtained by the enzymatic resolution approach and to the lower enantiomeric 
excess used for the polarimetry measurement. Quantification of the peak areas was used for 
determination of the enantiomeric ratio (er) or excess (ee) of the catalyzed hydroxylation 
reaction (see 3.13.4). 
In contrary to 3-heptanol, the 2-heptanol enantiomers could not be separated on the chiral GC 
column. The enantioselectivity of the P450 BM3-catalyzed hydroxylation of n-heptane was 
determined by a subsequent lipase-catalyzed resolution of the (S)-2-heptanol enantiomer. Patel 
et al.[172] published a method for resolution of racemic 2-heptanol based on the enantioselective 
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Figure 4-14: Separation of possible n-heptane conversion products via GC and absolute configuration of 
(R/S)-3-heptanol. A) Authentic standards of 1-, (rac)-2, (rac)-3-, 4-heptanol and 2-, 3-, 4-heptanone. B) Chiral 
resolution of racemic-3-heptanol (black) was performed either with the (R)-specific alcohol dehydrogenase from 
Lactobacillus brevis (Lb-ADH)[158] (red curve; (S)-3-heptanol, 10.0 min, ee 90.3%) or the (S)-specific ADH 
from Rhodococcus erythropolis (RE-ADH)[157] (blue curve; (R)-3-heptanol, 9.87 min, ee 19.8%). Taken from 
Müller et al.[175] 
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acetylation of the (R)-2-heptanol enantiomer by means of incubation with Lipase B and 
succinic anhydride as acetylating agent. The reaction products were (R)-2-heptyl hemisuccinate 
and (S)-2-heptanol, the latter with an ee of 99.3%. This protocol was used with some 
modifications for resolution of 2-heptanol as a product from the P450 BM3-catalyzed 
hydroxylation reaction, as shown in Figure 4-15. Comparison of the products from the 
acetylation reaction and a reference reaction without Lipase (no acetylation) allowed the 
determination of the enantiomeric ratio (er) and the enantiomeric excess (ee) for each P450 
BM3 variant. 
 
 
 
The stereoselectivity of P450 BM3 NADH-dependent variants in terms of enantiomeric ratio 
(er) and enantiomeric excess (ee) is given in Table 4-2. 
 
P450 BM3 variant 2-Heptanol 3-Heptanol 
ee [%] er (S:R) ee [%] er (S:R) 
WTNADH 74 ± 0.1 (R) 13:87 50 ± 3 (R) 25:75 
19A12NADH 4 ± 3 (S)[a] 52:48 86 ± 2 (S) 93:7 
CM1NADH 46 ± 0.2 (R) 27:73 12 ± 1 (S) 56:44 
[a]
 High deviation is caused by low differences in the values of enantiomer peaks. Taken from Müller et al.[175] 
 
Remarkably, the stereo-preferences for chiral 2- and 3-heptanol differ significantly between 
WTNADH, 19A12NADH, and CM1NADH. WTNADH produces preferentially (R)-heptanols with an ee 
of 49% for (R)-3-heptanol and 74% for (R)-2-heptanol, whereas 19A12NADH favors the 
synthesis of (S)-3-heptanol in a higher excess of 86% and produces a nearly racemic mixture of 
2-heptanol (ee 3.9% for (S)-2-heptanol). CM1NADH shows also a slight excess of (S)-3-heptanol 
(ee 12%) and a clear preference for (R)-2-heptanol (ee 46%). 
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Figure 4-15: Lipase-catalyzed acetylation of (R)-2-heptanol. The GC spectra for the P450 BM3 variants 
WTNADH (A), 19A12NADH (B) and CM1NADH (C) show the products after acetylation of (R)-2-heptanol 
(14.46 min) and (R)-3-heptanol (13.0 min) leaving the (S)-heptanol enantiomer unreacted (red line). A reference 
reaction without Lipase (green line) allows for calculation of the enantiomeric ratio. Taken from Müller et al.[175] 
Table 4-2: Stereoselectivity of P450 BM3 WTNADH, 19A12NADH and CM1NADH in the hydroxylation of 
n-heptane. 
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In conclusion, WTNADH is (R)-selective towards 2- and 3-heptanol, whereas 19A12NADH and 
CM1NADH are (S)-selective with respect to 3-heptanol. In the case of CM1NADH, only two 
substitutions R255P and P329H are required to partially invert the enzymes stereoselectivity. 
Additionally, 19A12NADH is poorly stereoselective in the production of 2-heptanol in contrast 
to the (R)-stereoselective WTNADH and CM1NADH. 
4.2 In vitro double-oxidation of n-heptane with direct cofactor 
regeneration 
Monooxygenases are rarely employed in industrial scale, despite their synthetic potential for 
oxyfunctionalization of alkanes. C-H bond activation with O2 as clean oxidant has been 
described as a dream reaction in organic chemistry.[5a] 
Enzymatic cascade reactions for the oxyfunctionalization of alkanes are interesting as an 
alternative to chemical synthesis routes in case that challenges in cofactor supply, insufficient 
coupling rates, and stability issues can be addressed successfully. In this regard, significant 
progress has been achieved to improve stabilities and coupling rates of monooxygenases by 
rational design and/or directed evolution.[132b, 146, 185] The concept of the double oxidation 
cascade, as shown in Scheme 2, using molecular oxygen as sole oxidant and direct 
regeneration of the cofactor NADH, is synthetically attractive since use of additional 
cosubstrates can be omitted or at least be reduced. 
 
 
 
For a proof of concept of the biocatalytic one-pot double oxidation cascade, n-heptane was 
selected as substrate. As enzymatic components a P450 BM3 monooxygenase and a 
(S)-enantioselective, NADH-dependent alcohol dehydrogenase from Rhodococcus erythropolis 
(RE-ADH) were chosen. Three different P450 BM3 variants were selected to evaluate the 
concept of the double oxidation cascade. To ensure cofactor compatibility the NADH-
dependent P450 BM3 monooxygenases WTNADH, 19A12NADH, CM1NADH were employed. 
These NADH-dependent variants were previously purified and characterized in detail with 
regard to activity, to coupling efficiency and to selectivity for the catalyzed hydroxylation of 
n-heptane to 1-, 2-, 3-, and 4-heptanol (see chapter 4.1.3 and 4.1.4). For the variants 
Scheme 2: Double oxidation of n-heptane. Reaction scheme of the bicatalytic direct-oxidation of n-heptane to 
2-heptanone in aqueous medium, using a monooxygenase-dehydrogenase cascade and oxygen as sole oxidizing 
agent. Taken from Müller et al.[175] 
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19A12NADH and CM1NADH not only the cofactor preference was changed, but also higher 
product yields using NADH as cofactor were achieved. In the case of 19A12NADH 43% higher 
product formation was observed; for CM1NADH up to 80%. Subsequently, the activity of the 
alcohol dehydrogenase RE-ADH towards the oxidation of heptanol-isomers was determined. 
For a proof of concept, the influence of biotransformation parameters such as the substrate 
load, the use of cosolvent and additional cofactor regeneration via glucose dehydrogenase 
(GDH) was studied. To achieve a good performance of the cascade reaction these parameters 
were optimized. Finally, the catalyzed double oxidation of n-heptane was monitored over 24 h 
to characterize the reaction in terms of absolute product concentrations and total turnover 
numbers. 
 Determination of RE-ADH activity  4.2.1
The (S)-specific alcohol dehydrogenase from Rhodococcus erythropolis (RE-ADH) was 
selected for the oxidation of 2-heptanol due to its high activity and selectivity.[158] A protocol 
for heterologous protein expression in E. coli and purification of RE-ADH are published.[157] 
The RE-ADH is characteristic for its high thermo-stability up to 65 °C. Therefore, a simple and 
efficient purification by heat treatment is feasible. A good expression level of RE-ADH was 
achieved under the described conditions (chapter 3.6.2) and purification by heat treatment was 
performed (chapter 3.10.6), yielded protein with an estimated purity of >90% as shown in 
Figure 4-16. The protein content in the purified sample was measured by the method of 
Bradford using a calibration curve with Bovine Serum Albumin (BSA) as protein standard. A 
concentration of 8.3 mg mL-1 was calculated. 
 
 
 
Figure 4-16: Expression of RE-ADH and purification by heat treatment. RE-ADH visualized on a 10% 
SDS-PAGE gel as soluble protein fraction after expression in E. coli. (M): Molecular weight standard 
(Prestained PageRuler, Fermentas); (CCE-S): crude cell extract, soluble fraction; (CCE-P): Crude cell extract, 
pellet fraction. After heat treatment (HT) the soluble protein had an estimated purity of >90%. 
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To investigate the substrate acceptance and preferences of the RE-ADH towards the four 
heptanol isomers 1-, 2-, 3- and 4-heptanol, the volumetric and specific activity of the purified 
enzyme were determined photometrically (Table 4-3). The photometric activity measurement 
was performed at a pH of 8.0 using 0.1 M KPi-buffer, conditions which were used later for the 
double oxidation cascade reaction. In case of 2- and 3-heptanol the racemic compound was 
employed for the measurements, whereupon only the (S)-enantiomers are converted by the 
selective RE-ADH. 
 
Substrate Volumetric activity [U mL-1][a] Specific activity [U mg-1][b] 
1-heptanol 11 ± 1 1.3 
2-heptanol (racemate) 387 ± 34 46.7 
3-heptanol (racemate) 56 ± 2 5.8 
4-heptanol 7 ± 0.3 0.9 
[a] The reaction contained 10 mM substrate, 1 mM NAD+, 0.1 µL RE-ADH in 0.1 M KPi-buffer (pH 8.0). 
[b] A concentration of 8.3 mg mL-1 was used for calculations.  
 
RE-ADH displays a high preference for (S)-2-heptanol over the other heptanol regioisomers 
with a specific activity of 47 U mg-1. (S)-3-heptanol is converted to a lesser extent, showing an 
8-fold lower specific activity of 6 U mg-1. The activities for the non-chiral isomers 1- and 4-
heptanol are 36- and 52-fold lower than with the preferred substrate 2-heptanol. RE-ADH 
accepts a broad range of substrates, from aliphatic and aromatic ketones or alcohols (also 
halogenated acetophenones) to β-keto esters. The previously reported specific activities for the 
reduction of ketones as substrate, for example with 2-heptanone and 2-decanone reach 
>100 U mg-1, and for p-Cl-acetophenone an activity of 846 U mg-1 was determined.[155, 157] The 
activities for the oxidation reaction are usually lower, in the case of 2-heptanol displaying a 
2-fold decrease. A low KM value for the RE-ADH-catalyzed reduction of 2-heptanone was 
reported (0.48 mM), representing a high affinity for this substrate.[186] The KM value for the 
oxidation of 2-heptanol is not determined yet. However, the same authors reported a KM value 
for the reduction of p-Cl-acetophenone of 0.82 mM, which is higher than the value for the 
oxidation of p-Cl-phenylethanol (0.38 mM), suggesting a higher affinity of the RE-ADH for 
the alcohol compared to the ketone. These findings could be investigated for 2-heptanol in 
future studies. 
Besides, to characterize more in detail the capacity of the cofactor regeneration by RE-ADH in 
the double oxidation cascade, the KM and Vmax values for the reduced cofactor form NAD+ 
were determined (Figure 4-17). 
Table 4-3: Activity of purified RE-ADH towards heptanol isomers 
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The KM value of the RE-ADH for NAD+ using 2-heptanol as substrate is 84 ± 9 µM and Vmax 
reaches 0.005 s-1. Abokitse measured a KM value of 90 µM for the reduction of NAD+ with 
p-Cl-phenylethanol as substrate using also the recombinant RE-ADH from E. coli.[186] This 
value is in good accordance to the KM value determined for 2-heptanol in this study. 
 Reaction engineering of the double oxidation cascade 4.2.2
First approaches for the double oxidation of n-heptane in one-pot proved that this novel 
synthesis concept could be successfully applied with the selected enzymatic components (P450 
BM3 and RE-ADH) and the selected substrate n-heptane. The biocatalytic production of 
heptanone starting from n-heptane was detected by GC. However, total product concentrations 
with all testes P450 BM3 monooxygenases were low. It was observed, that quantification of 
absolute products concentrations instead of substrate conversion was more accurate due to 
possible evaporation of n-heptane during the reaction and the sample work-up (boiling point of 
98.4 °C). To minimize evaporation of n-heptane and to ensure the substrate availability in the 
course of the reaction, tightly closed screw top vials (containing silicon/PTFE sealing disks) 
were used for each individual reaction sample. 
Varying concentrations of RE-ADH from 10 to 40 U mL-1 were tested to achieve an optimal 
ketone to alcohol ratio. A RE-ADH concentration of 10 U mL-1 yielded the best result (data not 
shown). In further experiments the influence of substrate and P450 BM3 concentrations, as 
well as the use of ethanol as cosolvent were investigated. 
Figure 4-17: Determination of KM and Vmax values of the alcohol dehydrogenase from Rhodococcus 
erythropolis (RE-ADH) for the cofactor NAD+. 2-heptanol was used as substrate (10 mM in 0.1 M KPi-
buffer, pH 8.0; 0.18 U RE-ADH). Data was fitted using a Michaelis-Menten plot and Origin 8.6 software 
(OriginLab Corporation, Northampton, MA, USA). Taken from Müller et al.[175] 
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Figure 4-18 shows the product concentrations and the corresponding conversion (quantified 
over product and not over substrate) for the in vitro double oxidation cascade with varying 
concentration of n-heptane as starting substrate. Concentrations from 0.5 mM to 1 M were 
employed. 
 
 
 
A concentration of 50 mM n-heptane yielded the highest product concentration, but only a 
conversion of 1.7%. A maximal conversion of 43% was achieved with the lowest tested 
n-heptane concentration of 0.5 mM. The biocatalytic system shows up to 50 mM an inverse 
proportionality between product formation and substrate conversion. For higher concentrations 
of n-heptane (0.1 to 1 M) the product formation declines. In the case of 0.1 M n-heptane only 
0.5% (v/v) ethanol was used as cosolvent and for the concentrations 0.5 and 1 M no cosolvent 
was used. The solubility of n-heptane is water, with a logPo/w value of 4 is extremely low (3.4 
mg L-1 at 25 °C).[187] Therefore, a reduced product formation could result from insufficient 
substrate availability caused by the poor n-heptane solubility in the aqueous systems if only 
low amounts or no cosolvent are used. 
The effect of ethanol as cosolvent, to ensure higher substrate solubility in the aqueous reaction 
phase was investigated further. Product concentrations after hydroxylation of n-heptane were 
compared with and without supplementation of ethanol (1.3% v/v) in the reaction as shown in 
Table 4-4. The addition of D-glucose and glucose dehydrogenase (GDH) to achieve 
regeneration of the cofactor NADH during the hydroxylation reaction was also tested. 
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Figure 4-18: Effect of the n-heptane concentration on product formation and conversion rates. The total 
product concentration is the sum of total heptanol and heptanone isomers via GC. The conversion was 
calculated on the basis of quantified product (ratio of total product to starting concentration of substrate. The 
reaction contained 0.1 M KPi buffer (1 mL; pH 8.0), 0.2 µM P450 BM3 19A12NADH, 600 U catalase, 10 mM 
D-glucose, 3 U GDH, 2 mM NADH and varying n-heptane concentrations in ethanol (0.5-2% v/v) as cosolvent. 
For 500 and 1000 mM n-heptane no cosolvent was used applying n-heptane directly to the reaction mix. 
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Components[a] Product concentration [µM] 
No cosolvent 1.3% (v/v) ethanol 
P450[a] 301 519 
P450 + GDH[b] 461 641 
[a] The reaction contained 50 mM n-heptane, 1.3% (v/v) ethanol, 0.2 µM P450 BM3 19A12NADH, 600 U catalase, 2 mM NADH 
in 0.1 M KPi buffer (1 mL; pH 8.0) and [b]additionally 10 mM D-glucose, 3 U GDH. 
 
The use of ethanol as cosolvent enhances the product formation by 72% when sole P450 BM3 
is used and by 39% when the cofactor is additionally regenerated over GDH. Therefore, an 
amount of 1.3% (v/v) ethanol was selected for the double oxidation cascade. 
 Additional cofactor regeneration using glucose dehydrogenase 4.2.2.1
In order to explore if the cofactor regeneration is a limiting factor in the double oxidation 
cascade an additional NADH-regeneration strategy over D-glucose/glucose dehydrogenase 
(GDH)[24, 188] was investigated as shown in Scheme 3. 
 
 
 
Additional cofactor regeneration over glucose/GDH can improve the regeneration capacity and 
can compensate for cofactor losses as a result of the low coupling efficiencies of P450 
monooxygenases, where NADH is utilized for undesired (uncoupling) reactions. GDH 
regenerates the oxidized cofactor NAD+ to NADH by oxidation of D-glucose to glucono-1,5-
lactone, which hydrolyzes spontaneously, in dependence of the applied pH and buffer to 
gluconic acid.[66] The reaction equilibrium will therefore be shifted to the product side (Scheme 
Table 4-4: Effect of ethanol as cosolvent in the P450 BM3 19A12NADH-catalyzed hydroxylation of 
n-heptane. 
Scheme 3: Double oxidation of n-heptane using a P450 BM3 monooxygenase and an alcohol 
dehydrogenase from Rhodococcus erythropolis (RE-ADH) with supporting cofactor regeneration via 
glucose dehydrogenase (GDH). In the first oxidation step n-heptane is converted by the P450 monooxygenase 
to heptanol under NADH consumption yielding NAD+. In the second oxidation step RE-ADH catalyzes the 
chiral resolution of the in situ produced (R)-heptanols and the synthesis of the corresponding ketones under 
reduction of NAD+ to NADH (cofactor regeneration). The conversion of D-glucose to D-gluconolactone enables 
also the reduction of NAD+ to NADH, as a supporting cofactor recycling system. R: CH3, C2H5 or C3H7; R': 
C5H11, C4H9 or C3H7. Taken from Müller et al.[175] 
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3). The beneficial effect of using GDH in the double oxidation cascade for additional cofactor 
regeneration was previously confirmed in chapter 4.2.2, Table 4-4. It is important to take into 
account, that in the presence of RE-ADH and GDH two NAD+-consuming reactions run in 
parallel. The main goal was to achieve complete conversion of the targeted heptanol isomers 
by the alcohol dehydrogenase, accompanied by sufficient regeneration of the oxidized cofactor 
NADH. The effect of additional cofactor regeneration is shown in Figure 4-19, where three 
different systems consisting of the P450 BM3 monooxygenase (19A12NADH) in combination 
with the RE-ADH (1), the GDH (2) or both RE-ADH and GDH (3) were analyzed. The sole 
regeneration of NADH over D-glucose/GDH yields a 1.4-fold higher product concentration 
(567 µM; 2) compared to the double oxidation reaction with RE-ADH (402 µM; 40% heptanol, 
60% heptanone; 1). In the coupled reaction consisting of all three enzymatic components – 
P450 BM3, RE-ADH and GDH – a similar product concentration is achieved (551 mM; 3). 
However, in this case, the RE-ADH-catalyzed oxidation of heptanols to the corresponding 
ketones is nearly suppressed, yielding only a 15 times lower concentration of heptanone (4%) 
than in the reaction without GDH. 
 
 
 
Evaluation of the coupled enzymatic approach with supporting cofactor regeneration over 
GDH lead to the assumption, that both dehydrogenases compete for the available amount of 
reduced cofactor NAD+. Hence, in order to compare the affinity of GDH and RE-ADH for 
NAD+ the corresponding KM and Vmax values of GDH were determined in an analogue manner 
to the determination of the kinetic values for the RE-ADH (see Figure 4-20). 
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Figure 4-19: Evaluation of glucose dehydrogenase for cofactor regeneration. The reaction contained 10 mM 
n-heptane, 0.1 µM P450 BM3 19A12NADH, 2.5 U catalase, 10 mM D-glucose and 2 mM NADH in 0.1 M KPi 
buffer (1 mL; pH 8.0); additionally in (1) 0.2 U RE-ADH, in (2) 0.2 U GDH and in (3) 0.2 U RE-ADH and 0.2 
U GDH. 
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The GDH from Pseudomonas sp. shows a KM of 113 ± 15 µM and a Vmax of 0.017 s-1 for 
NAD+, when D-glucose is used as substrate. The determined KM value for NAD+ is in a similar 
range to the previously reported value for the GDH from Bacillus sp. (Amano Enzyme) of 
182 µM at a pH of 8.0. At a lower pH of 6.4 also a lower KM value (77 µM) was measured.[66] 
Compared to the kinetic data of RE-ADH for the oxidation of 2-heptanol (KM 84 ± 9 µM, Vmax 
0.005 s-1, chapter 4.2.1) the GDH displays a slightly lower affinity for NAD+ but achieves a 
nearly 3-fold higher oxidation velocity of the cofactor. If a higher concentration of glucose 
than of 2-heptanol is available, NAD+ will be most likely consumed faster by the GDH than the 
RE-ADH. In other words, depending on the substrates availability, the GDH can out-compete 
the RE-ADH leading to activity loss in the second oxidation step of the enzymatic cascade 
reaction. Therefore, the effect of different D-glucose concentrations in the cascade reaction was 
further investigated as shown in Figure 4-21. The graph shows the dependency of product 
yields and product distribution (total heptanols and heptanones) on the employed concentration 
of glucose. 
Up to a glucose concentration of 2 mM the ratio of heptanone to heptanol remains nearly 
constant (71:29% ± 1%) and a comparably high concentration of total product (1.12 mM) is 
achieved. A slightly higher product concentration is yielded using 5 mM glucose (1.15), but the 
overall amount of heptanone is reduced. Higher glucose concentrations (10 to 20 mM) repress 
entirely the RE-ADH-catalyzed oxidation of heptanols to heptanones. 
Figure 4-20: Determination of KM and Vmax values of the glucose dehydrogenase (from Pseudomonas sp.) 
for the cofactor NAD+. D-Glucose was used as substrate (10 mM) in 0.1 M KPi-buffer, pH 8.0; 0.16 U GDH. 
Data was fitted using a Michaelis-Menten plot and Origin 8.6 software (OriginLab Corporation, Northampton, 
MA, USA). Taken from Müller et al.[175] 
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These results prove that fine-tuning of the glucose concentration represents a key parameter to 
ensure sufficient cofactor supply for the enzymatic counterparts. In order to maximize the 
product formation and shift the reaction equilibrium towards completion of the RE-ADH 
catalyzed oxidation, a concentration of 2 mM was finally selected for the enzymatic cascade 
reaction. 
 Study on the inhibitory effect of products 4.2.2.2
A possible inhibition of the products from the n-heptane hydroxylation on the activity of 
selected P450 BM3 monooxygenase was evaluated. For this experiment the P450 BM3 variant 
19A12NADH was chosen. The effect of a pre-incubation step with the regioisomers 2-Heptanol 
and 2-heptanone, which are the main products of the 19A12NADH-catalyzed double oxidation, 
was investigated. It was assumed, that the remaining heptanol and heptanone regioisomers will 
interact in a similar manner with the enzyme. The P450 BM3 enzyme was incubated for 5 min 
with 1 mM 2-heptanol or 2-heptanone prior to starting the hydroxylation reaction of n-heptane 
in a cuvette (1 mL) by addition of NADH. A reference reaction without a pre-incubation step 
was run in parallel. Each reaction was monitored photometrically at 340 nm until the cofactor 
was entirely depleted. The products were extracted for GC analysis (3.13.1 and 3.13.2) to 
enable comparison of the product formation with and without a pre-incubation step. Initial 
NADH-oxidation rates (calculated as described in chapter 3.10.5) and product concentrations 
are shown in Table 4-5. 
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Figure 4-21: Effect of D-glucose concentrations on the double oxidation reaction of n-heptane under 
supplementation of glucose dehydrogenase (GDH from Pseudomonas sp.). Concentrations of total heptanol 
(black) and total heptanone (gray) are displayed as sum of the corresponding regioisomers based on GC-
quantification. The reaction contained n-heptane (50 mM) in 1 mL 0.1 M KPi buffer (pH 8.0), NADH (2 mM), 
catalase (600 U), P450 BM3 19A12NADH (0.2 µM), RE-ADH (10 U), GDH (3 U) and D-glucose (varying 
concentrations from 0.1 to 20 mM). Modified from Müller et al.[175] 
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No. Reaction type Initial oxidation 
rate [min-1] 
Product concentration [µM] 
2-Heptanol 3-Heptanol 
1 Standard[a] 1928 ± 3 74.3 ± 6.8 33.8 ± 2.7 
2 Pre-incubation 2-heptanol 1909 ± 41 68.1 ± 6.2 33.7 ± 1.9 
3 Pre-incubation 2-heptanone 1884 ± 21 72.3 ± 6.8 31.3 ± 2.4 
[a] The reaction contained 50 mM n-heptane, 1.3% (v/v) ethanol, 0.2 µM P450 BM3 19A12NADH and 0.4 mM NADH in 1 mL 
0.1 M KPi buffer (pH 8.0); additionally pre-incubation step with 1 mM 2-heptanol[b] or 1 mM 2-heptanone[c]. 
 
The product concentrations achieved in the standard reaction (entry 1), as well as in the 
reaction with a pre-incubation of P450 BM3 with 2-heptanol (entry 2) or 2-heptanone (entry 3) 
are within a standard deviations of <3.5%. The initial oxidation rates of all three reactions are 
within a standard deviation rate of less than 1%. Based on these results it can be assumed that a 
short term inhibition of the P450 BM3 monooxygenase by the n-heptane hydroxylation 
products 2-heptanol and 2-heptanone will not take place. 
 Double oxidation of n-heptane: conversion and total turnover numbers 4.2.3
The reaction in Scheme 4 shows the double oxidation of n-heptane, catalyzed by a P450 BM3 
monooxygenase and the alcohol dehydrogenase RE-ADH. 
 
 
 
 
During the initial oxidation reaction n-heptane is hydroxylated by P450 BM3 WTNADH or 
variants (19A12NADH, CM1NADH) to the heptanol isomers (product (S)/(R)-2). In the subsequent 
step the (S)-specific RE-ADH catalyzes the further oxidation of the preferred (S)-alcohols 
[(S)-2] to the corresponding ketones (product 3), thus enabling an in situ resolution of the 
Table 4-5: Effect of pre-incubation with the double-oxidation products 2-heptanol and 2-heptanone on the 
activity of P450 BM3 19A12NADH. 
Scheme 4: Double oxidation of n-heptane using P450 BM3 monooxygenases and an alcohol 
dehydrogenase from Rhodococcus erythropolis (RE-ADH) as cascade catalysts. In the first oxidation step 
n-heptane (1) is converted by a P450 BM3 monooxygenase (WTNADH, 19A12NADH, and CM1NADH) to heptanol 
(enantiomeric mixture of (S)/(R)-2) under NADH consumption yielding NAD+. In the second oxidation step 
enzymatic resolution[28] of the in situ produced (R)-heptanols ((R)-2) and synthesis of the corresponding ketones 
(3) is achieved under reduction of NAD+ to NADH (cofactor regeneration). R: CH3, C2H5 or C3H7; R': C5H11, 
C4H9 or C3H7. Taken from Müller et al.[175] 
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(R)-enantiomers (product (R)-2). The second oxidation is accompanied by the reduction of 
NAD+ to NADH. The regenerated cofactor NADH can be reused by the monooxygenase for 
hydroxylation of n-heptane. 
Figure 4-22 shows the performance of WTNADH, 19A12NADH, and CM1NADH in the initial 
hydroxylation step (upper part) and in the double oxidation reaction (lower part). 
 
 
 
Conversion of n-heptane in the single hydroxylation reaction with WTNADH, 19A12NADH, or 
CM1NADH stops nearly after 1 hour yielding product concentrations of 0.23, 0.69, and 0.62 mM 
heptanols respectively. In contrast, during the double oxidation reaction the product formation 
increases continuously over more than 4 hours. This can be attributed to the NADH cofactor 
recycling during the double oxidation. A detailed comparison in terms of total product 
concentrations shows an increase from 0.23 to 0.56 mM for WTNADH (Figure 4-22 A→D), 
from 0.69 to 1.3 mM for 19A12NADH (Figure 4-22 B→E), and from 0.62 to 1.1 mM CM1NADH 
(Figure 4-22 C→F). 
RE-ADH determinates due to its specificity for the (S)-isomers the product ratio between 
heptanones and heptanols in the coupled reaction. This ratio differs significantly between 
19A12NADH and CM1NADH. 19A12NADH/RE-ADH produces twice the amount of heptanones 
(0.85 mM vs. 0.43 mM heptanol), whereas CM1NADH/RE-ADH produces twice the amount of 
heptanols (0.78 mM vs. 0.35 mM heptanone). BM3 WTNADH achieves a product concentration 
Figure 4-22: Conversion of n-heptane to heptanols (initial hydroxylation step; upper part) and conversion 
of n-heptane to heptanones (double oxidation; lower part). Initial hydroxylations are shown for (A) WTNADH, 
(B) 19A12NADH or (C) CM1NADH and the double oxidations in presence of the RE-ADH: (D) WTNADH, (E) 
19A12NADH, and (F) CM1NADH. Total heptanol (●) and total heptanone (◊) concentrations are shown as sum of 
the corresponding regioisomers (1-, 2-, 3-, and 4-heptanol) which were quantified via GC after a reaction time of 
0.17, 0.5, 1, 2, 4 and 24 h (for details on reaction conditions see chapter 3.11.3). Taken from Müller et al.[175] 
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of approximately 0.56 mM when coupled to the alcohol dehydrogenase (Figure 4-22 D). 
Nevertheless, the concentration of heptanones achieved with BM3 WTNADH is very low 
(69 µM vs. 0.5 mM heptanol) and differs significantly from 19A12NADH and CM1NADH. 
Notably, when starting from the alkane n-heptane the double oxidation concept also allows 
producing (R)-alcohols due to the selectivity of the RE-ADH. Table 4-6 summarizes the yields 
obtained on (R)-2- and (R)-3-heptanol in the double oxidation cascade. The yields from the 
enzymatic resolution experiment are calculated based on the overall amount of the chiral 
((R)/(S)-2- and (R)/(S)-3-heptanol) and their non-chiral products (2- and 3-heptanone), which 
were set to 100% disregarding the conversion of 1- and 4-heptanol. The highest yields on 
(R)-heptanols were obtained for the BM3 variants WTNADH (89% (R)-2-heptanol), followed by 
CM1NADH (72% (R)-2-heptanol). Comparably low yields were achieved with 19A12NADH (51% 
and 20% (R)-2- and (R)-3-heptanol respectively). 
 
  
Yield [%][a] 
  (R)-2-Heptanol (R)-3-Heptanol 
P450 BM3 WTNADH 89 ± 1 82 ± 2 
P450 BM3 19A12NADH 51 ± 3 20 ± 1 
P450 BM3 CM1NADH 72 ± 3 58 ± 3 
[a] See Table 4-2 for details on the theoretical composition (enantiomeric ratio er) of the heptanol mixture which 
serves as substrate. Conversion of (S)-2-heptanol and (S)-3-heptanol by RE-ADH was determined to be >99%. 
 
The theoretical composition of the heptanol mixture from the initial hydroxylation step, which 
serves as substrate for the RE-ADH-catalyzed second oxidation, should be equivalent to the 
enantiomeric ratio (er) values in Table 4-2. However, the calculated yields for the resolution of 
(R)-heptanols in the cascade reaction are in most of the cases higher than the expected values 
from the single, non-coupled hydroxylation reaction (Table 4-6 vs. Table 4-2). The biggest 
differences are found for the resolution of (R)-3-heptanol in the cascade with 19A12NADH and 
CM1NADH. Here, 32% and 185% more (R)-heptanol was yielded respectively, compared to the 
enantiomeric ratios achieved in the single hydroxylation reaction. The differences are probably 
caused by a shift in the product distribution and reaction equilibrium that takes place during the 
double oxidation, due to the continuous regeneration and therefore higher availability of the 
cofactor. 
Figure 4-23 shows the results of the double oxidation with WTNADH, 19A12NADH, and 
CM1NADH in presence of the D-glucose/GDH-regeneration system. The produced NAD+ during 
Table 4-6: Obtainable yields for the RE-ADH catalyzed resolution of (R)/(S)-heptanols in the 2nd step of 
the double oxidation cascade. Taken from Müller et al.[175] 
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the initial oxidation step is utilized simultaneously by the RE-ADH and the GDH for the 
second coupled oxidation and regeneration step. 
 
 
 
The total product concentrations in the double oxidation cascades with supporting cofactor 
regeneration (D-glucose/GDH) are significantly higher. In the case of BM3 WTNADH a maximal 
product concentration of 0.73 mM is obtained (215% higher than without GDH; Figure 4-23 
A). The variants 19A12NADH and CM1NADH produced 1.57 and 1.8 mM total product, which 
correspond to a 129% and 188% increased product formation (Figure 4-23 B and C). Product 
distribution patterns in the double oxidation cascades as well as conversion and yields in the 
second oxidation step remained within standard deviations in presence and absence of the 
D-glucose/GDH regeneration system. 
Based on the quantified product concentrations after a reaction time of 24 hours, total turnover 
numbers (TTN) were determined for the single and the double oxidation reactions as well as 
for the double oxidation reactions with supporting cofactor regeneration (D-glucose/GDH) and 
are given in Table 4-7. The employed monooxygenases (WTNADH, 19A12NADH, CM1NADH) 
displayed a >1.8-fold improved TTN (entry 2) in the double oxidation cascades compared to 
the single hydroxylation reaction in absence of RE-ADH (entry 1 and 2). 
Supplementation of a NADH regeneration system with D-glucose as a cosubstrate and GDH 
yielded higher product concentrations for all three BM3 variants and consequently TTNs 
increased up to 3-fold (entry 1 vs. 3). 19A12NADH and CM1NADH achieved comparably high 
TTN values (up to 3591) which are under all tested reaction conditions more than 2-fold higher 
than the corresponding TTN-values of WTNADH. 
 
Figure 4-23: Double oxidation of n-heptane with a supporting regeneration system (D-glucose/GDH) for 
the cofactor NADH. Figures A-C show: (A) BM3 WTNADH, (B) 19A12NADH and (C) CM1NADH. Total heptanol 
(●) and total heptanone (◊) concentrations are displayed as sum of the corresponding regioisomers which were 
quantified via GC after a reaction time of 0.17, 0.5, 1, 2, 4 and 24 h (for details on reaction conditions see 
chapter 3.11.3). Taken from Müller et al.[175] 
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  TTN
[a]
 
No. Components WT
NADH
 19A12
NADH
 CM1
NADH
 
1
[b]
 only P450 462 ± 56 1374 ± 2 1247 ± 30 
2
[c]
 P450 + RE-ADH  1128 ± 27 2514 ± 92 2196 ± 167 
3
[d]
 P450 + RE-ADH + GDH 1457 ± 24 3146 ± 213 3591 ± 186 
[a]
 TTN: Total Turnover Number (µmolTotal product µmolP450-1); total product is the sum of all quantified heptanol and 
heptanone isomers (24 h). 
[b]
 The reaction mixture contained n-heptane (50 mM) in KPi buffer (1 mL, 0.1 M; pH 8.0), ethanol (1.3% v/v), 
NADH (2 mM), catalase (600 U), P450 BM3 (0.5 µM). 
[c]
 Additionally to entry 1: RE-ADH (10 U). 
[d] Additionally to entry 1: RE-ADH (10 U), D-glucose (2 mM), GDH (1 U). 
 
19A12NADH was selected as reference based on its catalytic performance for the conversion of 
n-heptane (18 substitutions) showing a TTN of 5360 ± 1020, which is to the best of our 
knowledge the highest reported value for biocatalytical hydroxylation of this compound.[59] 
The total turnover numbers for 19A12NADH reached in this study up to 3150. Differences to the 
previously reported TTN might be attributed to the altered cofactor specificity (NADH instead 
of NADPH) and the employed regeneration system (GDH vs. isocitrate dehydrogenase) as well 
as the reaction conditions. 
The catalytic characterization of BM3 CM1NADH showed a comparably high activity with 
n-heptane (TOF value of 604 min-1 or 10 s-1 with NADH; Figure 4-11) as found for other 
engineered P450 BM3 variants for the oxidation of non-natural substrates like octane (variant 
53-5H, TOF of 660 min-1 using NADPH)[145]. A fine compilation of kcat values for P450 BM3 
is reported in the review by Whitehouse et al.[58] 
The oxyfunctionalization of alkanes under mild conditions was summarized in a recent 
review.[4] Oxidation of n-heptane to the corresponding alcohols and ketones was reported for a 
Mn(TDCPP)Cl-complex together with H2O2 as oxidant with a TTN of 202.[4, 189] Total turnover 
numbers for 19A12NADH and CM1NADH are 15-fold higher (see Table 4-7) and the modular 
concept with a RE-ADH allows in addition to produce chiral alcohols.  
Some general trends for the described double oxidation cascade transformations of n-heptane 
were identified. Coupling of two oxidation reactions with direct cofactor regeneration boosts 
the product formation by more than 1.8-fold (up to 1.3 mM/ 150 mg L-1 total product; Figure 
4-22). The cofactor recycling during the second oxidation step enables an improved product 
formation, which is reflected in higher total turnover numbers (up to 2500) compared to the 
single hydroxylation reaction. The product formation can however be further increased (3-fold) 
Table 4-7: Total turnover numbers of n-heptane oxidation with P450 BM3 WTNADH, 19A12NADH and 
CM1NADH. Reaction in absence of RE-ADH (entry 1), in presence of RE-ADH (entry 2) and in presence of RE-
ADH with additional NADH regeneration (GDH/D-glucose; entry 3). Taken from Müller at el.[175] 
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to 1.8 mM/ 207 mg L-1 by means of a supporting cofactor regeneration system (Figure 4-23); in 
case of D-Glucose/GDH TTNs up to 3500 without changes in the stereo-selectivities were 
obtained (Table 4-7). 
These results demonstrate that the direct regeneration of NADH through enzyme-coupling 
compensates the losses of the cofactor due to the uncoupling of the monooxygenase-catalyzed 
oxidation. The coupling efficiencies of P450 BM3 achieved in this work are comparable to 
those of previous evolutionary studies for non-natural substrates which are often below 
80%.[132b, 137, 177a, 190] Nevertheless, enhancing coupling efficiency of monooxygenases and 
thereby reducing the amount of generated hydrogen peroxide remains an important challenge 
to improve process stability and total turnover numbers of P450s in general. The coupling 
efficiency of P450 BM3 was significantly improved by protein engineering for NADH from 9 
to 44% in this study, and up to 95% (NADPH) in others.[146] The regioselectivity of P450 BM3 
could also be improved significantly for non-native substrates like limonene[191], steroids[192], 
and 2-aryl-acetic acid esters[193]. In this regard, tuning of P450 enzymes for non-native 
transformations was recently reviewed in a comprehensive way by Fasan.[194] 
The stereo-preferences of the employed ADH opens up the possibility of a non-racemic 
resolution of enantiomers starting from a n-alkane substrate and yielding (R)- or (S)-alcohols as 
value added products in double oxidation cascade reactions. The specificity of the RE-ADH 
((S)-selective), which accepts only (S)-alcohols for NADH production reduces the amount of 
regenerated cofactor. In an ideal case, two enzymes with matching KM-values and specificities, 
and a highly coupled cofactor oxidation would be sufficient to overcome constraints in the 
cofactor availability. 
4.3 Whole cell double oxidation of alkanes by P450 BM3 
monooxygenases and alcohol dehydrogenases 
The use of whole cell catalytic approaches can enable a cost-effective and simpler route for the 
production of key-intermediates in organic synthesis.[25] Compared to an in vitro reaction 
system the whole cell system provides through compartmentalization a natural environment for 
the enzyme under physiological conditions, resulting in a higher stability of the catalyst.[75] A 
further striking advantage of whole cells over in vitro systems is the intracellular availability of 
redox equivalents and the possibility to regenerate cofactors by mean of the cells metabolism. 
In particular, oxidation reactions that require the regeneration of a cofactor or multi-enzymatic 
pathways can be operated very efficiently in whole cells.[76] The aim of the following study 
was to establish and investigate a whole cell system for the one-pot double oxidation of 
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alkanes. In chapter 4.2 the coupled oxidation of n-heptane by means of a P450 BM3 
monooxygenase and the alcohol dehydrogenase from Rhodococcus erythropolis (RE-ADH) 
was described.[175] The concept was extended by generating an E. coli production host for 
coexpression of both catalysts in a single cell. The generated whole cell catalyst should be 
employed in the multi-enzymatic double oxidation of alkanes as shown in Scheme 5. 
 
 
 
In this alternative process only a few components are required: resting cells in an aqueous 
medium (catalyst), glucose for cofactor regeneration, oxygen as oxidizing agent and the target 
substrate. The double oxidation enables the direct synthesis of ketones or chiral alcohols that 
represent important building blocks for the pharmaceutical, agrochemical and food industry.[28] 
For instance, aliphatic ketones are employed in the production of flavors and fragrances and 
cycloalkanones in the manufacture of synthetic polymers (polyamides).[43] Different 
coexpression strategies were compared, among them a novel system for coexpression of two 
recombinant genes as a fused operon. The system was expanded to a second alcohol 
dehydrogenase, an (R)-selective NADPH-dependent ADH from Lactobacillus brevis (Lb-
ADH)[158] with complementary selectivity to the RE-ADH. By applying two stereo-
complementary alcohol dehydrogenases a complete oxidation of the intermediate alcohols to 
the alkanones is strived for. In this way, the multi-enzymatic concept can be used similar to a 
biocatalytic tool-box, either for synthesis of chiral alcohols or for production of pure ketones. 
The biocatalytic cascade consisting of an initial oxyfunctionalization of the unsaturated 
hydrocarbons of n-heptane and cyclooctane as model substrates, and a second oxidation to the 
alkanones was evaluated using the described system. 
Scheme 5: Whole cell double oxidation of alkanes using a multi-enzymatic cascade reaction. 
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 Coexpression of NADH-dependent P450 BM3 monooxygenases and alcohol 4.3.1
dehydrogenases 
The heterologous coexpression of multiple proteins in a single host allows the production of a 
whole cell catalyst containing all enzymatic components that are necessary for a biocatalytic 
cascade. The P450 BM3 variant CM1NADH, together with RE-ADH were chosen as target genes 
to determine the optimal coexpression strategy for the designed biocatalytic cascade (Scheme 
5). Part of the preliminary work in chapter 4.3.1, 4.3.2 and 4.3.3 was accomplished by Tim 
Welters within the frame of his bachelor thesis.[195] 
Three distinctive coexpression strategies were tested. Figure 4-24 shows the properties of each 
generated vector construct that was used for coexpression of the two genes of interest. 
 
 
 
 
A first strategy consisted in the transformation of two expression plasmids in E. coli. The 
plasmids pALXtreme-1a (containing P450 BM3) and pKA1 (containing RE-ADH) were 
selected (vector maps, appendix Figure 6-1 and Figure 6-2) as two-plasmid expression system. 
Compatibility of the selected vectors for coexpression in one host strain is ensured by the 
different origin of replication (replicon) and antibiotic resistance in both plasmids (see 
chapter 3.4, Table 3-2). 
As a second strategy the commercial vector pACYCDuet-1 (Merck, Darmstadt, Germany) was 
employed.[159] This vector comprises two expression regions each consisting of a T7 
promotor/lac operator and a separate ribosome binding site (RBS), followed by a multiple 
cloning site (MCS1 and MCS2) and a terminator region for simultaneous expression of two 
proteins (vector map, appendix Figure 6-3). 
Figure 4-24: Different strategies for coexpression of two genes of interest (P450 BM3 monooxygenase and 
RE-ADH). The three investigated systems are: 2-plasmid-system (A), commercial pACYCDuet-system (B), 
operon-fusion system (C). The amount of recombinant DNA transformed in an E. coli cell as expression host is 
given in kbps. 
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The third coexpression strategy is based on the generation of a synthetic operon-fusion or 
polycistronic plasmid[196], for simultaneous expression of both proteins regulated by a single 
T7 promoter, operator and terminator originated from the pALXtreme-1a vector (vector map, 
Figure 3-1). Figure 4-25 shows a simplified representation of the constructed operon-fusion 
vector. 
 
 
 
The expression of all systems is induced by supplementation of IPTG, resulting in case of the 
operon-fusion construct (Figure 4-25) in the transcription of a single polycistronic mRNA that 
contains the information for both the P450 monooxygenase and the ADH. The polycistronic 
mRNA harbors two ribosome binding sites for translation of the single proteins, each of them 
upstream of the start codon in 6 bps distance. The described synthetic operon-fusion resembles 
therefore a simplified bacterial operon.[197] 
The generated strains were cultivated in shake flask and the whole cells were subsequently 
analyzed in regard to the expression level of P450 BM3 and ADH (Figure 4-26). Furthermore, 
the catalytic performance of the whole cell catalyst in the one-pot double oxidation of 
n-heptane was investigated (Figure 4-27). 
 
 
 
Figure 4-25: Schematic representation of the operon-fusion vector construct for coexpression of a P450 
BM3 monooxygenase and an alcohol dehydrogenase. RBS: ribosome binding site. 
Figure 4-26: Coexpression of P450 BM3 CM1NADH and RE-ADH. Protein expression from two independent 
shake flask experiments (a) and (b) visualized on a 10% SDS-PAGE gel (lysate from 0.6 mg cell wet weight per 
lane). Coexpression strategies: (1) operon-fusion, (2) pACYCDuet-1-vector system, (3) 2-plasmid system; (M) 
Molecular weight standard (Prestained PageRuler, Fermentas).  
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A rather balanced over-expression of P450 BM3 CM1NADH and RE-ADH was achieved with 
best results using the operon-fused construct (pALXtreme-1a P450 BM3-RE-ADH) as shown 
in Figure 4-26 (1a and 1b). The ADH was expressed in higher amounts with the 2-plasmid and 
the pACYCDuet-1 system. However, this two vector constructs (2-plasmid system and 
pACYCDuet-1) showed a significantly lower expression of the threefold larger P450 BM3 
monooxygenase (119 kDa) compared to RE-ADH (39 kDa). The catalytic activities of P450 
monooxygenases are in general significantly low compared to other enzyme classes.[41b] RE-
ADH shows a considerably higher activity of 47 U mg-1 for the oxidation of 2-heptanol 
compared to the P450 BM3 CM1NADH activity of 5 U mg-1 for the hydroxylation of n-heptane 
(chapter 4.2.1 and 4.1.3). Therefore, it was important to ensure a high concentration of the 
P450 monooxygenase in the whole cell catalyst to avoid a rate limiting initial oxidation step. 
To determine the intracellular concentration of P450 BM3 in each coexpression strain the yield 
of active P450 BM3 protein YP450/x (in mgP450 gCDW-1; x = cell dry weight) was calculated. The 
product yields on catalyst (Yp/x) for the double oxidation of n-heptane and the P450 yields 
(YP450/x) are shown in Figure 4-27. These values were calculated for each strain after 
expression in shake flask, as well as for one selected construct (P450 BM3 CM1NADH-RE-
ADH, operon-fusion) after expression in the fermentor under controlled growing conditions 
(see chapter 3.8). 
 
 
 
The expression in shake flask yielded for the pACYCDuet and the operon-fusion constructs 
higher P450 BM3 content per cell dry weight, as determined by quantification via CO-
Figure 4-27: Comparison of three different coexpression strategies of P450 BM3 CM1NADH and RE-ADH 
in E. coli cells. E. coli BL21(DE3) Gold (lacIQ1) containing three different constructs (see Figure 4-24), 
expression in shake flask (light gray) and in Fermentor (operon-fusion, dark gray); Product yields (A) and P450 
yields (B) were calculated in relation to the cell dry weight. Reaction conditions: Resting cells in 0.1 M KPi 
buffer pH 8.0 (1 mL; OD600 40), 10 g L-1 D-glucose, 200 µL n-heptane, 51 h stirring at RT. 
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difference spectroscopy (1.5 and 1.6 mgP450 gCDW-1; Figure 4-27 B). On the contrary, the 
corresponding product yields of 1 and 8 mg gCDW-1 were lower than the yield of 14 mg gCDW-1 
achieved with the 2-Plasmid system (Figure 4-27 A). Besides, the analysis by SDS-PAGE 
electrophoresis of expression for the operon-fusion construct P450 BM3 CM1NADH-RE-ADH 
in shake flask did not correlate entirely with the measured concentration by CO-difference 
spectroscopy (Figure 4-26 vs. Figure 4-27 B). A possible reason for the differing result would 
be the occurrence of a high content of inactive (miss folded) monooxygenase, which would not 
be detected by the CO-spectroscopic measurement. The use of the 2-Plasmid system showed 
however differences compared to the operon-fusion system. It was observed, that the growth of 
the E. coli strain containing two plasmids was nearly twofold slower than the strains containing 
only one plasmid (pALXtreme-1a or pACYCDuet) and the amount of biomass produced was 
nearly 2-fold lower. For cultivation, expression and maintenance of both plasmids two 
antibiotics are required, not only increasing the metabolic burden of the host cell but also the 
production costs of the catalyst. The synthesis of high levels of antibiotic resistance genes 
along with the targeted genes requires considerable amounts of energy, debilitating the cell and 
lowering the cell density.[198] The negative effects on growth of two co-transformed plasmids 
encoding each one antibiotic resistance genes on the growth of Pseudomonas putida cells was 
reported before.[199] In the case of the pACYCDuet-vector construct the poor product yield 
achieved (1 mgproduct gCDW-1, Figure 4-27 A) renders its application not feasible. This result is 
surprising since the P450 yield in the pACYCDuet-vector system and the operon-fusion system 
is very similar (1.6 vs. 1.5 mgP450 gCDW-1; Figure 4-27 B). Other properties such as the 
concentration of active ADH or the effect of antibiotics on the cells metabolism could have a 
strong influence on the catalytic performance of each coexpression strain.   
Coexpression of the target proteins or also other proteins using the described operon-fusion 
strategy has several advantages over other coexpression methods. Using the described ligase-
independent cloning technology (PLICing)[153] the insertion of target genes in the expression 
vector is not dependent on the availability or compatibility of restriction sites, as in the case of 
restriction cloning methods[196]. In addition, multiple genes can be cloned in only one step 
while consecutive steps are required for restriction cloning. Moreover, several genes can be 
expressed using only one plasmid, thereby reducing the metabolic burden on the host cell. It 
was demonstrated, that a higher plasmid copy number increases the metabolic load and more 
energy is required for DNA maintenance.[200] As an example, the relative specific growth rate 
of E. coli HB101 cells was correlated to the DNA content and plasmid copy number. The 
growth rate decreased from 1.0 to 0.92 upon transformation of one plasmid (12 copies) and to 
0.91 when two plasmids where transformed (24 copies).[201] It was also reported, that due to 
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higher plasmid content the cell increases significantly the concentration of several enzymes 
involved in the citric acid cycle to replenish the intermediates required for nucleotide 
synthesis.[200] A small plasmid size, as in the case of the employed vector pALXtreme-1a, not 
only reduces the energetic burden on the host but also leads to higher cell density during 
cultivation[198b]. The recombinant DNA content is in the case of the 2-plasmid-system nearly 
2-fold higher (11.7 kbps) than the DNA content of the operon-fusion system (6.1 kbps; Figure 
4-24). As surplus, higher transformation efficiencies are achieved using smaller plasmids for 
gene cloning.[153, 202] This becomes more evident when more than three enzymes have to be 
clones in one vector. The lower metabolic burden and energy requirement could be from 
significant benefit for the application of operon-fusion systems in biotransformations with 
growing cells.  
 Fermentation of operon-fusion strains 4.3.2
The three E. coli BL21 (DE3) Gold lacIQ1 strains containing the different monooxygenases as 
operon-fusion vector system, P450 BM3 WTNADH-RE-ADH, 19A12NADH-RE-ADH and 
CM1NADH-RE-ADH, were selected for cultivation and expression under controlled conditions 
in a bioreactor. During the fermentation important cultivation parameters such as dissolved 
oxygen (pO2) and pH were monitored online (appendix, Figure 6-8). The pH was kept at all 
times constant at 7.1. Cell densities (measured as OD600) and expression levels of P450 BM3 
and RE-ADH by SDS-PAGE electrophoresis were determined during the entire fermentation 
process. In all three fermentations an OD600 of 18 to 19 was achieved after 26 hours of induced 
protein expression (in total ~30 h run time). This value corresponds to a biomass concentration 
of nearly 4 gCDW L-1. After induction the expression of P450 BM3 increased gradually 
throughout the entire course of fermentation as monitored by SDS-PAGE analysis (appendix 
Figure 6-9). The expression level of RE-ADH was in contrast rather constant until 8 h after 
induction and was slightly higher at the end of the fermentation (21 h). The monooxygenase 
expression level in the operon-fusion strain CM1NADH-RE-ADH was the highest of all three 
strains. A final cell concentration of 3.86 gCDW L-1 containing a P450 BM3 concentration of 
0.31 gP450 L-1 (2.64 µM) was determined for this strain. This represents a specific protein 
formation of 683.5 nmolP450 gCDW-1 (P450 yield YP450/x of 81.3 mgP450 gCDW-1). The specific 
protein formation that was determined for this strain is slightly higher (6%) than the value of 
644 nmolP450 gCDW-1 that was reported by Pflug et al. for the heterologous expression of P450 
BM3 WT in E. coli (BL21(DE3) pET28a(+)-system) in a fed-batch fermentation process.[203] 
This is to best of our knowledge the highest previously reported production yield for this 
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enzyme. However, the batch-fermentations presented in this study yielded 5-fold lower final 
cell mass concentrations (3.8 - 4 gCDW L-1). In the reported fed-batch fermentation process the 
reported cell concentration of 19.8 gCDW L-1 was achieved by inducing protein expression at a 
significantly higher optical density and using an optimized feeding and aeration strategy.[203] 
Through controlled fermentation it was possible to enhance significantly the P450 BM3 
content in the cells, in case of P450 BM3 CM1NADH-RE-ADH by 54-fold compared to the 
shake flask cultivation as shown in Figure 4-27 A (81 vs. 1.5 mgP450 gCDW-1). The translational 
coupling of both genes using a single operon is beneficial to achieve a high expression level of 
both enzymes, probably through a ribosome-mediated positive regulation of the translation 
event.[204] This means that a positive effect can be observed when the translation of 
neighboring genes is tightly coupled. One possible mechanism for positive regulation would be 
that ribosomes terminating translation of the first gene may be able to re-initiate translation on 
the second gene.[204b] An improved expression in the fermentor compared to the one in shake 
flask is probably the result of controlled pH and stirring, allowing to adjust a constant pH, as 
well as a homogenous mixing of the culture broth and a higher aeration rate. 
Using the maximal specific activity of 5073 U gP450-1 for P450 BM3 CM1NADH as reference 
value (purified enzyme, see chapter 4.1.3) it is possible to calculate the theoretical specific 
activities of the whole cell catalyst. The fermentation of the operon-fusion construct enabled 
the production of cells with a theoretical specific activity of 411 U gCDW-1. Compared to a 
theoretical specific activity of 7.6 U gCDW-1 for cells from shake flask expression, the gain in 
activity through overexpression of the protein by means of fermentation is impressive. 
Using the cell mass from fermentation in the biotransformation of n-heptane the product yield 
was increased by 7-fold from 8 to 58 mg gCDW-1 (Figure 4-27 B). The increase in product yield 
Yp/x is nearly proportional to the increase in P450 yield YP450/x. This result highlights the 
importance of optimizing the heterologous expression of the monooxygenase in the employed 
production host to achieve higher specific activities. Duetz et al. estimated that the theoretical 
specific activities of intact cells containing NAD(P)H-dependent oxygenases with high kcat 
values (5-75 s-1) could reach a value between 150 and 4500 U gCDW-1.[75] In a recent study 
Blank et al. estimated an activity of 367 U gCDW-1 for redox-reactions in resting E. coli cells, 
under consideration of the maintenance energy demands and NAD(P)H regeneration via 
glucose with a maximal glucose uptake rate of 2.4 mmol gCDW h-1.[68] It was pointed out that in 
the practice activities significantly higher than 500 U gCDW-1 have not been reached so far.[75-76] 
Therefore, further bottlenecks such as product inhibition or mass transfer rate limitations have 
to be addressed carefully and integrated in the process development.[75] 
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 Reaction engineering for whole cell biotransformations 4.3.3
In addition to protein and strain engineering this thesis emphasized also on reaction 
engineering to optimize important parameters that influence the operational performance of a 
whole cell P450-ADH catalyst in a multi-enzymatic reaction. 
Key parameters such as glucose concentration, pH-value, reaction medium, substrate, and cell 
mass (catalyst) concentrations were evaluated and optimized to achieve higher product 
concentrations in the double oxidation of n-heptane to chiral heptanols and heptanones. The 
performance of resting cells was evaluated in phosphate buffer and E. coli Minimal Medium 
(EEM; pH of 7.0), which are widely applied in whole cell conversions.[205] As further 
modification of the 0.1 M potassium phosphate buffer the pH value was varied from 7.0 to 8.0 
and the supplementation of different D-glucose concentrations was investigated, as shown in 
Figure 4-28. 
 
    
 
The highest product concentration (total product heptanol and heptanone) was achieved with a 
glucose concentration of 10 g L-1 and 0.1 M KPi-buffer at a pH of 8.0. In the absence of 
glucose a very low product concentration is achieved (0.1 mM). Since no nicotinamide 
cofactor is added externally, the product formation without supplementation of glucose is 
probably facilitated by the remaining intracellular concentration of cofactors. A rather 
sigmoidal dependency between the glucose concentration and the product formation is 
observed. At a glucose concentration of 5 to 10 g L-1 the reaction reaches saturation. 
In the established oxidoreductase-catalyzed in vivo biotransformation approach, the essential 
cofactor NADH for the P450-catalyzed reaction is regenerated most likely via the glucose 
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Figure 4-28: Effect of glucose and different reaction media on the whole cell double oxidation of n-
heptane.  Reaction conditions: BL21 Gold (DE3) lacIQ1 pALXtreme-1a P450 BM3 CM1NADH-RE-ADH in (A) 
OD600 50 (11 gCDW L-1, 7.3 µM P450), 80 mM n-heptane in EEM pH 7.0 (1 mL), varying D-glucose 
concentration (0-10 g L-1), 20 h at RT; in (B) OD600 70 (15 gCDW L-1, 10 µM P450), 10 g L-1 D-glucose, 300 µL 
n-heptane, varying reaction medium (1 mL; 0.1 M KPi, pH 7.0, 7.5, 8.0 or EEM), 24 h at RT. 
A B 
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metabolism of the E. coli host and in part by the artificial cascade for substrate coupled 
regeneration of NADH. Resting, but metabolically active cells are used, implying that redox 
cofactors and biomass precursors should not be consumed for the synthesis of biomass 
allowing a higher NADH yield.[68] Yet, the required energy for cell maintenance has to be 
provided throughout the conversion reaction. The regeneration rate of NADH will partially 
depend on the regeneration capacity of the cells, which can represent a limiting factor in 
biocatalytic redox process.[68, 206] The supplementation with glucose is therefore beneficial for 
supporting the necessary cofactor regeneration as confirmed by the results in Figure 4-28 A. 
Blank et al. estimated the metabolic capacity for NADH regeneration in resting E. coli cells.[68] 
For an optimal glucose uptake rate of 2.4 mmol gCDW-1 h-1 a theoretical NADH-formation rate 
of 22 mmol gCDW-1 h-1 was calculated. Under assumption of an equimolar stoichiometry 
between NADH and the biocatalytic product, the maximal biocatalytic activity for 
oxidoreductases would reach 367 U gCDW-1. At higher glucose uptake rates the oxidation of 
glucose will not be complete (overflow metabolism) resulting in the catabolic production of 
byproducts like acetate and CO2.[68] Using 10 g L-1 glucose and a cell mass concentration of 
11 gCDW L-1 (Figure 4-28 A), the available concentration of glucose can be calculated as 5.04 
mmol gCDW-1. At this concentration the product concentration reaches a maximum of 1.41 mM 
which is slightly higher than for 5 g L-1 glucose. At a glucose concentration of 2.4 mM the 
effect on productivity is detrimental (overflow metabolism, altered glucose flux, pH shifts due 
to acid formation), therefore the whole cell becomes a “black box”. 
Metabolic stress caused by high bioconversion rates or formation of reactive oxygen species as 
a result of uncoupling can also lead to production of acetate or other metabolites.[206] Bühler et 
al. reported a strong pH-dependency on the specific activity of growing cells in the long-term 
two-liquid-phase oxidation of 3,4-dimethylbenzyl alcohol. At pH 7.4 a significantly higher 
activity was reached compared to pH 7.1. The authors concluded that a pH-influenced 
competition for NADH between the heterologous expressed catalyst (xylene monooxygenase) 
and the respiratory chain took place. In short term experiments of 5 min with resting cells this 
pH-effect was not significant. Long-term studies were however not conducted.[206] 
Based on the presented results from Figure 4-28 (A) it can be concluded, that the pH of the 
reaction medium has a strong effect on the biocatalytic activity, also when resting cells are 
used. A difference of 1.0 in the pH value (from 7.0 to 8.0) enhanced the product concentration 
by 2-fold. The enhanced productivity is probably caused by pH-influenced changes in the cell 
metabolism or/and in the interaction between the expressed oxidoreductases and the 
regeneration capacity of the cell. The higher pH value of 8.0 gives the system a better buffering 
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capacity against acidifying byproducts (e.g. acetate as product from overflow metabolisms) 
when higher glucose amounts for regeneration are employed. The higher pH is therefore 
beneficial for the bioconversion of n-heptane. A scale-up of the whole cell reaction process 
using a bioreactor and the possibility to monitor and control the pH would be desirable for 
further optimization of the reaction conditions. 
To determine the correlation between substrate concentration and product yield different 
n-heptane concentrations ranging from 1 to 1045 mM were applied. Additionally, the use of 
n-heptane not only as substrate but also as organic carrier for a two-liquid-phase system was 
investigated. Concentrations of 93, 440 and 1045 mM are equivalent to an n-heptane volume of 
15, 75 and 200 µL and a volumetric content of the organic component in an aqueous-organic 
two phase system of 1.5, 7 and 17 % (v/v) respectively. In case of 200 µL (1450 mM) 
n-heptane an aqueous-organic bilayer was formed. Product formation using different n-heptane 
concentrations, as well as the product yield based on substrate consumption Yp/s (equivalent to 
molproduct molsubstrate-1 x100%) were determined as shown in Figure 4-29. 
 
 
 
The highest product yield Yp/s (19%) was obtained employing 1 mM substrate. However, 
decreasing product yields (Yp/s) are the result of the higher substrate load used in the remaining 
measurements. Higher product concentrations (up to 2 mM) were measured for the substrate 
concentrations 440 and 1045 mM, which correspond to a volumetric content of 7 and 17% 
Figure 4-29: Effect of varying n-heptane concentrations on product concentration and yield. Total product 
concentrations (●) and product yields Yp/s over substrate (∆) were calculated taking into account the sum of all 
heptanol and heptanone isomers. Reaction conditions: BL21 Gold (DE3) lacIQ1 pALXtreme-1a P450 BM3 
CM1NADH-RE-ADH in 0.1 M KPi buffer pH 8.0 (1 mL; OD600 70, 15 gCDW L-1, 10 µM P450), 10 g L-1 
D-glucose, varying n-heptane concentration; 24 h stirring at RT. 
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(v/v) n-heptane. Here an aqueous-organic two-phase reaction system is present. The advantage 
of this system lies on the use of n-heptane as organic carrier solvent, which serves 
simultaneously as substrate reservoir and product sink.[207] It is generally accepted, that the 
biocompatibility of an organic solvent used as second phase in bicatalytic processes correlates 
to the logPo/w value - the octanol/water partition coefficient - as a measure of the solvent 
hydrophobicity. Solvents with logPo/w ≥ 4 are regarded as biocompatible, mainly for free 
enzymes in two-liquid-phase systems.[207a] For whole cell systems this correlation depends 
strongly on the microorganism species.[207b] In some cases a transition into a toxic range was 
observed for logPo/w values from 3 to 5.[1, 208] n-Heptane has a logPo/w value of 4.66 (at 
25 °C).[187a, 187b] In fact, the logPo/w value gives rather a precise correlation for the mutual 
solubility of organic solvents and water in water-immiscible systems.[209] Taking into account 
the higher solubility of n-heptane in water than water in n-heptane, the use of a two-phase 
system should enable higher substrate availability throughout the biotransformation process. 
Heptanol and heptanone as main products of the cascade reaction, with logPo/w values of 
around 2.22 [210] and 1.98[187a] respectively, are more apolar than the substrate n-heptane. They 
will most likely accumulate in the organic phase, enabling an in situ product removal and 
avoiding a possible product inhibition of the catalyst. The results of this study imply that the 
use of n-heptane as organic carrier in the described approach for E. coli whole cells is feasible. 
Other advantages of two-phase systems for biocatalytic transformations are besides the in situ 
product recovery a simpler work up by separation of the phases and a possible recycling of the 
organic phase for further biotransformations.[81] The low price of n-heptane as bulk chemical 
make an application in a higher amount as organic liquid phase feasible, then it serves 
simultaneously as starting material for the synthesis of value-added products. Due to the fact 
that P450 BM3 hydroxylates a broad range of organic substrates[58] the selection of a suitable 
organic solvent is strongly limited. Besides, the use of n-heptane and other alkanes like 
n-hexane, cyclohexane, n-octane and isooctane as organic solvent in biphasic 
biotransformations have being described previously for cell free enzymes[83c] as well as whole 
cell processes[148, 174, 211]. 
The biotransformation was further optimized in regard to cell mass concentrations for each 
P450 BM3 construct. The correlation between optical cell density (OD600) and cell dry weight 
(CDW) was calculated for cells harboring the operon-fusion constructs P450 BM3 WTNADH-
RE-ADH, 19A12NADH-RE-ADH and CM1NADH-RE-ADH after expression in the fermentor. 
The corresponding P450 BM3 concentrations were determined by CO-difference spectroscopy 
(appendix Figure 6-10). The correlation between cell dry weight and P450 concentration is 
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linear (2 to 13 gCDW L-1). Based on this correlation the intracellular expression titer of P450 
BM3 or simplified, the P450 yield (YP450/x), was calculated for each monooxygenase variant 
(see chapter 4.3.4, Table 4-8). The highest expression level of P450 BM3 monooxygenase was 
achieved for the construct CM1NADH-RE-ADH with a P450 yield of 81 mgP450 gCDW-1. 
The effect of different cell mass concentrations on the product yield was evaluated as well. The 
maximal product yields are shown in Figure 4-30. 
 
 
 
Product yields for the three selected P450 BM3 monooxygenases are strongly dependent on the 
concentration of cell mass employed in the reaction. Each batch of cells containing one of the 
P450 BM3 monooxygenase variants displays a distinctive optimal cell mass concentration. The 
highest product yields were achieved using 6.3 gCDW L-1 (OD600 of 30) for the strain containing 
P450 BM3 19A12NADH, 7.7 gCDW L-1 (for (OD600 of 30) for WTNADH and 8.4 gCDW L-1 (OD600 
of 40) for CM1NADH. This CDW values correspond to monooxygenase concentrations of 0.16, 
0.58 and 0.68 gP450 L-1 respectively. Interestingly, the product yield is not proportional to the 
amount of P450 BM3 monooxygenase employed in the reaction. This yield is most likely 
dependent on the intracellular concentration ratio between both cascade-enzymes 
(monooxygenase and dehydrogenase), but also on possible mass transfer limitations (substrate, 
products, oxygen) at high cell mass concentrations. In this regard, a limitation in the oxygen 
supply can lead to a reduce monooxygenase activity.[75] The reduction of oxygenase activity 
caused by high cell concentrations was also observed by Baldwin and Woodley.[212] The 
authors proposed that a heterologous expressed oxygenase, which have a lower affinity (higher 
Figure 4-30: Product yields in the whole cell biotransformation of n-heptane using different operon-fusion 
strains. The strains are: BL21 Gold (DE3) Gold lacIQ1 pALXtreme-1a P450 BM3 WTNADH-RE-ADH (red), 
19A12NADH-RE-ADH (blue) and CM1NADH-RE-ADH (black). Reaction conditions: Resting cells in 0.1 M KPi 
buffer pH 8.0 (1 mL), 10 g L-1 D-glucose, 200 µL n-heptane with varying cell concentrations (CDW from 2 to 
13 g L-1), 48 h stirring at RT. 
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KM value) for oxygen than the respiratory chain of the cell, will not be able to compete 
efficiently for the dissolved oxygen if the exogenous cell respiration exceeds a certain 
threshold. The P450 monooxygenase catalyzed reaction, affected by mass transfer limitations 
and by a lower catalytic activity, is probably slower than the cell metabolism. 
The determined optimal cell mass concentrations for each coexpression strain were employed 
in the following biotransformation reactions. 
 Whole cell multi-enzymatic catalysis: double oxidation of n-heptane and 4.3.4
cyclooctane 
The biotransformation of n-heptane with whole cells co-expressing P450 BM3 and RE-ADH 
was performed under the optimized conditions described in chapter 3.12.2. The schematic 
representation of the cascade reaction catalyzed by recombinant E. coli cells is displayed in 
Scheme 6. 
 
 
 
The multi-enzymatic cascade allows the production of heptanones and the chiral resolution of 
(R)-heptanols in a coupled activity of the recombinant expressed P450 BM3 monooxygenase 
and ADH in E. coli. The biotransformation was monitored over 48 hours using cells expressing 
P450 BM3 CM1NADH-RE-ADH. The progress of the cascade reaction in terms of product 
concentrations is shown in Figure 4-31. An overview of the performance parameters in the 
double-oxidation reaction is given in Table 4-8 (entry 5). 
 
 
Scheme 6: Whole cell double oxidation of n-heptane catalyzed by a P450 BM3 monooxygenase variant 
and an ADH from Rhodococcus erythropolis (RE-ADH). In the initial cascade step n-heptane is hydroxylated 
by the P450 BM3 monooxygenase to the corresponding heptanol isomers. The second step is comprised by the 
oxidation of (S)-heptanol to the corresponding ketones, enabling the accumulation of the (R)-heptanol 
enantiomers and the concomitant regeneration of the cofactor NADH. 
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A total product concentration of 5.7 mM (658 mg L-1) was measured after 48 hours, consisting 
of 4.1 mM alcohol and 1.6 mM ketone. The product formation rate was nearly linear until 
8 hours, with the highest specific activity of 0.76 U gCDW-1 (9.3 U gP450-1) and a maximal space 
time yield (STY) of 45 mg L-1 h-1 after 4 hours. From 8 hours onwards the product formation 
rate decreases, but product accumulated constantly until the end of the reaction at 48 h. A total 
turnover number for the reaction time of 48 h was determined as 968 molproduct molP450-1. The 
maximal specific activity reached with the system is 541-fold less thanthe theoretical specific 
activity of 411 U gCDW-1 that was calculated for whole cells expressing P450 BM3 CM1NADH 
(refer to chapter 4.3.1). Different parameters such as mass transfer limitations, enzyme 
inactivation or loss of cell viability and cofactor regeneration capacity could lead to the lower 
specific activity reached with the multi-enzymatic system so far. It is worth mentioning, that 
the biotransformation process was performed in a small scale with a reaction volume of 1 mL 
and magnetic bar stirring. To investigate the bottlenecks of the system and optimize product 
yields a scale-up using a bioreactor with controlled process parameters like pH, stirring and 
aeration rate would be advantageous.   
A direct comparison of the performance of the single hydroxylation as well as the double 
oxidation of n-heptane was carried out (Table 4-8). For this purpose the strains expressing the 
sole P450 BM3 variant CM1 (NADPH-dependent) and CM1NADH (NADH-dependent) were 
employed under the optimized biotransformation conditions. 
Figure 4-31: Whole cell conversion of n-heptane over 48 hours. Total product concentrations (black) 
consisting of heptanol (purple) and heptanone (blue), as sum of the corresponding regiomers (GC 
quantification), measured after a reaction time of 0.5, 1, 2, 4, 8, 16, 24, 28 and 48 h at RT. Reaction conditions: 
E. coli BL21 (DE3) Gold lacIQ1 pALXtreme-1a P450 BM3 CM1NADH-RE-ADH (OD600 40; 8.5 gCDW L-1, 5.9 µM 
P450) in 0.1 M KPi buffer pH 8.0 (1 mL), 10 g L-1 D-glucose, 200 µL n-heptane as second phase. 
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Entry Multi-enzyme system 
  
Product concentration Product yield 
on catalyst Yp/x 
P450 yield on 
catalyst YP450/x 
 [µM] [mg L-1] [mg gCDW-1] [mgP450 gCDW-1] 
 Single expression (shake flask) 
1 P450 BM3 CM1 1133 ± 110 132 ± 13 16 ± 2 53 
2 P450 BM3 CM1NADH 2319 ± 74 269 ± 9 40 ± 1 58 
 Operon-fusion (Fermentation) 
3 P450 BM3 WTNADH-RE-ADH 2952 ± 6 342 ± 31 44 ± 4 74 
4 P450 BM3 19A12NADH-RE-ADH 3400 ± 69 390 ± 8 61 ± 1 25 
5 P450 BM3 CM1NADH-RE-ADH 5671 ± 344 656 ± 40 76 ± 5 81 
 In vitro system     
6 P450 BM3 CM1NADH + RE-ADH 1800 207 -- -- 
[a] Product concentrations are the sum of all quantified heptanol and heptanone isomers; the reaction mixture 
contained E. coli cells (OD600 40 for P450 BM3 CM1, CM1NADH and CM1NADH-RE-ADH; OD600 30 for 
WTNADH-RE-ADH and 19A12NADH-RE-ADH) in 0.1 M KPi buffer pH 8.0 (1 mL), 10 g L-1 D-glucose, 
1045 mM (200 µL) n-heptane as second liquid phase. 
 
Despite of a similar P450 BM3 content in CM1 and CM1NADH after shake flask expression (53 
and 58 mgP450 gCDW-1 respectively), the product formation with the NADH-dependent variant is 
2-fold higher and the product yield, normalized to the amount of cells in the reaction, even 
2.5-fold improved (Table 4-8, entry 2 vs. 1). This values show the direct benefit of using the 
engineered NADH-dependent monooxygenase as whole cells catalyst over the native NADPH-
dependent counterpart.  
In the double oxidation cascade with cells containing CM1NADH-RE-ADH the product yield of 
76 mgproduct gCDW-1 is nearly doubled compared to the reaction with cells containing only P450 
CM1NADH (Table 4-8, entry 5 vs. 2). The improved performance of this catalyst can be 
explained by the 1.4-fold optimized intracellular expression of the P450 monooxygenase 
(Table 4-8, 81 vs. 58 mgP450 gCDW-1). 
The highest product yield of 76 mgproduct gCDW-1 was measured for the strain containing 
CM1NADH-RE-ADH, which also displayed the highest intracellular content of P450 BM3 
(Table 4-8, 81 mgproduct gCDW-1). Product yields as well as P450 BM3 expression levels were 
lower for WTNADH-RE-ADH and 19A12NADH-RE-ADH. A low P450 yield of 25 mgP450 gCDW-1 
was achieved in the case of the 19A12NADH operon-fusion compared to the other two expressed 
monooxygenase variants, despite of cultivation in the fermentor under optimized growing 
conditions (Table 4-8, entry 3, 4 and 5). The poor expression of P450 BM3 19A12[175] is 
Table 4-8: Process performance for the whole cell single hydroxylation and the double oxidation of 
n-heptane with P450 BM3 and RE-ADH[a]. The product concentration for the in vitro double-oxidation system 
is given as reference. 
RESULTS AND DISCUSSION 
 
 
106 
 
probably caused by the low stability of this monooxygenase variant as previously discussed in 
chapter 4.1.1. These results highlight the importance of an elevated expression level besides of 
the enzymes activity to achieve the best catalytic performance. Especially for the strain 
containing the operon-fusion CM1NADH-RE-ADH the significant benefit of a good expression 
was proven, obtaining a 54-fold improved production of the monooxygenase after expression 
in fermentor compared to the expression in shaking flask (Figure 4-27 B) and a 7-fold 
enhanced product yield Yp/x (Figure 4-27 A). 
Final product concentrations in the double oxidation of n-heptane achieved with all three 
selected P450 BM3 monooxygenases are considerably higher using the in vivo instead of the in 
vitro biotransformation system. A comparison to the best results of the in vitro cascade 
reaction, under supplementation of cofactor regeneration via GDH (chapter 4.2.3), shows that 
with P450 BM3 WTNADH a 4-fold, with CM1NADH a 3-fold and with 19A12NADH a 2-fold higher 
product concentration is achieved using whole cell catalysis (Table 4-8, entry 3-5 vs. Figure 
4-22, panel D-F).  
To proof a broad applicability of the whole cell double oxidation concept, the coexpression of 
the respective catalysts was extended to a third enzyme, a second alcohol dehydrogenase, the 
(R)-selective NADPH-dependent ADH from Lactobacillus brevis (Lb-ADH)[158]. The Lb-ADH 
has a complementary selectivity to the (S)-specific RE-ADH[157]. 
 
 
 
 
Coexpression strains containing two enzymes, the Lb-ADH and an NADPH-dependent P450 
BM3 monooxygenases (19A12 or CM1), as well as strains containing three enzymes, two 
dehydrogenases - Lb-ADH, RE-ADH - and one P450 BM3 monooxygenase (NADH-
dependent 19A12NADH or CM1NADH) were generated by transformation of the Lb-ADH using a 
second plasmid (pKA1 vector) as shown in Figure 4-32. These generated strains for the 
Figure 4-32: Coexpression of multiple enzymes in E. coli cells using a 2-plasmid-system. The (R)-selective, 
NADPH-specific Lb-ADH is expressed from a second plasmid (pKA1), together with P450 BM3 
monooxygenase (NADPH-dependent) in a two-enzyme system (A), or with the operon-fusion between P450 
BM3 monooxygenase (NADH-dependent) and (S)-selective NADH-specific RE-ADH in a three-enzyme system 
(B). 
RESULTS AND DISCUSSION 
 
 
107 
 
coexpression of multiple enzymes are listed in the appendix section (Table 6-8). The strains 
were expressed in shake flask (chapter 3.6.3) and successful expression of all enzymatic 
components was evaluated by SDS-PAGE gel electrophoresis (appendix Figure 6-11). A very 
high expression level of the Lb-ADH was achieved in all generated strains, while the 
expression of P450 BM3 and RE-ADH were comparably low. Lb-ADH is encoded by the 
smallest of all three genes (765 bps) in a separate plasmid. It has been reported, that Lb-ADH 
is expressed in a highly efficient way and the stability of the enzyme is remarkably high 
compared to other ADHs.[158, 213] 
 
    
 
 
 
n-Heptane and cyclooctane were selected as substrates for the whole cell multi-enzymatic 
cascade reaction. The double oxidation of cyclooctane using an in vitro system was proven 
Scheme 7: Whole cell double oxidation of n-heptane (A) and cyclooctane (B) by multi-enzymatic 
expression in E. coli. Coexpression of a P450 BM3 monooxygenase variant and an alcohol dehydrogenases 
from Lactobacillus brevis (Lb-ADH) in a two-enzyme system (1) or additionally an alcohol dehydrogenase from 
Rhodococcus erythropolis (RE-ADH) in a three-enzyme system (2). With the multi-enzymatic system in A.1 
heptanone and (S)-heptanol are produced, whereas in A.2 complete oxidation to heptanone is achieved. The 
system in B.1 and B.2 allows the synthesis of cyclooctanone. 
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successfully in a previous report.[174] A representation of the catalyzed reaction using a two-
enzyme or a three-enzyme system consisting of a P450 BM3 monooxygenase and alcohol 
dehydrogenases Lb-ADH and RE-ADH is shown in Scheme 7. 
The biotransformations were performed under the conditions described in chapter 3.12.2. The 
performance of the whole cell double oxidation cascade using Lb-ADH is summarized in Table 
4-9. The product distribution patterns for each employed strain and substrate are given in Table 
4-10. 
 
Entry Whole cell catalysts 
(shake flask expression)  
Total product 
concentration 
TTN[c] Product yield 
on catalyst Yp/x 
P450 yield 
YP450/x 
 [µM] [mg L-1] 
 
[mg gCDW-1] [mgP450 gCDW-1] 
 Substrate: n-Heptane[a]      
1 BM3 19A12 + Lb-ADH 471 ± 19 54 ± 2 2930 ± 121 8 ± 0.3 3 
2 BM3 CM1 + Lb-ADH 230 ± 17 26 ± 2 854 ± 65 4 ± 0.3 5 
3 BM3 19A12NADH-RE-
ADH + Lb-ADH 
851 ± 80 97 ± 9 1393 ± 132 16 ± 2 12 
4 BM3 CM1NADH-RE-ADH 
+ Lb-ADH 
291 ± 6 33 ± 1 534 ± 11 6 ± 0.1 11 
 Substrate: Cyclooctane[b]      
5 BM3 19A12 + Lb-ADH 3916 ± 70 494 ± 9 23736 ± 426 72 ± 1.3 3 
6 BM3 19A12NADH-RE-
ADH + Lb-ADH 
5168 ± 74 652 ± 9 8303 ± 121 111 ± 1.6 12 
[a] Product concentrations as sum of heptanol and heptanone isomers; the reaction mixture contained E. coli cells 
(OD600 40) in 0.1 M KPi buffer pH 8.0 (1 mL), 10 g L-1 D-glucose, 200 µL n-heptane as second phase.  [b] Product concentrations as sum of cyclooctanol and cyclooctanone; the reaction mixture contained E. coli cells 
(OD600 40) in 0.1 M KPi buffer pH 8.0 (1 mL), 10 g L-1 D-glucose, 10 mM cyclooctane, 2% (v/v) ethanol as 
cosolvent. 
[c]
 TTN: Total Turnover Number (µmolTotal product µmolP450-1) 
In the biotransformation reaction of n-heptane through the coupled P450 BM3 and Lb-ADH 
catalyzed oxidations the product concentrations are 2-fold higher for the variant 19A12 
compared to the variant CM1 (Table 4-9, entry 1 and 2). A further enhanced productivity of 
80% for the variant 19A12NADH and of 30% for the variant CM1NADH was achieved using the 
strains containing the second alcohol-dehydrogenase RE-ADH (Table 4-9, entry 3-4 vs. 1-2). 
In this case the monooxygenase and the RE-ADH share the same cofactor preference for 
NADH, while Lb-ADH is NADPH dependent. A striking difference between the two and the 
three enzyme system is the concentration of P450 monooxygenase, calculated as P450 yield 
(YP450/x). In the three enzyme systems the P450 content is 4-fold and 2-fold higher (entry 3 and 
Table 4-9:  Process performance of the multi-enzymatic whole cell double oxidation of n-heptane and 
cyclooctane 
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4, 12 and 11 mgP450 gCDW-1 respectively). The higher P450 concentrations are in accordance to 
the higher product concentrations obtained with each system. 
Entry Catalysts Relative amount [% GC area] 
  Heptanol isomers (ee of (S)) Heptanone isomers[a] 
  1- 2- 3- 4- 2- 3- 4- 
1 P450 BM3 19A12 + Lb-ADH 0 26 /n.d. 15 (>99) 0 41 18 0 
2 P450 BM3 CM1 + Lb-ADH 0 0 11 (>99) 1 14 31 43 
3 P450 BM3 19A12NADH-RE-ADH + 
Lb-ADH 
0 0 0 0 67 31 2 
4 P450 BM3 CM1NADH-RE-ADH + 
Lb-ADH 
0 0 0 0 15 41 44 
  Cyclooctanol Cyclooctanone Unidentified peak areas 
5 P450 BM3 19A12 + Lb-ADH 0.3 96.6 3 
6 P450 BM3 19A12NADH-RE-ADH + 
Lb-ADH 
0.1 94.4 5.4 
[a] Heptanal was not detected. 
n.d.: not determined 
 
Coupling the P450 monooxygenase with the (R)-enantioselective Lb-ADH leads to 
accumulation of the (S)-heptanol isomers, while the (R)-heptanols are oxidized to the 
corresponding heptanones (Table 4-10, entry 1 and 2). In the 19A12NADH-Lb-ADH-catalyzed 
cascade reaction a relative amount of 59% ketone is obtained (2- and 3-heptanone; entry 1) and 
in case of CM1NADH-Lb-ADH 88% (2-, 3- and 4-heptanone; entry 2). Chiral resolution of 
(S)-3-heptanol is achieved in an amount of 15% and 11% respectively. In contrast to the two-
enzyme system, employing three enzymes (P450 + RE-ADH + Lb-ADH) the intermediate 
(R/S)-heptanols that are produced during the initial P450 BM3-catalyzed hydroxylation step are 
completely oxidized to the corresponding ketones (Table 4-10, entry 3 and 4). In the latter 
case, the absolute amount of the heptanone-isomers corresponds precisely to the sum of the 
heptanol and heptanone regioisomers in the two-enzyme system. This is remarkable, since two 
ADHs are present that are capable to perform the reversible reaction. 
The product distribution of the synthesized heptanones in the in vivo system is in accordance to 
the regioselectivity of each P450 BM3 variant that was determined in vitro (chapter 4.1.4). 
Cells containing the P450 BM3 variant 19A12NADH produce predominantly 2-heptanone 
followed by 3-heptanone (Table 4-10, entry 3, 67 % and 31%). With the variant CM1NADH 
higher amounts of 4- and 3-heptanone are produced (Table 4-10, entry 4, 44% and 41% 
respectively). The complete oxidation of the heptanol intermediates lead therefore to an 
improved availability of redox cofactors, which is demonstrated by the enhanced product 
Table 4-10: Selectivity of the whole cell double oxidation of n-heptane and cyclooctane 
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formation (Table 4-9, 1.8-fold entry 3 vs. 1; 1.3-fold entry 4 vs. 2). In addition, the 1.8-fold 
higher product concentration in case of 19A12NADH can be explained by the rather (S)-selective 
character of this P450 variant as determined for the purified enzyme in vitro (chapter 4.1.4, 
Table 4-2). In presence of the (S)-enantioselective RE-ADH all produced heptanol is oxidized, 
driving the reaction equilibrium to the side of the ketones. Therefore, the enzyme-coupled 
cofactor regeneration during the second oxidation step is more efficient when the two stereo-
complementary dehydrogenases -Lb-ADH and RE-ADH- are present. 
Nevertheless, the three-enzyme coexpression system consisting of P450NADH-RE-ADH + 
Lb ADH displays overall lower absolute product yields (up to 13-fold difference) when 
compared with the two-enzyme coexpression system consisting of P450NADH and RE-ADH 
(Table 4-9, entry 4 and 5 vs. Table 4-8, entry 3 and 4). This may be caused by the up to 7-fold 
reduced P450 BM3 yield (YP450/x) in the three-enzyme system compared to the two-enzyme 
system. The lower expression is a result of the non-optimal cultivation in shake flasks 
employing a two-plasmid coexpression strategy. 
The concept of double oxidation of alkanes was successfully transferred to a new substrate 
class, converting cyclooctane to cyclooctanone in the whole cell multi-enzymatic process. 
Cycloalkanones are important building blocks for the production of synthetic polymers, e.g. 
polyamide.[43] A three component system consisting of P450 BM3 19A12NADH-RE-ADH and 
Lb-ADH (Table 4-9, entry 6) yielded a very high product concentration of 5.2 mM 
(652 mg L-1) and the highest product yield (over catalyst) of 111 mg gCDW-1. Compared to the 
system with two enzymes (Table 4-9, entry 6 vs. 5) a 32% improved product formation was 
achieved. As previously described for the multi-enzymatic double oxidation of n-heptane the 
difference in product formation correlates to the difference in P450 BM3 content. The cells 
containing three enzymes (P450 19A12NADH-RE-ADH + Lb-ADH; Table 4-9 entry 6) had a 
4-fold higher P450 BM3 content (12 mgP450 gCDW-1) than cells with two enzymes (P450 19A12 
+ Lb-ADH; Table 4-9 entry 5, 3 mgP450 gCDW-1). The higher P450-concetration led to an 
improved product formation during whole cell catalysis.  
However, in terms of total turnover numbers (TTN) the two-enzyme system P450 BM3 19A12 
+ Lb-ADH displayed the highest value of 23736. The excellent TTN value is caused in this 
case by the relative high product concentration of 494 mg L-1 in relation to a relatively low 
intracellular P450 BM3 concentration (3 mgP450 gCDW-1; Table 4-9, entry 5). This means, in this 
strain the cofactor regeneration is very effective for the low concentration of P450 available, 
allowing a high efficiency in the product formation. For the other strains with higher P450 
content, the regeneration is limiting, resulting in lower TTN values. The TTN of 23736 is 
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6.6-fold higher than the best TTN of 3591 determined for the in vitro double oxidation of 
n-heptane with P450 BM3 CM1NADH-RE-ADH and cofactor regeneration over D-glucose/GDH 
(chapter 4.2.3, Table 4-7). In addition, it represents one of the highest TTN reported for a P450 
BM3 catalyzed reaction. Higher TTNs have been reported for the in vitro conversion of 
dodecanoic acid with the NADH-dependent P450 BM3 variant WTNADH (substitutions 
R966D/W1046S; TTN of 66700) and for the conversion of propane with the P450 BM3PMOR2 
variant (TTN of 45800).[146, 214] 
The conversion of cyclooctane was performed in a highly effective way (Table 4-10) with 94 
to 97% towards cyclooctane as product. Only trace amounts of cyclooctanol as intermediate of 
the double oxidation cascade were detected (up to 0.3%). In addition, other product peaks were 
detected, probably as a result of overoxidation or secondary hydroxylations catalyzed by the 
P450 BM3 monooxygenase. These phenomena are commonly encountered in the application 
of oxygenases[39, 41a], especially in the case of P450 BM3[215]. However, the relative amount of 
other products did not exceed 5% and should not interfere with later purifications. Based on the 
GC-quantification it was observed that a significant loss of the cyclooctane substrate during the 
reaction or the work up occurred. An apparent yield of 52% on cyclooctanone for the P450 
BM3 19A12NADH-RE-ADH + Lb-ADH system (entry 6) was calculated based on an initial 
substrate concentration of 10 mM. An advantage of cyclooctane as substrate for the double 
oxidation directly to cyclooctanone is given by the fact, that stereo centers cannot be generated 
upon single hydroxylation of the molecule. Therefore, almost all intermediate cyclooctanol can 
be oxidized by the employed ADHs in a chemoselective way.  
The cell toxicity of cyclooctane is similar to that of n-heptane with a slightly lower LogPo/w 
value of 4.45.[216] Cyclooctanone as main product of the multi-enzymatic cascade has a 
predicted LogPo/w of 2.11[216], which is significantly lower than the value of the substrate. In 
the biotransformation of cyclooctane 2% (v/v) ethanol was used as cosolvent. Accumulation of 
the more polar product cyclooctane in the cosolvent, in a similar way like the effect of 
n-heptane as organic carrier in a biphasic system, could lead to a beneficial product removal 
outside of the cell. In this case, a shift of the reaction equilibrium towards the double oxidation 
product cyclooctanone instead of the intermediate alcohol cyclooctanol would be expected. 
The use of a two-liquid-phase system for conversion of cyclooctane could ensure higher 
substrate availability and enhanced in situ product removal to achieve improved catalytic 
performance and product yields. 
Furthermore, the enzyme-coupled cofactor regeneration with two recombinant ADHs instead 
of one seems to be beneficial for the catalytic performance in the cell. The employed ADHs are 
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not only stereo-complementary but display also an opposite cofactor specificity (NADH-
dependent RE-ADH and NADPH-dependent Lb-ADH). The employed P450 BM3NADH 
variants are able to use both phosphorylated and non-phosphorylated cofactors as shown by the 
catalytic characterization data with purified enzyme (chapter 4.1.3, Figure 4-11). In this way, 
all regenerated cofactors NADH and NADPH become available for the P450-catalyzed 
hydroxylation. The over-expression of the P450 BM3 monooxygenase in the host cell is 
beneficial to drive the reaction to completion towards the ketones or the pure chiral alcohols. 
Based on the product quantification results for both substrates n-heptane and cyclooctane, with 
more than 94% cyclooctanone and >99% heptanone as main products, it can be assumed that 
the concept of the double-oxidation cascade is therefore advantageous to shift the reaction 
equilibrium to the side of the ketones. The alcohol dehydrogenases can perform the reversible 
reductive reaction. However, in the developed system accumulation of the alcohols was 
negligible. 
The benefits of the multi-enzymatic expression using the operon-fusion strategy were 
summarized in the previous chapter 4.3.1. For the two-enzyme system consisting of a P450 
BM3 and an RE-ADH the advantage of expressing two catalysts as a fused-operon was 
demonstrated. In the same way, coexpression of all three enzymatic components – P450 BM3, 
RE-ADH and Lb-ADH – using an operon-fusion would be more advantageous to achieve 
improved protein and product yields. 
The benefit of employing stereo-complementary ADHs for the double oxidation of non-
activated alkanes direct to the ketones was demonstrated, resulting in a complete oxidation of 
the intermediate alcohols and in an enhanced regeneration capacity. Using the whole cell 
multi-enzyme approach up to 650 mg L-1 total product for the conversion of n-heptane as well 
as cyclooctane was achieved. This represents a more than 3-fold improved product 
concentration compared to the best results of the in vitro multi-enzymatic cascade (200 mg L-1 
for P450 BM3 CM1NADH + RE-ADH + D-glucose/GDH; chapter 4.2.3). In the case of linear 
alkanes like n-heptane chiral resolution of the enantiomeric alcohols can be performed. The 
biotransformation of cyclic alkanes like cyclooctane directly to cyclooctanone is achieved with 
selectivity of 94%. 
The described synthesis concept can be defined as a “modular” multi-enzymatic reaction 
system. It was demonstrated, that multiple enzymatic component can be coexpressed in a 
single E. coli cell to generate a whole cell catalyst. The enzymatic components can be 
exchanged according to the desired chemo- regio and enantioselectivity in the reaction. The 
selection of the biocatalysts, P450 monooxygenase and ADHs, as well as the target substrate 
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(aliphatic vs. cyclic alkane) showed a significant impact on the system´s performance. Other 
monooxygenases and ADHs with different substrate selectivities could be implemented in the 
described process concept as well as any other beneficial catalyst. 
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5 Summary and Conclusion 
Biocatalysis offers alternative routes for the cost-effective and environmental friendly use of 
hydrocarbons as raw material for the production of fine chemicals, pharmaceuticals and 
building blocks for the chemical industry. Therefore, the enzymatic functionalization of 
alkanes allows the sustainable use of petrochemicals for production of value-added 
compounds, instead of their constricted application in combustion processes. Cytochrome P450 
monooxygenases are one class of enzymes, which have the remarkable capability of using 
molecular oxygen as sole oxidizing agent for alkane functionalization. This type of reaction is 
difficult to achieve by chemical synthesis. Some of the most striking advantages of enzymes 
over metallo- or organo-catalysts for the hydroxylation of non-activated C-H bonds are higher 
chemo- and stereoselectivities, mild reaction conditions, and usually higher turnover rates and 
numbers. 
A novel strategy is the application of biocatalytic oxidation cascades using cytochrome P450 
monooxygenases for the enzyme-catalyzed oxyfunctionalization of alkanes. In this work semi-
rational protein engineering was used to design a P450 monooxygenase for its subsequent 
implementation in the whole cell multi-enzymatic double oxidation cascade. The coupled 
reaction should consist of a P450 monooxygenase-catalyst functionalization of the alkane, 
followed by an ADH-catalyzed oxidation of the intermediate alcohol. The second oxidation 
reaction serves also for efficient cofactor regeneration of the cofactor NAD(P)H. 
Eighteen amino acid residues were rationally selected, saturated and screened for improved 
hydroxylation of n-heptane. Employing an optimized GC-FID protocol for separation of all 
heptanol isomers, rescreening and characterization of the best variants in regard to the 
regioselective hydroxylation of n-heptane was performed. A highly active P450 BM3 
monooxygenase variant (CM1) was detected, which, under screening conditions, showed a 
49-fold improved product formation rate compared to the wild type enzyme. The engineered 
variant P450 BM3 CM1 contains two unreported amino acid substitutions R255P and P329H, 
both located in the heme-domain and in close distance to the substrate binding pocket and 
active site cavity. It was proven in a SDM study, that both amino acids act in a synergistic 
manner to enable this remarkable catalytic activity despite of the low mutational load. Variant 
19A12 contains eighteen mutations, which lead to a low monooxygenase expression level 
compared to the WT enzyme. 
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To design an economically more favorable process, the cofactor preference was switched from 
NADPH to NADH in the P450 BM3 WT, variant CM1, and variant 19A12. The altered 
cofactor specificity not only allows the use of the cheaper and more stable cofactor NADH, but 
also ensures the compatibility with NADH-dependent alcohol dehydrogenases for an enzyme 
coupled cofactor regeneration. To evaluate the influence of the switched cofactor selectivity a 
detailed catalytic characterization of the generated NADH-dependent monooxygenases was 
performed. The variants P450 BM3 CM1NADH and 19A12NADH showed enhanced 
hydroxylation activities for n-heptane with TOF values of 604 min-1 and 485 min-1 and 
coupling efficiencies for the cofactor NADH of 44% and 32%, respectively. All three 
engineered P450 BM3 variants WTNADH, CM1NADH and 19A12NADH have a distinctive 
hydroxylation pattern when n-heptane is used as substrate. The regioselectivity of WTNADH is 
similar to the one observed with fatty acids, where all three subterminal carbon atoms are 
hydroxylated in amounts higher than 24%. On the contrary, the variant CM1NADH produces 
mainly 4-heptanol (48%) and 3-heptanol (42%), while 19A12NADH shows a preference for 
2-heptanol (64%) and 3-heptanol (33%). Furthermore every variant displayed a characteristic 
stereoselectivity profile. Interestingly, in P450 BM3 CM1NADH the stereo-preferences for the 
hydroxylation of n-heptane were partially inverted by the substitutions R255P and P329H. This 
variant is (S)-selective with respect to 3-heptanol and (R)-selective in case of 2-heptanol.  
The three engineered P450 BM3 monooxygenase variants were further used to evaluate the 
multi-enzymatic oxidation of n-heptane and cyclooctane. A double-oxidation cascade concept 
was developed by coupling a monooxygenase- and an alcohol dehydrogenase-catalyzed 
reaction with integrated cofactor regeneration. The use of three different P450 BM3 
monooxygenase variants, displaying distinctive regio and stereoselectivities, and two stereo-
complementary ADHs – the (S)-selective RE-ADH and the (R)-selective Lb-ADH - was 
evaluated by determination of catalytic parameters such as specific activity, product 
concentrations, enantiomeric excess, TTN, product yields (on catalysts, Yp/x) and P450 yields 
(YP450/x). The P450 BM3 variant was used for the initial hydroxylation of the alkane, followed 
by the selective oxidation of the alcohol by means of the alcohol dehydrogenase. The 
biocatalytic double oxidation concept allowed the direct synthesis of alkanones from alkanes 
by simultaneous regeneration of the cofactor NAD(P)H. In addition, when n-heptane was 
employed as substrate, depending on the stereoselectivity of the employed ADH, the enzymatic 
resolution of (S)- or (R)-heptanols was achieved. Therefore, the synthesis concept offers a 
direct route from an inexpensive alkane to valuable high-priced synthons for the 
pharmaceutical, agrochemical and food industry. The described synthetic concept was 
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implemented in a cell free biotransformation (in vitro) as well as in a whole cell catalytic 
system (in vivo).  
The in vitro conversion of n-heptane was performed under mild reaction conditions, i.e. at 
room temperature, in water and using molecular oxygen as sole oxidant which is superior to 
most chemical hydroxylation reactions. In the P450 BM3 CM1NADH-RE-ADH catalyzed 
double oxidation a total product concentration of 1.3 mM (150 mg L-1; (R)-heptanols and 
heptanone) was obtained. The product formation was 1.8-fold higher compared to the single 
P450 BM3-catalyzed hydroxylation of n-heptane employing the same amount of starting 
cofactor. A further increase in the system performance was achieved by supplementation of a 
supporting cofactor regeneration system containing D-glucose and GDH. Fine-tuning of the 
glucose concentration in the cascade reaction proved to be a key parameter to optimize 
cofactor regeneration and increase the product formation. In the multi-enzymatic cascade 
containing P450 BM3 CM1NADH, RE-ADH and GDH a total product concentration of 1.8 mM 
(207 mg L-1) and a TTN of 3500 were obtained, without changes in the stereoselectivity of the 
reaction. The TTNs of the P450 BM3 variants 19A12 and CM1 for the oxyfunctionalization of 
n-heptane outperforms state-of-the-art chemical catalysts by 15-fold. 
Furthermore, the implementation of a multi-enzymatic cascade into a whole cell process was 
pursued. This would represent a more cost-effective alternative to in vitro reaction systems for 
an industrial application of oxidoreductases. In this regard, major advantages are that the 
addition of expensive external cofactors (NAD(P)H) and supplementary enzymes is not 
required. To extend the concept of the double oxidation of alkanes to whole cells catalysis, 
three coexpression strategies for P450 BM3 and ADH in E. coli were evaluated and optimized. 
The best coexpression strategy consisted in the generation of an operon-fusion between P450 
BM3 and RE-ADH in the pALXtreme-1a vector. For the operon-fusion strategy that was 
developed in this thesis a remarkably high specific protein formation (protein yield) of 
680 nmolP450 gCDW-1 (81 mgP450 gCDW-1) was obtained by fermentation under controlled 
cultivation conditions. This represents the highest obtained yield for expression of P450 BM3 
in E. coli reported so far and allows further optimization, not only for P450 monooxygenases. 
Remarkably, the obtained P450 BM3 concentration was 54-fold improved compared to the 
standard cultivation in shake flask.  
For whole cell conversion of n-heptane a two-liquid-phase process was established. The system 
consisted in an aqueous phase, containing E. coli cells (catalyst) and glucose for cofactor 
regeneration in buffer, and the organic phase - applying n-heptane both as organic carrier and 
substrate - in a volumetric ratio of 17% (v/v). Using the cells containing the operon-fusion 
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P450 BM3 CM1NADH-RE-ADH a total product concentration of 5.7 mM (656 mg L-1; 
(R)-heptanols and heptanones) and a product yield (on catalyst) of 76 mg gCDW-1 was obtained. 
Hence, the whole cell double oxidation with P450 BM3 and RE-ADH yielded up to 3-fold 
improved product concentrations compared to the in vitro system. A high expression of the 
P450 monooxygenase in the whole cell catalysts was identified as determining factor to 
achieve the best process performance. The cascade (P450 monooxygenase variants and 
(S)-specific RE-ADH) was extended by a third enzyme, the (R)-specific Lb-ADH. A complete 
oxidation of n-heptane to the corresponding heptanones with a chemoselectivity of >99% was 
achieved employing the three enzyme system, consisting of both stereo-complementary ADHs 
and P450 BM3. 
As a final step, the multi-enzymatic whole cell double oxidation concept was expanded to 
cyclic alkanes, choosing cyclooctane as model compound. The conversion of cyclooctane with 
the three enzyme system P450 BM3 19A12NADH-RE-ADH-Lb-ADH was highly 
chemoselective yielding 94% cyclooctanone with a product concentration of 5.2 mM 
(652 mg L-1) and a product yield (on catalysts) of 111 mg gCDW-1. In addition, the third highest 
reported TTN for P450 BM3 monooxygenase of 23700 was reached using the two enzyme 
system containing P450 BM3 19A12 and Lb-ADH. It was successfully demonstrated that by 
means of the multi-enzymatic double oxidation cascade the reaction equilibrium could be 
shifted completely to the side of the ketone upon oxyfunctionalization of the alkanes. 
In conclusion, a significantly high expression of the P450 BM3 monooxygenase turned out to 
be crucial to achieve a good performance in the whole cell catalysis. The reported multi-
enzymatic bicatalytic cascade represents the first concept in which a chiral resolution of 
alcohols is achieved after functionalization of an alkane, including a product based cofactor 
regeneration in a one-pot reaction. Product ratios for alcohols and ketones can be fine-tuned by 
simple catalyst selection, overcoming the drawbacks of low selectivities of the employed P450 
BM3 catalyst. The developed double oxidation concept can be optimized in vitro and directly 
be transferred to an in vivo process. The multi-enzymatic process is a tunable and modular 
system, in which the employed enzymes (monooxygenases and alcohol dehydrogenases) can 
be exchanged depending on the targeted specificity and selectivity. As a toolbox the multi-
enzymatic system enables the synthesis of enantiomerically pure alcohols or ketones. The 
concept of the double oxidation cascade can further be expanded to other stereoselective 
oxidoreductases or further enzyme classes such as aminotransferases or lyases. 
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6 Appendix 
6.1 Abbreviations 
AADH   Amino acid dehydrogenase 
ABTS   2,2'-Azino-di-(3-ethyl-benzthiazoline-6-sulphonic acid) 
ADH   Alcohol dehydrogenase 
ALA   Aminolevulinic acid  
BM   Bacillus megaterium 
BSA   Bovine Serum Albumin 
BVMO  Baeyer-Villinger Monooxygenase 
CCE   Crude cell extract 
CDW   Cell dry weight 
cfu   Colony-forming units 
Cm   Chloramphenicol 
CRS   Cofactor regeneration system 
CYP   Cytochrome P450 monooxygenase  
D-AAO  D-amino acid oxidase 
dATP Deoxyadenosine triphosphate 
dCTP Deoxycytidine triphosphate 
ddH2O   Double-distilled water 
DEAE   Diethylethanolamine 
dGTP Deoxyguanosine triphosphate 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
dNTPs Deoxynucleotide triphosphate solution mix (equimolar concentration of 
dATP, dCTP, dGTP, dTTP 
dTTP Deoxythimidine triphosphate 
E. coli   Escherichia coli 
e.g.   exempli gratia (for example) 
ee   enantiomeric excess 
EEM   Escherichia coli minimal medium  
ep   error prone 
er   enantiomeric ratio 
et al.   et alii (and others) 
FAD   Flavin adenine dinucleotide 
FDH   Formate dehydrogenase 
FID   Flame ionization detector 
FMN   Flavin mononucleotide 
Fwd   Forward 
GC   Gas chromatography 
GDH   Glucose dehydrogenase 
h   hour(s) 
HSDH   Hydroxysteroid dehydrogenase 
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HT   Heat treatment 
HTS   High Throughput Screening 
i.e.   id est (that is) 
IPTG   Isopropyl ß-D-thiogalactopyranosid 
Kan   Kanamycin 
kb   Kilobase(s) 
KM   Michaelis-Menten constant 
KPi-buffer  Potassium phosphate (inorganic) buffer 
L. brevis  Lactobacillus brevis 
LB   Lysogeny broth 
Lb-ADH  Alcohol dehydrogenase from Lactobacillus brevis 
LDH   Lactate dehydrogenase 
LeuDH  Leucine dehydrogenase 
logPo/w logarithm of the partition coefficient P of a solvent in a 1:1 mixture of 
octanol and water 
MCS   Multiple cloning site 
min   Minute(s) 
mRNA   Messenger ribonucleic acid 
MS   Mass spectrometry 
MTBE   Methyl tert-butyl ether (2-Methoxy-2-methylpropane) 
MTP   Microtiter plate 
n.d.   Not determined 
NAD+   Nicotinamide adenine dinucleotide (oxidized form) 
NADH   Nicotinamide adenine dinucleotide (reduced form) 
NADP+  Nicotinamide adenine dinucleotide phosphate (oxidized form) 
NADPH  Nicotinamide adenine dinucleotide phosphate (reduced form)  
NDT   Oligonucleotide triplet (N: G or A or C or T; D: G or A or T) 
NNK Oligonucleotide triplet (N: G or A or C or T; K: G or T) 
NPG   N-palmitoyl glycine 
OD600   Optical density at a wavelength of 600 nm 
P450   Cytochrome P450 monooxygenase 
PCR   Polymerase chain reaction 
pH Decimal logarithm of the reciprocal of the hydrogen ion activity 
PLICing  Phosphorothioate-based ligase-independent gene cloning 
PVDF   Polyvinyl idenfluoride 
R Rectus (right, clockwise) 
R. erythropolis Rhodococcus erythropolis 
rac   racemic 
RBS   Ribosome binding site 
RE-ADH  Alcohol dehydrogenase from Rhodococcus erythropolis 
Ref   Reference 
Rev   Reverse 
rpm   Revolutions per minute 
RT   Room temperature 
s   Second(s) 
S Sinister (left, counterclockwise) 
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S. cerevisiae Saccharomyces cerevisiae 
SD   Shine-Dalgarno sequence 
SDM   Site Directed Mutagenesis 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
sec   secondary 
SOC   Super optimal broth with catabolite repression 
sp. Species 
SSM   Site Saturation Mutagenesis 
TA   Transaminase 
TB   Terrific broth 
tert   tertiary 
TFB   Transformation buffer 
TOF   Turnover frequency 
Tris   Tris(hydroxymethyl)aminomethane  
TTN   Total turnover number 
UV   Ultraviolet  
Vmax   maximal reaction rate 
WT   Wild type 
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6.5 List of primers 
In this work oligonucleotide primers were used for the amplification and cloning of the target 
genes P450 BM3 (Table 6-1) and RE-ADH (Table 6-2). 
 
 Nr. Targeted DNA Primer identifier Sequence (5´-3´) Tanneling 
[°C] 
1 P450 BM3 gene Fwd_BM3 Insert-PLIC catgggcatgacAATTAAAGAAATGC
CTCAG 
58 
2 P450 BM3 gene Rev-BM3 Insert-PLIC cgacggagctcgAATTCTTATTACCC
AGC 
58 
3 pET28a(+)-based 
vectors 
Fwd_pET28-BM3-PLIC cgagctccgtcgACAAGCTTGCG 58 
4 pET28a(+)-based 
vectors 
Rev_pET28-BM3-PLIC gtcatgcccatgGTATATCTCCTTC 58 
5 pALXtreme-1a P450 
BM3 
BM3 Fwd_Op_PTO gctaacaaagccCGAAAGGAAGCTG
AGTTGGC 
55 
6 pALXtreme-1a P450 
BM3 
BM3 Rev_1046S_Op_ 
PTO 
gaacagtggatcATGATTACTAGTGG
GTTACCCAGCGCTCACGTCTTT
TG 
55 
Table 6-1: Oligonucleotide primers for cloning by PLICing 
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7 RE-ADH RE-ADH Fwd_Op_PTO gatccactgttcAATAAGGAGGTATA
CCATGAAGGCAATCCAAGTAC
ACG 
55 
8 RE-ADH RE-ADH Rev_Op_PTO ggctttgttagcTTACAGACCAGGGAC
CACAACCGC 
55 
 
Nr. Primer identifier Sequence (5´-3´) 
1 RE-ADH_F_NdeI  GGAGATATACATATGAAGGCAATCCAG 
2[a] RE-ADH_R_EcoRV  GCAGCCGATATCTTACAGACCAGGGACCACAACC 
[a] The underlined nucleotides serve for introduction of the restriction site EcoRV (are not complementary). 
 
Single mutations were introduced by SDM (Table 6-3).and the generation of different SSM 
libraries was achieved employing primers in Table 6-4 and Table 6-5. The generated mutants 
were than sequenced with gene- or vector-specific primers (Table 6-6). 
 
Nr. Amino acid 
exchange 
Primer identifier Sequence (5´-3´) 
1 Arg255Pro SDM BM3 R255P_F CGCTTGATGACGAGAACATTCCTTATCAAATTATTAC
ATTC 
2 Arg255Pro SDM BM3 R255P_R GAATGTAATAATTTGATAAGGAATGTTCTCGTCATC
AAGCG 
3 Pro329His SDM BM3 P329H_F GCTTATGGCCAACTGCTCATGCGTTTTCCCTATATGC 
4 Pro329His SDM BM3 P329H_R GCATATAGGGAAAACGCATGAGCAGTTGGCCATAA
GC 
5 Arg966Asp SDM BM3 R966D_F GCTTCATACCGCTTTTTCTGACATGCCAAATCAGCC 
6 Arg966Asp SDM BM3 R966D_R GGCTGATTTGGCATGTCAGAAAAAGCGGTATGAAGC 
7 Trp1046Ser SDM BM3 W1046S_F GATACGCAAAAGACGTGAGCGCTGGGTAATAAGAA
TTCG 
8 Trp1046Ser SDM BM3 W1046S_R CGAATTCTTATTACCCAGCGCTCACGTCTTTTGCGTA
TC 
 
 
 
 
 
 
Table 6-2: Oligonucleotide primers for amplification of RE-ADH 
Table 6-3: Oligonucleotide primers for Site-Directed Mutagenesis 
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Nr. Amino acid 
position 
Primer 
identifier 
Sequence (5´-3´) 
1 Arg47 SSM_R47_F CGAGGCGCCTGGTNNKGTAACGCGCTACTTATC 
2 Leu52 SSM_L52_F CGTGTAACGCGCTACNNKTCAAGTCAGCGTCT 
3 Val78 SSM_V78_F GTCAAGCGCTTAAATTTNNKCGTGATTTTGCAGGAGACG 
4 Ala82 SSM_A82_F GCTTAAATTTGTACGTGATTTTNNKGGAGACGGGTTATTTAC 
5 Pro142 SSM_P142_F GATGAGCATATTGAAGTANNKGAAGACATGACACGTTTAACG 
6 Thr175 SSM_T175_F CAGCCTCATCCATTTATTNNKAGTATGGTCCGTGC 
7 Ala184 SSM_A184_F GTCCGTGCACTGGATGAANNKATGAACAAGCTGCAGCGAGC 
8 Leu188 SSM_L188_F GATGAAGCAATGAACAAGNNKCAGCGAGCAAATCCAGACG 
9 Phe205 SSM_F205_F GATGAAAACAAGCGCCAGNNKCAAGAAGATATCAAGG 
10 Ser226 SSM_S226_F GCAGATCGCAAAGCANNKGGTGAACAAAGCGATG 
11 His236 SSM_H236_F CGATGATTTATTAACGNNKATGCTAAACGGAAAAGATC 
12 Glu252 SSM_E252_F GAGCCGCTTGATGACNNKAACATTCGCTATCAAATTATTAC 
13 Arg255 SSM_R255_F GCTTGATGACGAGAACATTNNKTATCAAATTATTACATTC 
14 Ala290 SSM_A290_F CCACATGTATTACAAAAANNKGCAGAAGAAGCAGCACG 
15 Ala328 SSM_A328_F GCTGCGCTTATGGCCAACTNNKCCTGCGTTTTCCCTATATG 
16 Leu353 SSM_L353_F GAAAAAGGCGACGAANNKATGGTTCTGATTCCTCAGC 
17 Ile366 SSM_I366_F CTTCACCGTGATAAAACANNKTGGGGAGACGATGTGG 
 
Nr
. 
Amino acid 
position 
Primer identifier Sequence (5´-3´) 
1 Val184 SSM_V184_F GTCCGTGCACTGGATGAANNKATGAACAAGCCGCA
GCGAGC  
2 Ala74 SSM_A74_F CTTAAGTCAANNKCTTAAATTTTTCCGTGATTTTTC
AGG  
3 Arg47/Tyr51 SSM_R47/Y51_F CGAGGCGCCTGGTNNKGTAACGCGCNNKATATCAA
GTCAGCG 
4 Phe87 SSM_F87_F CAGGAGACGGGTTANNKACAAGCTGGACGCATG  
5 Val26 SSM_V26_F GTTATTAAACACAGATAAACCGNNKCAAGCTTTGA
TGAAAATTGC 
6 Ile263/Glu267 SSM_I263/E267_F CAAATTATTACATTCTTANNKGCGGGACACNNKAC
AACAAGTGGTC 
7 Ala264/Thr268 SSM_A264/T268_F CATTCTTAATTNNKGGACACGAANNKACAAGTGGT
CTTTTATC 
 
Nr. Primer identifier Sequence (5´-3´) 
1 T7 promoter (forward)  TAATACGACTCACTATAGGG 
2 P450BM3_2.1 CTTTAACAGCTTTTACCGAGATCAGC 
3 P450BM3_2-4 CGGAAAAGATCCAGAAAC 
4 P450BM3_3-4 GCAACGCTTGATTCACAC 
8 T7 terminator (reverse) CTAGTTATTGCTCAGCGGT 
Table 6-4: Oligonucleotide forward-primers for Site-Saturation Mutagenesis of P450 BM3 WT 
Table 6-5: Oligonucleotide forward-primers for Site-Saturation Mutagenesis of P450 BM3 19A12 
Table 6-6: Oligonucleotide primers for the sequencing of P450 BM3 
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6.6 Overview of generated E. coli strains 
The generated E. coli strains are listed in Table 6-7 and 6-8. 
 
Recombinant Protein Substitutions (1-letter code) Origin/ Ref. 
P450 BM3 WT - [57] 
P450 BM3 WTNADH W1046S, R966D SDM/ this work; [148]  
P450 BM3 19A12 R47C, L52I, V78F, A82S, K94I, P142S, T175I, A184V, 
L188P, F205C, S226R, H236Q, E252G, R255S, A290V, 
A328F, L353V, I366V 
Heme fragment ordered 
as synthetic DNA; [146]  
P450 BM3 19A12NADH 18 mutations from 19A12; W1046S, R966D SDM of 19A12; this 
work 
P450 BM3 19A12 A74E 18 mutations from 19A12; additionally A74E  SSM of 19A12; this 
work 
P450 BM3 19A12 
V184S 
18 mutations from 19A12; additionally V184S  SSM of 19A12; this 
work 
P450 BM3 19A12 
P188Q 
18 mutations from 19A12; additionally P188Q  SSM of 19A12; this 
work 
P450 BM3 CM1 R255P, P329H SSM of WT; this work 
P450 BM3 CM1NADH R255P, P329H, W1046S, R966D SDM of CM1; this 
work 
P450 BM3 R255P R255P SDM of WT; this work 
P450 BM3 P329H P329H SDM of WT; this work 
 
E. coli 
strain 
Plasmid and recombinant protein Features 
BL21 (DE3) 
Gold lacIQ1 
pALXtreme-1a P450 BM3 WTNADH+ pKA1 RE-ADH 2-Plasmid-System (5.1 kb/ KanR 
+ 6.6 kb/ CmR respectively); 
both contain T7 promoter/lac 
operator 
pALXtreme-1a P450 BM3 19A12NADH + pKA1 RE-ADH 
pALXtreme-1a P450 BM3 CM1NADH + pKA1 RE-ADH 
BL21 (DE3) 
Gold lacIQ1 
pALXtreme-1a P450 BM3 WT+ pKA1 Lb-ADH 2-Plasmid-System (5.1 kb/ KanR 
+ 6.2 kb/ CmR respectively); 
both contain T7 promoter/lac 
operator 
pALXtreme-1a P450 BM3 19A12 + pKA1 Lb-ADH 
pALXtreme-1a P450 BM3 CM1 + pKA1 Lb-ADH 
BL21 (DE3) 
Gold 
pACYCDuet-1 P450 BM3 WTNADH (MCS1) + RE-ADH 
(MCS2) 
Duet expression system 
(Novagen); 8.2 kb/ CmR ; 2x T7 
Promoter/lac operator, 2x RBS pACYCDuet-1 P450 BM3 19A12NADH (MCS1) + RE-ADH 
(MCS2) 
pACYCDuet-1 P450 BM3 CM1NADH (MCS1) + RE-ADH 
(MCS2) 
 
 
 
 
 
 
Table 6-7: Overview of the E. coli BL21 (DE3) Gold lacIQ1 strains harboring the pALXtreme-1a vector 
for single expression of P450 BM3 monooxygenase variants. 
Table 6-8: Overview of E. coli strains for coexpression of multiple enzymes: P450 BM3 monooxygenase 
variants and alcohol dehydrogenases RE-ADH and Lb-ADH 
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BL21 (DE3) 
Gold lacIQ1 
pALXtreme-1a P450 BM3 WTNADH-RE-ADH „Synthetic“ operon-fusion;  
6.1 kb/ KanR; 1x T7 
promoter/lac operator, 2x RBS 
pALXtreme-1a P450 BM3 19A12NADH-RE-ADH 
pALXtreme-1a P450 BM3 CM1NADH-RE-ADH 
BL21 (DE3) 
Gold lacIQ1 
pALXtreme-1a P450 BM3 WTNADH-RE-ADH + pKA1 Lb-
ADH 
2-Plasmid-System, three 
enzymes (operon-fusion 6.1 kb/ 
KanR + 6.2 kb/ CmR);  
features see above 
pALXtreme-1a P450 BM3 19A12NADH-RE-ADH + pKA1 
Lb-ADH 
pALXtreme-1a P450 BM3 CM1NADH-RE-ADH + pKA1 
Lb-ADH 
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Figure 6-1: Plasmid map of the expression vector pALXtreme-1a containing the P450 BM3 
monooxygenase. The P450 BM3 gene (insert DNA) was introduced by PLICing. 
Figure 6-2: Plasmid map of the expression vector pKA1 containing the gene of the alcohol 
dehydrogenases RE-ADH (A) or Lb-ADH (B). The insert DNA was introduced by restriction cloning using 
NdeI and BamHI. 
APPENDIX 
 
 
131 
 
 
6.7 Supplementary information 
The analysis of reaction products was performed by gas chromatography as shown in Figure 
6-4 and products were quantified using calibration curves for each regioisomers (Figure 6-5). 
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Figure 6-3: Plasmid map of the expression vector pACYCDuet-1 containing the P450 BM3 
monooxygenase and alcohol dehydrogenase genes. Cloning was performed by restriction using for RE-ADH 
the endonucleases NdeI and BamHI. 
Figure 6-4: Identification of heptanol and heptanone regioisomers by gas chromatography using 
authentic standards. The graph shows as an example one point of the calibration curve used for quantification 
of product concentrations and regioselectivity of the enzymatic single or double oxidation of n-heptane. 
Separation of the regioisomers was achieved using a column FS-Supreme-5ms (30 m x 0.25 mm x 0.25 µm film 
thickness; CS-Chromatographie, Germany) fitted in a Shimadzu GC-2010 gas chromatograph with a flame 
ionization detector (FID) (Shimadzu, Japan). Column oven temperature program: 40 °C for 19.5 min, 
20 °C min-1 to 100 °C, 3 min. 
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Partial sequencing of the 10 best mutants for 17 saturated amino acid residues in P450 BM3 
WT revealed in eight clones additional mutations besides of a mutation at the targeted position. 
The additional mutations found are listed in Table 6-9. 
 
Amino acid position Clone nr. (rescreening) Substitution[a]  
  at targeted site at other site 
T175 6 T175E  F173I 
L188 3 L188F M185L 
F205 5 F205R D208E 
H236 8 H236A N240L 
H236 9 H236T M237L 
R255 2 R255P P329H 
L353 6 L353A I254V 
I366 10 I366S8 A327T 
[a] Mutations detected by partially sequencing (900 bp, fragment containing the saturated site) of the P450 BM3 clones; the 
possibility of other mutations at not sequenced sites cannot be excluded. 
 
The purification of P450 BM3 monooxygenases using anion-exchange chromatography 
(Toyopearl DEAE 650S matrix) was performed as shown in Figure 6-6. 
 
4.0 5.0 6.0 Ln(Conc. Ratio)
-6.0
-5.0
-4.0
-3.0
-2.0
Ln(Area Ratio)
1 
2 
3 
4 
5 
6 
7 
Figure 6-5: Calibration curve for 2-heptanol. A 7-point calibration curve, using authentic standards and an 
exponential fitting, was calculated for each heptanol and heptanone regioisomers in triplicate (RSD <10%; R2 
>0.99; Software GC Solutions, Shimadzu, Japan). The calibration curve for 2-heptanol is shown here 
exemplarily. 
Table 6-9: Additional mutations in P450 BM3 clones selected from rescreening 
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Generation of the operon-fusion constructs in the vector pALXtreme-1a was achieved by 
PLICing[153] after amplification of vector and insert DNA as shown in Figure 6-7. 
 
 
 
During fermentation of E. coli BL21 (DE3) Gold lacIQ1 containing the operon-fusion plasmids 
pALXtreme-1a P450 BM3 WTNADH-RE-ADH, 19A12NADH-RE-ADH and CM1NADH-RE-ADH 
different parameters were monitored online (pH, pO2, temperature, stirrer speed, addition of 
acid and base) as shown exemplarily for 19A12NADH-RE-ADH in Figure 6-8. The cell density 
(OD600) was monitored offline by sampling culture broth before and after induction of the 
recombinant protein expression. The expression level of P450 BM3 and RE-ADH was 
analyzed by SDS-PAGE (exemplarily for 19A12NADH-RE-ADH, Figure 6-9). 
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Figure 6-6: Purification profile of P450 BM3 CM1NADH using anion-exchange chromatography. An entire 
purification run in (A) consist of following steps: loading of crude cell lysate and protein binding, washing of 
the column matrix and elution of bounded proteins. A detail representation in (B) shows the elution of the target 
protein P450 BM3 (165-172 min) using a gradient of elution buffer from 14 to 25% (equal to 140 to 250 mM 
NaCl) and a conductivity increase from 17 to 22 mS cm-1. Elution fractions (5 ml) corresponding to the target 
peak were collected and analyzed by SDS-PAGE (10%). 
Figure 6-7: Amplification of pALXtreme-1a P450 BM3 and RE-ADH for generation of operon-fusion 
constructs by PLICing. Each pALXtreme-1a vector containing the P450 BM3 gene WTNADH (line 1), 
19A12NADH (line 2) or CM1NADH (line 3), as well as the insert gene RE-ADH (line 4), were amplified with 
sequence specific primers to generate upon chemical cleavage complementary overhangs for site specific 
hybridization. 
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Each fermentation batch of E. coli cells containing the operon-fusion constructs for 
coexpression of P450 BM3 monooxygenases (WTNADH, 19A12NADH, CM1NADH) and RE-ADH 
was characterized in terms of P450 content per cell dry weight as shown in Figure 6-10. The 
correlation of P450 concentration to cell dry weight was linear in this OD range and was used 
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Figure 6-8: Fermentation of E. coli BL21 (DE3) Gold lacIQ1 pALXtreme-1a P450 BM3 19A12NADH-RE-
ADH (operon-fusion) in a 5 L-bioreactor. 
Figure 6-9: Protein expression level during fermentation of E. coli BL21 (DE3) Gold lacIQ1 pALXtreme-
1a P450 BM3 19A12NADH-RE-ADH. SDS-PAGE (10%) of cell lysates from fermentation before induction (1) 
and 0.5 h (2), 2.5 h (3), 3.5 h (4), 4.5 h (5), 5.5 h (6), 8 h (7) and 21 h (8) after induction of the recombinant 
protein expression by addition of IPTG. 
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to calculate P450 yields YP450/x and total turnover numbers TTN in the double oxidation 
cascades. 
 
 
 
Figure 6-11 shows the SDS-PAGE analysis of P450 BM3 monooxygenases, RE-ADH and Lb-
ADH in the vector constructs for coexpression of two or three enzymes.  
 
 
 
Figure 6-10: Correlation between P450 concentration and cell dry weight of operon-fusion strains from 
fermentation. The strains are BL21 Gold (DE3) Gold lacIQ1 pALXtreme-1a P450 BM3 WTNADH-RE-ADH 
(red), 19A12NADH-RE-ADH (blue) and CM1NADH-RE-ADH (black). 
Figure 6-11: Single expression or coexpression of the alcohol dehydrogenase Lb-ADH, together with P450 
BM3 and RE-ADH. Visualization on a 10% SDS-PAGE gel. Single expression of recombinant proteins Lb-
ADH (1) and TE-ADH (2); Coexpression of two enzymes: P450 BM3 WT + Lb-ADH (3), P450 BM3 19A12 + 
Lb-ADH (4), P450 BM3 CM1 + Lb-ADH (5); Coexpression of three enzymes: P450 BM3 19A12NADH + RE-
ADH + Lb-ADH (6), P450 BM3 CM1NADH + RE-ADH + Lb-ADH (7); (M) Molecular weight standard 
(Prestained PageRuler, Fermentas). All strains were expressed in shake flask. 
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